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Overview and Summary
T
he following thesis is concerned with the study of proteins and protein-
protein complexes of biomedical importance by Nuclear Magnetic
Resonance spectroscopy (NMR). Understanding how biological systems operate
from the level of a single protein to more complex protein-protein complexes,
and ﬁnally to the transduction of signal holds the key for ﬁnding cure for many
diseases. Cancer is one such disease which is characterized by unregulated cell
division often promoted by protein kinases [Teicher, 2000]. Therefore, protein
kinases are often targeted by small molecule inhibitors, albeit with the problem of
insufﬁcient target selectivity due to the high sequence similarity between different
kinase family members [Fabbro et al., 2002; Noble et al., 2004].
Akt/PKB is a protein kinase that has been found frequently in a constitutively active
form in human cancers. Akt/PKB is a clinically validated target and hence small
molecule inhibitor towards this kinase are highly desirable [Brognard et al., 2001;
Hanada et al., 2004].
Akt/PKB cannot easily be expressed in E. coli, and hence cAMP dependent kinase
(PKA) which has high sequence homology to Akt/PKB, has been used as a surrogate
kinase for drug design.
As alternative route, drugs that inhibit the molecular chaperone Hsp90 are currently
in clinical trials due to their ability to promote degradation of many kinases
[Whitesell and Lindquist, 2005]. More recently Cdc37, a cochaperone of Hsp90 in
mammalian cells, has been identiﬁed to target protein kinases. It is upregulated in
various cancers [Lee et al., 2002; Pearl, 2005]. The protein-protein (Hsp90-Cdc37)
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complex forms with a KD = 1.2 M, and is considered to mediate carcinogenesis by
stabilizing a variety of different oncogenic kinases in malignant cells.
The method in this thesis to study these proteins or protein-protein complex
in high resolution is a combination of liquid-state NMR spectroscopy and X-
ray crystallography. It is important to characterize this interaction at very high
resolution as it will enable us in identifying ‘Hot spots’ in the protein-protein
interaction interface and in further developing small molecule inhibitors [Wells and
McClendon, 2007].
The ﬁrst part of the thesis introduces the reader to the world of Structural
proteomics and its importance. Chapter 2 discusses various projects undertaken
by the world community in the post human genome era, in order to obtain the
three-dimensional structures of a substantial set of proteins of an organism, the
‘proteome’. Chapter 2 also gives special emphasis on Structural Proteomics in
Europe (SPINE), which decided to limit its study to proteins and protein-protein
complexes of biomedical importance and also explicitly provides PDB statistics
about three-dimensional structures of high molecular weight proteins solved by
NMR spectroscopy. The importance of the study of Cancer-related proteins like
protein kinases, Hsp90 and Cdc37, are introduced in Chapter 3. Chapter 4 gives the
reader a taste and importance of developing small molecule inhibitors in disrupting
protein-protein interactions in order to prevent diseases. Finally, Chapter 5 reviews
various NMR spectroscopy methods used to study protein-protein interaction. This
chapter also introduces the reader the importance of protein-protein interaction in
the cellular processes.
The second part of the thesis, which is a cumulative part, encompasses the original
research work conducted. Chapter 6 describes how NMR spectroscopy was used to
access the correct folding of protein kinase A (PKA) and the mutants. Further, it
reports how mutations of phosphorylation sites in PKA affect the expression level,
stability and activity of the kinase.
Achievements:
 Establishment of PKA with three phospho-mutations, can easily be expressed
in E. coli, which otherwise is a major obstacle for most of the kinases
 Establishment of the correct fold of the three phospho-mutants of the 40 kDa
PKA by NMR3
Figure 1.1: Folding and activity
of cAMP-dependent protein kinase
mutants. Comparison of TROSY
spectra of wild-type PKA (black)
with "dephospho"-PKA mutant, PKA-
3P(green) shows that the mutants are
correctly folded. For more details see
Chapter 6.
 Revelation that there will be no mixtures of isoforms due to differential
phosphorylation, since there is now only one phosphorylation site in the
activation loop, which makes it highly suitable for studying protein-ligand
interactions
 Establishment of the fact that these mutants are active and well folded which
can now be highly advantageous for further functional and structural studies
Chapter 7 exempliﬁes how we achieved the structure determination of a 40 kDa
human Cdc37M-Hsp90N protein-protein complex by using NMR spectroscopy in
combination with X-ray crystallography. Further, by using NMR spectroscopy we
could pinpoint the ‘Hot Spot’ in the large interaction interface of this protein-protein
complex.
Achievements:
 Establishment of the domain boundaries, puriﬁcation and NMR conditions for
the, rather challenging, 45 kDa protein Cdc37
 Achievement of complete (99.5 %) backbone resonance assignment of the
Hsp90 binding domain of Cdc37
 Determination of the structure of the human Hsp90 binding domain of Cdc37
by X-ray crystallography in collaboration with Prof. Dr. Roy Lancaster
 Mapping of the interaction interface of the Cdc37-Hsp90, by using multitude
of NMR techniques, which sets an example for further studies of large protein-
protein complexes4 Chapter1. Overview and Summary
Figure 1.2: NMR studies of human Cdc37M-Hsp90N complex. A combination of domain
optimization, NMR spectroscopy methods (resonance assignment, chemical shift perturbation
mapping, cross-saturation transfer, RDC’s), X-ray crystallography and docking using HADDOCK
was used to determine the solution structure of 39 kDa human Cdc37M-Hsp90N complex. For
more details see Chapter 7.
 Successful usage of residual dipolar couplings (RDCs) for more accurate
structure determination of the protein-protein complex
 Determination of the structure of 40 kDa human Cdc37-Hsp90, by using a
combination of ‘state-of-the-art’ techniques NMR, X-ray and docking
 PDB statistics show that till date there are only 49 structures above 39 kDa out
of 7728 structures solved by NMR. The structure of Cdc37-Hsp90 complex is
one of the 49 structures solved by NMR
 Identiﬁcation of the ‘Hot Spot’ in the large interaction interface by NMR and
also conﬁrmed it further, by a combination of single point mutation and NMR
Finally, Chapter 8 describes the achievement by NMR that celastrol, a recently
identiﬁed triterpene, targeting Hsp90, in fact binds to Cdc37 and disrupts the
Cdc37-Hsp90 complex. Further, it also describes the molecular mechanism of
inhibition of Cdc37 as solved by NMR.5
Figure 1.3: Celastrol binds to Cdc37. The cell division cycle protein 37 (Cdc37) and the
heat shock protein (Hsp90) are molecular chaperones, crucial for the folding and stabilization of
protein kinases including the oncogenic kinases. Here we show by NMR that celastrol, a recently
identiﬁed triterpene targeting Hsp90, in fact binds to Cdc37 and disrupts the Cdc37-Hsp90
complex. Celastrol inactivates Cdc37 through a thiol-mediated mechanism. For more details see
Chapter 8.
Achievements:
 Discovery of Cdc37 as the right target for celastrol within the protein-protein
(Cdc37-Hsp90) complex by NMR
 Establishment of the exact mechanism of interaction between celastrol and
Cdc37 by NMR
 Revelation that the N-terminal and the Middle domain of Cdc37 are responsi-
ble for the binding of celastrol
 Importantly, this study will shift the focus of the medicinal chemistry efforts
towards the correct target within the protein-protein complex.6 Chapter1. Overview and Summary
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Structural Proteomics: An Overview
2.1 Introduction
S
uccessful completion of the Human genome sequencing has opened
up new avenues in the ﬁeld of biology and medical sciences [Lander
et al., 2001; Venter et al., 2001]. This achievement was considered and foreseen
to revolutionize and reveal new treatment strategies for diseases and broaden
our understanding of Biology. Forgotten however, has been the fact that these
meager complete sequences (three billion bases), does not per se mean anything,
unless they are given a meaning, by ﬁguring out the proteins that these genes
encode and what they do for a living. Further, understanding how these proteins
collaborate (protein-protein interaction) with each other, in order to carry out the
complex cellular events, is the real challenge ahead. Hence, we move from the
completion of ‘Genome’ towards the task of completing the ‘Proteome (Structural
genomics/Structural proteomics)’ [Fields, 2001].
Unlike genomics, proteomics comes with much more bigger challenge, due to the
fact that proteins are much more versatile than nucleic acids. A single gene can code
for multiple proteins and further these proteins can undergo modiﬁcations (such
as phosphorylation, glycosylation, acetylation, ubiquitation) or a single protein
can have different functions under different physiological conditions or multiple
proteins could also do the same function. All these arguments imply that the human
proteome will be an order of magnitude more complex than the genome. Hence,
the task ahead needs a conﬂuence of scientists from various disciplines, from
geneticists, biochemist to structural biologists. The last two decades, the pre-
proteomic era, have witnessed characterization of thousands of proteins, which is
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a result of the conﬂuence of scientists from various disciplines, advancements in
technology to study these proteins involved in cellular processes and also a result
of conservation of fundamental mechanisms between the organisms. In comparison
to traditional biological research which was mainly based on speciﬁc models of
cellular behavior, proteomics aims at more systematic studies.
In the post human genome era it was envisaged that, in analogy to sequencing
(genomics), structural genomics is deﬁned as the determination of the three di-
mensional structures of all the proteins coded by a genome. The successful use of
high-throughput sequencing methods now encouraged to use the same technology
to solve the three dimensional structures of proteins. But solving the structures
of all proteins is an impractical goal because many of the proteins are not still
amenable to puriﬁcation, in a form suitable for structure determination or in fact
are inherently unstructured. Hence different organizations across the world deﬁned
their structural genomics goals and started a focused research in achieving those
targets.
2.2 Global structural efforts and target selection
strategies
In the mid-to-late 1990s in both Japan and USA, the concept of structural genomics
was already taking birth, encouraged by the success of the use of High-throughput
(HTP) sequencing methods for sequencing the genome. It was envisaged that
similar application of HTP could even be used to achieve the three-dimensional
structures of substantial fraction of proteins of a given organism [Kobe et al., 2008;
Sussman and Silman, 2003].
2.2.1 Japan
In October, 1998, the Protein Research Group was established at the RIKEN Genomic
Sciences Center in Japan. Since its establishment it has elucidated the structures and
functions of many important proteins. In 2002, the Ministry of Education, Culture,
Sports, Science and Technology (MEXT) started this national project to obtain
deep insight into the biological network by solving over 3,000 protein structures
(“National Project on Protein Structural and Functional Analyses” (the “Protein
3000” Project, 2002-2006) and determining functions of biological and medical
importance. While almost 90 laboratories in universities and research institutions2.2. Global structural efforts and target selection strategies 9
joined this project, the RIKEN Structural Genomics/Proteomics Initiative (RSGI)
conducted systematic and comprehensive research to elucidate protein structures
and functions at the RIKEN Genomic Sciences Center and the SPring-8 Center. RSGI
chose primary protein targets which were involved in signal transduction, nucleic
acid binding and were of medical importance from various species like humans,
mice, and Arabidopsis thaliana. In March 2007, “ Project 3000” was declared
over and aim achieved with RSGI solving about 2500 protein structures and 500
structures coming from other research centers across Japan. Currently, Systems and
Structural Biology Center (SSBC) established in April, 2008, is moving forward with
all the experiences gained from the previous projects in order to solve the structures
of more complex proteins. RIKEN through Systems and Structural Biology Center
(SSBC), aims to build a bridge between life science and medical science, to expand
the logical design of biomolecular mechanisms and to increase predictability in life
science.
2.2.2 United States of America (USA)
On April 24, 1998, a one day meeting (as a follow up of larger meeting held in the
same year at Argonne National Laboratory) was held to discuss issues related to a
genome-directed Protein Structure Initiative (PSI) and ﬁnally in 2000, the Protein
Structure Initiative (PSI) was started and funded together by the National Institutes
of Health (NIH) and National Institute of General Medical Sciences (NIGMS). The
main aim of this structural genomics initiative was the structure determination of
a representative from every possible protein fold or motif. The total number of
different folds varies between 1000 to nearly 10,000, spread across various species;
hence the structures of these projects would come from different genomes. The
structure with respect to one protein fold from one organism would then be used
to model related structures in other organisms by homology modeling. To discover
all protein folding motifs, it is estimated that on the order of 3,000-5,000 new
protein structures must be determined experimentally. PSI is a 10 year project which
will be implemented at different phases. PSI phase I (PSI-1 or also known as Pilot
phase) was initiated in year 2000 and 2001, were conducted in nine centers, and
were completed in 2005, with more than 1300 structures having been deposited in
the PDB. Among this more than 700 structures had less than 30 percent sequence
identity. All-in-all PSI-1 achieved its purpose of developing new tools, technologies
and methodology to increase the success rates and lower the costs of structure
determination. Phase II (PSI-2) studies were immediately started with a goal of
producing 4000 new structures within ﬁve years. Within two years of operation10 Chapter2. Structural Proteomics: An Overview
PSI-2 deposited 1200 structures in the PDB, thus surpassing ﬁve-year combined
production output of the PSI-1. Currently, PSI-2 is still continuing with the aim
basically the same as PSI-1, but with more focused and clearly deﬁned objectives in
order to attain its overall goal.
2.2.3 North America
In 2003, a major joint venture between government and industry resulted in the
establishment of the Structural Genomics Consortium, an international project
funded by governments of Canada and Sweden, the Wellcome Trust in the UK
and industries, with laboratories in Oxford, Stockholm and Toronto. The Structural
Genomics Consortium (SGC) is a not-for-proﬁt organization that aims to determine
the three dimensional structures of proteins of medical relevance, and place them
in the public domain without restriction. It focused on proteins and protein families
from human and apicomplexan (e.g. Plasmodium falciparum which causes malaria)
that are either potential drug targets or have been implicated in human disease
processes. In the period from July 2004 to June 2007, the SGC deposited the
structures of 450 proteins from its Target List of 2,000 proteins, to achieve a
deposition rate of 200 structures per year. SGC’s areas of interest include proteins
of signaling pathways, protein kinases and human cytosolic sulfur transferases. The
consortium has solved more than 80 novel human kinase structures till date. SGC
has also studied a total of 1008 genes from P. falciparum and has resulted in the
determination of more than 36 structures. The results are now being actively applied
for the development of vaccines and small molecule therapeutics. Currently, it has
deposited 716 structures out of 4594 targets, and the rest are in the different stages
of structure determination.
2.2.4 Structural proteomics in Europe (SPINE)
On 1st October, 2002, SPINE was started as a three-year project funded by the
European Union Fifth Framework Program (EU FP5) [Stuart et al., 2006]. Unlike
all the previous structural genomics programs, SPINE was named differently as
Structural Proteomics program in order to differentiate itself from others. The
selection of targets was driven by the motto “human health targets”. It aimed
mainly at solving proteins and protein complex structures directly relevant to
human health and diseases. SPINE aimed at developing technologies for HTP
structure determination both by X-ray and NMR involving proteins and protein
complexes from eukaryotes and prokaryotes. Apart from trying to establish2.2. Global structural efforts and target selection strategies 11
European centers of Excellence it also aimed at training young scientists and
technicians to take part in the above program. SPINE chose its targets mainly
in two phase, ﬁrst involving identiﬁcation of targets with possible biomedical
importance, and the second being an assessment of whether the target is
amenable for structural studies. SPINE produced 375 structures of which 308
were unique proteins and the rest were protein-ligand complexes. It should not
be forgotten that one of the challenging aspects of SPINE project was to focus
on Human and other eukaryotic proteins that are potentially of high biomedical
importance. A signiﬁcant high number of 170 structures solved by SPINE come
from eukaryotic origin. Current version of SPINE is SPINE2-complexes funded by
the European Union Framework 6. The full title of the project is “From Receptor
to Gene: Structures of complexes from signalling pathways linking immunology,
neurobiology and cancer”. It aims to focus mainly on protein-protein and protein-
nucleic acid complexes of biomedical importance. Frankfurt has been a member of
SPINE and SPINEII as subcontractor. In this thesis, we focus our study on proteins
related to cancer viz., protein kinases (protein kinase A (PKA)) and human Hsp90-
Cdc37, a kinome chaperone-cochaperone complex.
In summary, whatever was the individual aim of different Structural ge-
nomics/Structural proteomics (SG/SP) program throughout the world, they
have made and continue to make a major contribution to the development of
technology for all aspects of structural biology ranging from identiﬁcation of target
genes to reﬁnement of structures using X-ray and NMR. Table 2.1 summarizes the
list of Major Structural Genomics Organizations along with their target selection
criteria. Table 2.2 summarizes the overall achievement by the SG/SP collectively
throughout the world.
Table 2.1: List of major structural Genomics programs
Consortium Target Selection Criteria
1 Protein Structure Initiative, USA Structure determination of a representative of every
possible fold
2 Project 3000, Japan Novel sequences and biologically important or
human health related
3 Structural Genomics Centers, Canada, Sweden, UK Human proteins related to diseases and human
pathogens
4 Structural Proteomics in Europe (SPINE), UK Human health related proteins (cancer-related
proteins, Immune defense, neuronal development
and neurodegenerative diseases)12 Chapter2. Structural Proteomics: An Overview
2.3 Role of NMR in structural proteomics
Nuclear Magnetic Resonance (NMR) is a powerful tool to determine structures
of proteins in solution at atomic resolution. It neatly complements X-ray crystal-
lography, as many of the proteins do not produce diffraction quality crystals and
thus they are solely amenable to be determined by NMR [Sussman and Silman,
2003]. Noteworthy is the fact that NMR can be equally used for both eukaryotic
and prokaryotic proteins, while eukaryotic proteins crystallize less frequently than
prokaryotic proteins. As of March 6, 2009, there are about 1748 structures solved by
NMR within the Structural proteomics program throughout the world, as compared
to 6477 total structures solved. This attests the fact that nearly 27 % (Figure 2.1)
of the total structures solved comes from NMR. The success and importance of NMR
as a structure determination tool, is also due to the fact that there is no correlation
between the ‘crystallisability’ and the quality of its 2D 1H,15N HSQC NMR spectrum,
which shows one signal for each amino acid residue. Hence many proteins giving
rise to a high quality NMR spectra do not produce diffraction quality crystals and
vice versa.
Figure 2.1: Structural proteomics
contribution by X-ray and NMR. Protein
structure production by X-ray or NMR for all
Structural Proteomics Centers in the world
(March 2009). 1748 structures has been solved
by NMR from a total of 6477 solved. Data
obtained from http://targetdb.pdb.
org/statistics/TargetStatistics.html
(March2009) also see Table 2.2.
Currently, HTP high-quality NMR structural determination is limited to proteins of
molecular weights less than 25 kDa. This is because NMR lines increasingly broaden
when the overall tumbling of a protein slows down with increasing molecular
weight, while the number of resonance lines concomitantly increases with size. HTP
NMR structure determination involves preparation of 13C/15N-labeled proteins,
rapid acquisition of NMR data, (semi-) automated data analysis and structure
calculation and ﬁnally structure validation. The expression of labeled proteins
for HTP is now being achieved either by heterologous expression in E. coli cells
[Acton et al., 2005; Lundstrom, 2007; Yee et al., 2006], wheat-germ based cell-free
expression [Kigawa et al., 2004; Tabb et al., 2002; Vinarov et al., 2006] and also
recently developed cell-free protein expression using E. coli cell extract [Kigawa
et al., 2004]. Rapid NMR data acquisition is mainly aimed at “sensitivity limited2.3. Role of NMR in structural proteomics 13
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data acquisition regime” in which the instrument time is invested only to the extent
that the signal-to-noise ratios of most peaks reach reliable peak identiﬁcation. The
techniques like G-matrix Fourier Transform (GFT) NMR spectroscopy [Kim and
Szyperski, 2003], simultaneously acquired 13C/15N resolved NOESY [Shen et al.,
2005], L-optimization (Longitudinal relaxation optimization) have now signiﬁ-
cantly reduced the time of data acquisition [Pervushin et al., 2002]. (Semi-) Auto-
mated data analysis and structure determination for HTP structural determination
uses program like AUTOASSIGN [Huang et al., 2005], CYANA [Güntert, 2003] and
AUTOSTRUCURE [Huang et al., 2006].
2.4 Protein Data Bank (PDB) statistics for structures
solved by NMR
Recent technological advances in NMR have made it possible to contribute
signiﬁcantly to the structure determination of proteins. One of the major limitations
of structure determination by NMR is the molecular weight of proteins. Here we
summarize (Figure 2.2, Table 2.3) the current status of the protein data bank with
respect to structures solved by NMR, correlating it with the molecular weight.
PDB Current Holdings 
Breakdown
(March 2009)
NMR structures based on Molecular weight
(March 2009)
Figure 2.2: PDB statistics. The above picture summarizes the number of structures
contributed by diﬀerent experimental techniques. It also gives a detailed picture of the
correlation between molecular weight and number of structures solved by NMR. In
this thesis, we study the protein-protein complex (Hsp90-Cdc37) which has a molecular
weight of 39 kDa. Data obtained from http://www.rcsb.org/pdb/static.do?p=general_
information/pdb_statistics/index.html (March2009) also see Table 2.3.2.4. Protein Data Bank (PDB) statistics for structures solved by NMR 15
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Importance of Study of Various Protein Families of
Biomedical Relevance
3.1 Introduction
P
roteins perform multiple crucially important functions. They are involved
in almost every aspect of biological activity and process, ranging from
providing mechanical support viz., actin and myosin from contractile machinery to
more complex cellular process viz., signal transduction pathways involving kinases,
phosphatases, surface receptors.
The human genome is estimated to encode 30,000 to 40,000 proteins from a
relatively low number of genes encoding proteins [Venter et al., 2001]. Only 1.1
to 1.5 percent of the human genome encodes proteins. Computational analysis of
the predicted protein-coding sequences shows that over 40 percent of the proteins
cannot be ascribed a molecular function by methods that assign proteins to known
families and hence termed as ‘Unknown function’. Identiﬁcation of these unknown
families will be a major focus for many laboratories. Major classes of proteins
encoded by human genome are graphically represented in Figure 3.1.
Advances in molecular genetics reveal that human diseases are mostly dictated
by the changes in one or more of these proteins. Hence, an important goal of
molecular medicine is to identify such proteins whose presence, absence, or
deﬁciency is associated with speciﬁc physiologic state or disease. A classic example
is cystic ﬁbrosis, an inherited condition which involves the protein cystic ﬁbrosis
transmembrane conductance regulator (CFTR). In 65 % of reported cases a deletion
of single amino acid (phenylalanine) at position 508 in the 1500 residue protein
1718 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
Unknown, 12809, 41.7%
Nucleic acid enzymes, 2308, 7.5%
Transcription factors, 1850, 6.0%
Receptors, 1543, 5.0%
miscellaneous, 1318, 4.3%
Hydrolases, 1227, 4.0%
Select regulatory molecules) (eg, 
G proteins, cell cycle regulators, 
988, 3.2%
Protooncogenes, 902, 2.9%
oxidoreductase, 656, 2.1%
transferase, 610, 2.0%
Cell adhesion, 577, 1.9%
transporter, 533, 1.7%
extracellular matrix, 437, 1.4%
ion channel, 406, 1.3%
signalling molecule, 376, 1.2%
motor, 376, 1.2%
intracellular transporter, 350, 
1.1%
sythase and synthetase, 313, 
1.0%
structural protein of muscle, 296, 
1.0%
immnuoglobin, 264, 0.9%
transfer/carrier protein, 203, 0.7%
isomerase, 163, 0.5%
viral protein, 100, 0.3%
ligase, 56, 0.2%
select calcium binding protein, 
34, 0.1%
Kinases, 868, 2.8%
Cytoskeletal structural proteins, 
876, 2.9%
Chaperones, 159, 0.5%
lyase, 117, 0.4%
Figure 3.1: Molecular functional distribution of human genome. Distribution of the
molecular functions of human genes. Each slice lists the number and percentages of human gene
functions assigned to a given category of molecular function [Venter et al., 2001].
results in the disease. A change from glutamic acid to valine of the sixth amino
acid out of 574 amino acids in haemoglobin results in the disease sickle cell
anemia. Study of proteins and also protein-protein interaction during the signal
transduction holds the key for understanding the etiology of many diseases viz.,
cancer (protein kinases, phosphatases, chaperones etc).
3.2 Cancer
One of the major challenges of the 21st century is to overcome the challenges
posed by the disease cancer [Lewis, 2006]. Cancer is uncontrolled proliferation
of cells that have lost their normal regulated cell division often in response to
genetic or environmental trigger. The development of cancer is a multistep and3.2. Cancer 19
multifactorial phenomenon, often requiring several years. The accumulation of the
basic knowledge from the past few decades has resulted in signiﬁcant progress in
understanding the molecular basis of cancer. Although the process of tumorigenesis
is incompletely understood, it is clear that successive accumulation of mutations
in key genes is the force that drives towards cancer. These mutations can occur as
either,
 a multistep step process due to aging and such tumor can be considered as
Darwinian evolution on a microscopic scale with each successive step over-
coming the social rules of a normal cell and hence called “clonal evolution”
[Nowell, 1976]
 exposure to carcinogens either physical or chemical agents [Hennings et al.,
1993]
 epigenetic changes viz., hypermethylation of adenomatous polyposis coli
(APC) gene in colon cancer [Slattery et al., 2001]
3.2.1 Molecular basis of cancer phenotypes [Abraham et al., 2003]
Differentiating the tumor cells from the normal cells is the key to understanding the
cancer cells and ultimately leads to therapies that can target tumor cells. Some of
the features are,
 Immortality: Cancer cells proliferate indeﬁnitely due to abnormal up-
regulation of telomerase activity. Hence, telomerase is a useful therapeutic
target. A second cause could arise from mutations in the Retinoblastoma
(Rb) [Zheng and Lee, 2001] and p53 genes which are responsible for tumor
suppressor activity.
 Decreased dependence on the growth factors to support proliferation: In
contrast to the normal cells which obtain their growth factors extracellularly,
the tumor cells produce their own growth factors. These growth factors then
bind to, and continuously stimulate the receptors present on the same tumor
cells, which results in autocrine stimulation (self-generated proliferative sig-
nal) that drives proliferation. Epidermal growth factor receptor (EGFR) plays
a major role in the progression of most human epithelial tumors [Salomon
et al., 1995].
 Loss of anchorage-dependent growth and altered cell adhesion: Tumor
cells in contrast to normal cells can grow even in suspensions or on semi-solid20 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
agar gels as they have lost the anchorage-dependent growth. This results in
migration of the tumor cells to invade and metastasize foreign tissues. The
detachment of the tumor cells from its parent tissue is driven by the enzymes
Matrix metalloproteinases (MMPs), which otherwise are absent in normal
adult cells. Hence, MMPs have become targets for developing inhibitors.
 Cell cycle and loss of cell cycle control: The cell cycle can be considered
as the heart of the proliferation. All events must be completed in a timely
and sequence speciﬁc fashion in order to function as a normal cell. It is a
complex process which involves many regulatory steps and signal transduction
pathways, which also harbor oncogenes and tumor suppressor genes. Cell
division is divided into four phases G1, S, G2 and M. Out of these, G1 is the
only nonreplicative phase or in other terms the resting phase and needs strong
presence of growth factors and nutrients in order to exit to the next phase. The
phase transition from G1 to S is tightly regulated, and is misregulated in
neoplastic cells resulting in uncontrolled proliferation. In this thesis, we study
one of the proteins (Cdc37) which is required for the passage of the G1 phase of
the cell cycle and is implicated as target for developing therapeutics [Reed, 1980].
 Apoptosis and reduced sensitivity to apoptosis: Apoptosis is a genetically
controlled form of cell death required to maintain the correct number of cells
in adult life. Any imbalance in this process will also lead to uncontrolled
proliferation of cells. Hence, identifying and understanding apoptotic process
will give new targets for therapeutic manipulation. Examples include Tumor
Necrosis Factor Receptor 1 (TNFR1) and several other downstream proteins
involved in the signal transduction pathway [Chen and Goeddel, 2002]. Bcl-2
(B-cell lymphoma-2), which is overexpressed in cancer cells and has become
an important target for developing drugs [Zamzami et al., 1998].
 Increased genetic instability: The gain or loss of one or more speciﬁc
chromosomes results in genetic instability, which is a hallmark of cancer
cells. Acquisition of extra chromosome is one mechanism by which extra
copies of a growth promoting gene can be acquired by the tumor cells,
providing them the selective growth advantage. One example is Philadelphia
chromosome, which results from the translocation of chromosome 9 and
22. Two genes (c-Abl and Bcr, a tyrosine kinase and a GTPase activating
protein (GAP)) of completely unrelated proteins are spliced together, forming
a chimeric protein that results in powerful and constitutively active kinase that
drives proliferation [Stam et al., 1985].3.2. Cancer 21
 Angiogenesis: Lack of blood vessels will restrict the growth of tumor cells to
only a few millimeters. The hypoxic environment created inside the tumor
cells upregulates the expression of the transcription factor HIF1(Hypoxia
Inducible Factor) which is kept at a very low concentrations by the presence
of VHL tumor suppressor protein in normal cells. HIF1 along with Vascular
Endothelial Growth Factor (VEGF), in conjunction with other cytokines, pro-
motes neovascularization of tumors, allowing them to overcome the oxygen
diffusion and grow bigger in size. VEGF has become a clinically valid thera-
peutic drug target in suppressing tumor [Ferrara, 2001; Folkman, 1971].
3.2.2 Oncogenes as therapeutic targets [Croce, 2008]
Table 3.1 contains a summary of the targets and drugs (small molecules and
monoclonal antibodies) being used in the treatment of a variety of human cancers.
Table 3.1: Summary of cancer targets and drugs
Anticancer Drug Target Disease
Monoclonal antibodies
Trastuzumab (Herceptin, Genentech) ERBB2 Breast cancer
Cetuximab (Erbitux, ImClone) EGFR Colorectal cancer
Bevacizumab (Avastin, Genentech) VEGF Colorectal cancer, non-
small-cell lung cancer
Small molecules
Imatinib (Gleevec, Novartis) ABL, PDGFR, KIT Chronic myelogenous
leukemia,
gastrointestinal stromal
tumors, chordoma
Geﬁtinib (Iressa, AstraZeneca) EGFR Non-small-cell lung can-
cer
Erlotinib (Tarceva, Genentech) EGFR Non-small-cell lung can-
cer
Sorafenib (Nexavar, Bayer/Onyx) VEGFR, PDGFR, FLT3 Renal cell carcinoma
Sunitinib (Sutent, Pﬁzer) VEGFR, PDGFR, FLT3 Gastrointestinal stromal
tumors, renal-cell carci-
noma22 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
3.3 Protein Kinases
The enzymes carrying out phosphorylation reactions are called protein kinases
(Figure 3.2). Protein kinases are vital for many regulatory cellular processes such as
cell division, growth and death. These enzymes transfer phosphate from adenosine
triphosphate (ATP) onto target proteins, thereby activating or deactivating them.
Enz- Ser/Thr/Tyr OH Enz- Ser/Thr/Tyr O PO3
2-
ATP
Mg2+
ADP
KINASE
Figure 3.2: Protein kinases. Covalent modiﬁcation of a regulated enzyme by phosphorylation
of either serine, threonine or tyrosine residues.
3.3.1 Classiﬁcation of the kinome superfamily [Hanks and
Hunter, 1995; Sowadski and Epstein, 2000]
There are three major classes of protein kinases with differing protein targets:
1. Serine/Threonine protein kinases transfer a phosphate from ATP to a serine
or threonine residue in the target protein and are generally associated with
cytoplasmic signaling events. Example: Protein kinase A (PKA)
2. Protein tyrosine kinases transfer phosphate from ATP to tyrosine residues in
the target protein and are generally associated with cell surface receptors that
become activated after binding a growth factor or other ligand. Example: BCR-
ABL kinase
3. Dual speciﬁcity protein kinases transfer phosphate from ATP to both threonine
and tyrosine residues of the target protein. This group of protein kinases is
small in number. Examples: ERK1 and ERK2.
Another classiﬁcation of protein kinase superfamily is based on the structure and
function. The sole consideration in this type of classiﬁcation was similarity in kinase
domain amino acid sequence. Accordingly four groups were designated:
1. the AGC group, which includes the cyclic-nucleotide-dependent family (PKA
and PKG), the protein kinase C (PKC) family, the -adrenergic receptor kinase
(ARK) family, the ribosomal S6 kinase family and other close relatives.3.3. Protein Kinases 23
2. the CaMK group, which includes the family of protein kinases regulated by
calcium/calmodulin, the Snf1/AMPK family and other close relatives.
3. the CMGC group, which includes the family of cyclin-dependent kinases, the
Erk (MAP) kinase family, the glycogen synthase 3 (GSK3) family, the casein
kinase II family, the Clk (Cdk-like kinase) family and other close relatives.
4. the ‘conventional’ protein-tyrosine kinase (PTK) group.
3.3.2 Structural analysis of cAMP-dependent protein kinase
(PKA) and major classes of protein kinases [Sowadski and
Epstein, 2000]
Three-dimensional structures of the catalytic domains of serine/threonine
and protein tyrosine kinase family members have been solved by protein
crystallography. Comparison of both structural and sequence data of these kinases
allows us to deﬁne some common structural elements for all kinases. Figure 3.3
illustrates a representative from each subfamily for which structural data is
available.
Protein kinase A (PKA) is the ﬁrst kinase for which complete backbone NMR assign-
ment was achieved in our laboratory [Langer et al., 2004]. PKA is the ﬁrst kinase for
which crystal structure (catalytic domain) was solved [Knighton et al., 1991], since
then all the kinase structures solved till date carry the same architecture, consisting
of two lobes linked by a short peptide. The upper lobe consists of ﬁve antiparallel
-strands and helix C. The lower lobe consists of the substrate binding site and is
predominantly -helical. ATP binds in the deep cleft between the lobes. Figure 3.4
shows ribbon diagram of cAPK and its various subdomains. The overall topology of
the protein kinase catalytic domain, extending from -strand 1 through helix H, is
highly conserved (except helices A and B) among all other reported structures of
protein kinases and can be divided into the following subdomains:
 Phosphate anchor: Helix A is connected to -strand 1, followed by the phos-
phate anchor, encompassing the signature motif Gly50-X-Gly52-X-XGly55. The
phosphate anchor forms several hydrogen bonds with oxygens of the - and

-phosphates of ATP and is followed by -strand 2.
 Nucleotide binding motif: -strand 2 is followed by - strand 3, carrying
invariant Lys72, which binds oxygens of the - and -phosphates of ATP. Three
antiparallel -strands create the unique fold of the nucleotide binding site of24 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
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.3.3. Protein Kinases 25
protein kinases. -Strand 3 is followed by helix B (present only in cAPK), helix
C, and -strands 4 and 5.
 Helix C: In most of the protein kinase structures helix C shows the largest
displacement. The salt bridge between the Glu91 and Lys72 is also conserved
in most kinases, except for the inactive cyclin dependent protein kinase (Cdk2)
structure, but present in the crystal structure of its complex with an activator
cyclin A.
 Linker: The N- and C- lobe are connected by a linker. This portion of the
structure provides two main-chain hydrogen bonds to the 6-amino and N1
positions of the ATP adenine ring. The last residue of the linker Glu127 forms
a hydrogen bond with the 2’OH of ATP. Interesting fact is that the  and 
of the main chain of this linker region vary among different protein kinases,
reﬂecting displacement in the upper domain with respect to the lower. This
region also gives the conformational plasticity for the nucleotide binding
event.
 Catalytic loop: This loop connects the -strands 6 and 7 and harbors the
crucial set of residues required for the catalytic activity of the enzyme, starting
with Tyr164 and Arg165. Tyr164 forms a hydrogen bond with the conserved
Asp220 and Arg165 present in most of protein kinases, provides two hydrogen
bonds to the oxygen of the Thr197 phosphate. The conserved catalytic base
Asp166 and Asn171, the ligand to one of the metal sites, are located within
this loop. Ser/Thr and Tyr kinases show sequence diversity in this region. In
Ser/Thr kinases the Lys168 interacts with the 
-phosphate of ATP during
catalysis. In Tyr kinases this role of Lys is replaced by Arg, exempliﬁed by
Arg1136 in the crystal structure of Insulin receptor tyrosine kinase (InsR).
 Activation loop: The catalytic loop and -strand 7 are followed by -strand
8 and the conserved Asp184-Phe185-Gly186 (DFG) motif. The conserved
Asp184 forms co-ordinate complex with metal ion (Mg2+). This motif is fol-
lowed by -strand 9 and the activation loop with Thr197. Phosphorylation of
Thr or Tyr in the activation loop is often critical for activation of many protein
kinases. This is central for binding substrates with Ser or Tyr containing
protein kinases. The phosphorylation state of the activation loop is critical
for the substrate binding. Followed by the activation loop is the P+1 loop (P=
substrate P (Phosphorylation) site), which has the P+1 site of the substrate, a
critical speciﬁcity determinant for substrate recognition. The sequence PxxWx26 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
in this domain is conserved in tyrosine kinases and is responsible for speciﬁcity
of PTK versus Ser/Thr protein kinases.
 Structural pair Glu208-Arg280: The stabilization and positioning of the P+1
loop with respect to the C-lobe of protein kinase is brought by Glu208-Arg280
pair.
 C-terminal domain: This part of the kinase is composed of the helix F-J. This
part of the molecule undergoes large motional changes during the binding
events.
All of the above structural features are summarized pictorically in Figure 3.4.
3.3.3 Substrate speciﬁcity: How does a kinase recognize its
substrate?
All kinases transfer 
-phosphate from ATP either to Ser/Thr/Tyr of the substrate,
and hence recognition of speciﬁc substrate is vital for efﬁcient signal transduc-
tion. This recognition is accomplished at several stages viz.,
1. colocalization of the kinase and substrate in the same cell compartment
2. protein-protein interaction module
3. primary amino acid sequences near to and distant from the phosphorylation
site (P site).
3.3.4 Mechanism of regulation of protein kinase activity
Protein kinases play a vital and important role in the cellular signal transduction
process. The switching ON/OFF of various protein kinases is vital for the proper
functioning of the cell, this is regulated by various mechanisms viz.,
 Regulation by subunits: cAPK in its inactive state exists as a tetrameric
holoenzyme complex (R2C2) with its regulatory subunit (R) and catalytic
subunit (C). Binding of cAMP releases the monomeric active cAPK. Other
examples include CDK2 by cyclin A.
 Regulation by domains: Ca2+/calmodulin-dependent kinase is activated by
Ca2+-calmodulin binding to the C-terminal tail of the kinase. In the absence
of Ca2+-calmodulin, the tail blocks the substrate and ATP binding site and
illustrates a autoinhibitory mechanism.3.3. Protein Kinases 27
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Figure 3.4: Structural architecture of a typical protein kinase. The Catalytically
Active Conformation of the Protein Kinase A(Top) The crystal structures of protein kinase A
(PDB:1ATP, PKA, a serine/threonine kinase) [Zheng et al., 1993]. Key structural elements
within the kinase domain are colored and labeled. The PKI peptide inhibitor for PKA is
colored yellow. Bound nucleotide and several absolutely conserved residues within the active
site are indicated. (Bottom) The above structure has been schematized to clearly depict the
conformational transitions involved in the regulation of kinase activity, with particular emphasis
on the helix C and activation loop. The catalytic lysine and glutamate (Lys72 and Glu91 in PKA)
are shown schematically. The schematic representation reproduced from Huse and Kuriyan [2002].28 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
 Regulation by phosphorylation of the activation loop: Phosphorylation of
the Ser/Thr/Tyr residues within the activation loop of many kinases results
in conformational changes in the protein leading to activated state of the
protein. These include Cdk2, ERK2, src, hck, lck etc.
3.3.5 Oncogenic kinases in cancer
A cell can follow many paths to malignancy. The origin of cancer lies in the
genetic material of the cell. Up to 20 % of the 32,000 human genes sequenced and
among these are more than 520 kinases [Blume-Jensen and Hunter, 2001]. Most
of cellular signalling involves these kinases and their deregulation in human cancer
can initiate or alter signals that eventually lead to cell proliferation and transforma-
tion. Transmembrane (e.g. EGFR, PDGFR) or cytoplasmic (Src, Abl) tyrosine kinases
are found mutated in a variety of human tumors. Cytoplasmic serine threonine
kinases (Raf, Akt, Tpl-2) are also mutated or activated in several types of human
malignancies. Kinases transduce signals that lead to cell proliferation or inhibition
of programmed cell death by activating transcription factors (e.g. AP1, NFkappaB,
Myc), inhibiting pro-apoptotic molecules (e.g. Bad, Bax), or they participate in
deregulating the cell cycle control. The involvement of kinases in vital signaling
events renders them valuable targets for therapeutic intervention in human cancers
[Blume-Jensen and Hunter, 2001].
3.3.6 NMR studies on protein kinases
“A picture is worth a thousand words.” While this is true undoubtedly for all the
protein structures that have been solved by either X-ray crystallography or NMR
spectroscopy, but these static three-dimensional structures does not clearly explain
the functional biological enzymatic reactions nor is useful for rational drug design
[Kay, 1998]. Specially in case of protein kinases which has a large similarity in
amino acid sequence, the three-dimensional structures provide important snapshots
of different states, but fails to provide the underlying much important dynamic
process. The speciﬁcity of their function is mostly dictated by small differences in
the primary sequence and subtle changes in the overall conformation of the protein
occurring as a result of activation by phosphorylation or substrate binding. Studying
this dynamic process at atomic resolution with respect to time is the key for
elucidating a clear mechanism for biological function, protein engineering and
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NMR allows monitoring of a wide variety of such motional process [Jarymowycz
and Stone, 2006]. Methods like relaxation analysis, residual dipolar couplings has
been used to study these challenging protein kinases, as the catalytic domains
become accessible for NMR.
Table 3.2 provides a comprehensive list of protein kinases (either free or in
complex) studied by various parameters of NMR spectroscopy viz., backbone
assignment (a prerequisite for studying dynamic process by NMR), relaxation
studies, and residual dipolar couplings.
Table 3.2: Comprehensive list of published NMR backbone
dynamic studies on various domains of human protein kinases
NMR experiment Protein Form (free/bound) Reference
Complete or partial
backbone assignment of
human protein kinases
ABL kinase Bound to inhibitors
(imatinib, nilotinib,
and dasatinib)
[Vajpai et al., 2008]
cAMP-binding domain A of the PKA
regulatory subunit
free [Esposito et al., 2006]
mTOR domain responsible for ra-
pamycin binding
free [Veverka et al., 2006]
F-actin binding domain of human
Bcr-Abl/c-Abl
free [Wiesner et al., 2005]
Apo and peptide bound state of
SH2 domain of Rous sarcoma viral
protein Src
Free and bound
(peptide)
[Taylor et al., 2005]
Mitogen-activated protein (MAP) ki-
nase p38
free [Vogtherr et al., 2005]
SH2 domain of human feline sar-
coma oncogene FES
free [Scott et al., 2004]
Catalytic subunit of cAMP-
dependent protein kinase A
free [Langer et al., 2004]
SH3-SH2 domain pair from the
human tyrosine kinase
free [Schweimer et al., 2003]
Partial assignment of cAbl kinase free [Strauss et al., 2003]
Pleckstrin homology domain of hu-
man protein kinase B (PKB/Akt)
free [Auguin et al., 2003]
SH2 domain of the Csk (C-terminal
Src kinase) homologous kinase
free [Mulhern et al., 2002]
SH3 domain of phosphatidylinositol
3-kinase (PI3K) and D21N-mutant
free [Okishio et al., 2001]
Hck SH2 domain free [Zhang et al., 1997]
SH3 domain of human p56 Lck
tyrosine kinase
free [Hiroaki et al., 1996]
SH2 domain from Fyn tyrosine
kinase
free [Pintar et al., 1996]
SH2-SH3 domain of Abl kinase free [Gosser et al., 1995]
Relaxation studies of fast
backbone dynamics in
proteins
Receptor tyrosine kinase ephrin-BS
ectodomain
free [Ran et al., 2008]30 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
Table 3.2: (continued...)
NMR experiment Protein Form (free/bound) Reference
ABL kinase Bound to inhibitors
(imatinib, nilotinib,
and dasatinib)
[Vajpai et al., 2008]
Receptor tyrosine kinase ErbB2 free [Bocharov et al., 2008]
MARK3-UBA domain free [Murphy et al., 2007]
Phosphatidylinositol 3-kinase (PI3K)
SH3 domain
free [Ahn et al., 2006]
SH3 domains of drkN and mutant
Fyn
free [Bezsonova et al., 2006]
Pleckstrin binding domain of the
human protein kinase B (PKB/AKT)
free [Auguin et al., 2004]
Abl SH3 domain and crk SH2
domain
Free [Donaldson et al., 2002]
Backbone motions in ligand binding
to c-Src SH3 domain
Free and bound [Wang et al., 2001]
Residual dipolar
couplings (RDCs)
SH2 domain of Syk protein-tyrosine
kinase
Free [Zhang et al., 2008b]
ABL kinase Bound to inhibitors
(imatinib, nilotinib,
and dasatinib)
[Vajpai et al., 2008]
p38 MAP kinase-SB203580 Free and bound [Honndorf et al., 2008]
Coiled-coil domain of cGMP depen-
dent protein kinase I
free [Schnell et al., 2005]
SH3-SH2 domain orientation in Src
kinase Fyn
free [Ulmer et al., 2002]
3.4 Heat shock protein of 90 kDa (Hsp90)-a kinome
chaperone
Cancer cells are characterized by unregulated cell division often promoted by
protein kinases. Therefore, protein kinases are often targeted by small molecule
inhibitors, albeit with the problem of insufﬁcient target selectivity due to the high
sequence similarity between different kinase family members. As alternative route,
drugs that inhibit the molecular chaperone Hsp90 are currently in clinical trials
due to their ability to promote degradation of many kinases. In this section we will
review more about Heat Shock Proteins in general and more about Hsp90, and also
address how its function in cancer cells differs from healthy cells.
3.4.1 Introduction
Cells under normal physiological conditions are under perfect state of equilibrium,
which allows it to function normally and is termed as homeostasis. Exposure of
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metals, hypoxia and acidosis) causes an alteration in the homeostatic condition
of the cells. In order to maintain homeostasis, cells produce a small group of
proteins that are collectively called as ‘heat-shock’ or stress proteins [Leppä and
Sistonen, 1997]. Most of these heat shock proteins are actually proteins that
prevent improper associations and assist in the correct folding and maturation
of other cellular proteins and there by called as ‘molecular chaperones’ that
guard the cell. Their basal level expression helps the normal protein folding and
guards the cell from the dangers of protein misfolding and aggregation [Wegele
et al., 2004]. Their increased expression is an adaptive response to enhance cell
survival. Both these functions are needed in tumors and reﬂect the fact how
malignant cells are able to survive in hostile environment. These chaperones also
allow the tumor cells to tolerate mutations in the key signaling proteins, which
is lethal and drive oncogenesis [Jolly and Morimoto, 2000]. Chaperones also
impart many other physiological functions [Whitesell and Lindquist, 2005] and are
schematically summarized in Figure 3.5.
The molecular chaperone Heat shock protein of 90 kDa (Hsp90) in particular
has been identiﬁed as a potential anti-cancer target as it allows mutant proteins
to retain function hence allowing the cancer cells to tolerate the lacunae in
signaling created by such oncoproteins [Whitesell and Lindquist, 2005]. Hsp90
is an abundant and essential protein, accounting for 1-2 % of the total protein
amount in unstressed eukaryotic cells. A 2 to 10 fold higher expression level of
Hsp90 is found in cancer cells and virally transformed cells [Ferrarini et al., 1992;
Welch and Feramisco, 1982; Yufu et al., 1992], suggesting a crucial role of Hsp90
for growth and/or survival of tumor cells. Hsp90 is a protein chaperone that helps a
variety of client proteins to adopt their native conformation. Several co-chaperones
such as Hop/Sti1, FKBP52, cyclophilin 40, and p50/Cdc37 are identiﬁed to be
associated with Hsp90. These co-chaperones are required for binding to diverse
client proteins and controlling the ATPase cycle of Hsp90 [Picard, 2002; Terasawa
et al., 2005; Wegele et al., 2004]. The important components of Hsp90-based
chaperone machinery are summarized in Table 3.3. The ATP-binding site of
Hsp90 is located in the N-terminal domain. Low molecular weight compounds that
interfere with ATP-binding such as geldanamycin or radicicol inhibit the Hsp90
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Figure 3.5: Role of molecular chaperones in regulating protein homeostasis. Newly
synthesized, conformationally labile client proteins associate with multi-protein complexes
that contain various chaperones, co-chaperones and accessory molecules (diﬀerent colored
shapes). The particular components of a complex vary according to the client and also help
specify the function of a particular complex. Dynamic association of a client with chaperone
complexes can prevent its aggregation (a) and assist in its intracellular traﬃcking, especially its
translocation across membranous structures such as the endoplasmic reticulum (ER) (b). For
many clients involved in signal transduction pathways, association with the chaperone machinery
maintains the protein in a meta-stable state that allows it to be activated by speciﬁc stimuli such
as ligand binding, phosphorylation or assembly into multisubunit signalling complexes (c). In the
absence of appropriate stimuli, chaperone complexes can target the client for degradation through
the ubiquitin–proteasome pathway, thereby regulating its steady-state cellular level (d). Figure
reproduced from Whitesell and Lindquist [2005].
3.4.2 Chaperone alteration in cancer
Both solid tumors and haematological malignancies are characterized by increased
level of expression of HSPs [Ciocca et al., 1993; Conroy et al., 1998; Kaur and
Ralhan, 1995; Kimura et al., 1993; Ralhan and Kaur, 1995; Santarosa et al.,
1997]. Hsp90 and its co-chaperones also modulate tumor cell apoptosis. Many of
the client proteins of Hsp90 are crucial elements of the cellular signal transduction
pathway. A sample of the many Hsp90 client proteins that are known to be
involved in cancer, and organized according to their contributions to the malignant
phenotype, is provided in Table 3.4.
Protein kinases represent the largest class of Hsp90 client proteins and many have
been shown to cause cancer when deregulated. These protein kinases depend on
Hsp90 for their proper folding and functioning. The ﬁrst protein kinase shown3.4. Heat shock protein of 90 kDa (Hsp90)-a kinome chaperone 33
Table 3.3: Important components of Hsp90 chaperone machinery
Protein Family Classiﬁcation Function
Hsp90 Chaperone Supports meta-stable protein
conformations, especially in
signal transducers
Hsp70 Chaperone Helps fold nascent polypeptide
chains; participates in assembly
of multiprotein complexes
Hsp40 Co-chaperone Stimulates Hsp70 ATPase activity
HIP (Hsp70-interacting protein),
HOP (Hsp70/Hsp90-organizing
protein)
Adapters Mediate interaction of Hsp90 and
Hsp70
Cdc37 (cell division cycle protein
37)/p50
Co-chaperone Modulates interaction with ki-
nases
Aha1 (activator of Hsp90 ATPase
activity)
Co-chaperone Stimulates Hsp90 ATPase activity
p23 Co-chaperone Stabilizes Hsp90 association with
clients
Immunophilin Prolylisomerase Modulates interactions with hor-
mone receptors
Table 3.4: Hsp90 clients and the malignant phenotype
Phenotype Clients
Uncontrolled proliferation Receptor tyrosine kinases, ser-
ine/threonine kinases, steroid hor-
mone receptors
Immortalization Telomerase
Impaired apoptosis AKT
Angiogenesis HIFI (hypoxia-inducible factor
1)
Invasion/metastasis MMP2 (matrix mettaloprotease 2)
to interact with Hsp90 was v-Src tyrosine kinase. Since then, numerous other
kinases [viz., Tyrosine kinases (v-Src, c-Src, Lck, c-Fgr, Insulin receptor, etc), Serine-
threonine kinases (v-Raf, c-Raf, Gag-Mil, MEK, CDK4, etc) have been reported
to form stable complexes with Hsp90. In tumor cells, the dynamic low afﬁnity
interactions of Hsp90 with its client proteins such as kinases maintain them in a
latent but readily activated state. The conformationally unstable oncogenic mutants
of such clients require more of Hsp90 to stabilize them, hence justifying the over
expression of Hsp90 in tumors, suggesting that Hsp90 itself is a valid anti-cancer
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3.4.3 Hsp90 structure and function
Hsp90 primarily resides in the cytoplasm of the cell. In vertebrates two isoforms,
Hsp90 and Hsp90, which are 76% identical and are the consequences of a
gene duplication about 500 million years ago [Krone and Sass, 1994; Moore
et al., 1989]. Hsp90 is constitutively expressed and was also frequently denoted
as Hsp86 and Hsp84. In contrast, Hsp90 is inducible and is slightly smaller
than Hsp90. The functional differences between these two isoforms is poorly
understood [Sreedhar et al., 2004]. Apart from this, recently a membrane-
associated variant Hsp90N has been reported with limited details of its cellular
functions [Grammatikakis et al., 2002].
Hsp90 predominantly exists as a homodimer in the cytoplasm. Each of these
homodimer is made of three domains, which have important functional interactions,
as summarized in Figure 3.6.
Figure 3.6: Schematic representation of the Hsp90 dimer. The numbering 1-732
indicates the approximate positions in the amino acid sequence of the human protein that
deﬁne its functional domains. ‘CR’ refers to a charged region, which serves as a ﬂexible linker
between the N-terminal and middle domains. The locations where various small molecules bind
HSP90 (heat-shock protein of 90 kDa) and modulate its function are indicated (17AAG, 17-
allylaminogeldanamycin; GA, geldanamycin). The biochemical functions of each domain are also
indicated. Figure reproduced from Whitesell and Lindquist [2005].
The crystal structure of full length yeast Hsp90 was recently reported(Ali et al.,
2006). The N-terminal (both human and yeast) [Prodromou et al., 1997; Stebbins
et al., 1997] and middle domain (yeast) structures has also been reported [Meyer
et al., 2003].3.4. Heat shock protein of 90 kDa (Hsp90)-a kinome chaperone 35
The N-terminal domain of approximately 25 kDa, contains an unusual adenine-
nucleotide-binding pocket known as the Bergerat fold [Dutta and Inouye,
2000]. This domain is mainly responsible for the hydrolysis of ATP to ADP and plays
an essential role in the chaperoning activity of the Hsp90 dimer, for which two
models (yeast Hsp90 and human Hsp90) has been proposed [McLaughlin et al.,
2004; Meyer et al., 2003]. The model proposed after involving a study with yeast
Hsp90 indicates dimerization of N-terminal domain of Hsp90 upon ATP binding,
whereas there was no evidence found for dimerization in human Hsp90. Cdc37 a
co-chaperone of Hsp90, binds to the N-terminal domain and plays an important role
in recruiting kinases to the Hsp90 [Roe et al., 2004]. Disrupting the association of
Cdc37 to Hsp90 by designing small molecule inhibitors has been recently proposed
for increasing the selectivity in targeting oncogenic kinases [Gray et al., 2008;
Smith et al., 2009; Smith and Workman, 2009].
A charged linker connects the N-terminal domain of Hsp90 to its middle domain, of
approximately 35 kDa. Structure of this middle domain indicates an important role
of harboring the 
-phosphate of ATP molecules that bind to the N-terminal pocket
of Hsp90 [Meyer et al., 2003; Söti et al., 2002]. Additionally, AHA1, a co-chaperone
of Hsp90, promotes association of the N- and the middle domain and accelerates
the rate of ATP-hydrolysis [Meyer et al., 2004; Panaretou et al., 2002].
Finally, another ﬂexible linker connects the middle domain to the C-terminal
domain, of approximately 12 kDa. This domain is mainly responsible for the
dimerization, and whose deletion drastically impairs the ATPase activity of Hsp90,
providing a perfect example for intermolecular and intramolecular interactions
are required for enzymatic reaction. This domain also carries a conserved
EEVD motif responsible for the binding of various client proteins containing
tetratricopeptide containing repeats (TPR)-domain such as immunophilins, HOP
and protein phosphatase 5 (PP5), which increase the speciﬁcity of Hsp90 complexes
[Prodromou et al., 1999; Scheuﬂer et al., 2000].
3.4.4 Inhibition of Hsp90 function
Hsp90 plays a key role in the conformational maturation of oncogenic signalling
proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53 [Kamal
et al., 2003]. ATP-binding pocket residing in the N-terminal domain of Hsp90 is
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radicicol. Several other Hsp90 binding drugs are summarized in Table 3.5. The
drug-bound Hsp90 sensitises its client proteins to recruit E3 ubiquitin ligases such
as CHIP (carboxy-terminus of Hsp70-interacting protein), which otherwise would
have been stabilized by Hsp90-containing chaperone complexes. This recruitment
leads to increased proteasome-mediated degradation of the clients and depletion of
their cellular levels.
Table 3.5: Hsp90-binding drugs
Binding site Chemical class Selected examples
N-terminal ATP-binding pocket Benzoquinone
ansamycin
Geldanamycin (GA), 17AAG
(17-(demethoxy).17-allylamino
geldanamycin), 17DMAG (17-
(demethoxy).17-dimethyl-
aminoethylamino geldanamycin)
N-terminal ATP-binding pocket Macrolide Radicicol and related oxime
derivatives, -zearalenol
N-terminal ATP-binding pocket Purine scaffold PU24FC1
N-terminal ATP-binding pocket Pyrazole CCT018159
N-terminal ATP-binding pocket Hybrid Radamycin, GA dimmer, GA-
testosterone, GA-estrogen
C-terminus Novioylcoumarin
crosslinker
Novobiocin, coumermycin, cis-
platin
Unknown Histone deacety-
lase inhibitor
Depsipeptide
Clinical and preclinical observations have shown that Hsp90 inhibitors at thera-
peutic doses signiﬁcantly impair tumor growth with minimal effects on the normal
tissues. However it is now becoming more clear that the currently available drugs
also alter some of the normal functions of the cells [Whitesell and Lindquist,
2005]. Selectivity of the drugs towards the tumor cells in comparison to normal
tissues come from the fact that Hsp90 has an enhanced ATPase activity in tumor
cells, since it mainly exists as a multi-chaperone complex, when compared to its
mostly latent state in normal cells [Kamal et al., 2003].
3.5 Cell division cycle protein 37 (Cdc37)-a kinome
co-chaperone
In the previous section, we have seen that one of the major functions of Hsp90 is
stabilization of protein kinases. Hsp90 does not directly bind to protein kinases,
but this interaction is mediated by the co-chaperone Cdc37/p50. Hence, Cdc37 has
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[Hunter and Poon, 1997]. Interestingly, Cdc37 is also capable to act as a chaperone
by itself independent of Hsp90 [MacLean and Picard, 2003]. Hsp90-Cdc37 complex
is considered to mediate carcinogenesis by stabilizing a variety of different onco-
genic kinases in malignant cells. In this section, we will review more about Cdc37
in general and more about Cdc37-Hsp90 interaction, and also address potential
implications of Cdc37 as drug target.
3.5.1 Introduction
The cell division cycle protein 37 (Cdc37) was ﬁrst identiﬁed in S. cerevisiae as
a protein required for the ‘Start’ event in the cell division cycle [Reed, 1980]. In
yeast, cdc37 mutations cause synthetic lethality (as deﬁned by [Kaelin, 2005]), in
combination with thermosensitive cdc28 or kin28 mutations [Reed et al., 1985;
Valay et al., 1995]. The mammalian homolog of Cdc37, also referred to as p50cdc37,
was ﬁrst identiﬁed within a complex consisting of the Rous sarcoma virus encoded
oncogene pp60v-scr and Hsp90 [Brugge, 1986; Whitelaw et al., 1991]. Further
studies conﬁrmed that protein kinases are the most favored targets of Cdc37 [Mort-
Bontemps-Soret et al., 2002]. A plethora of other oncogenic kinases including
Raf isoforms, Akt, and ErbB2 have been identiﬁed as potential clients of Cdc37
(Figure 3.7) [Basso et al., 2002; Grammatikakis et al., 1999; Lamphere et al.,
1997]. Expression of Cdc37 is upregulated in cancer cells and tissues and can
promote tumorigenesis when overexpressed [Schwarze et al., 2003; Stepanova
et al., 2000a].
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Figure 3.7: Cdc37 is essential for
folding and stabilization of many
kinases. This list of kinases also
include several of the oncogenic kinases
like AKT, Raf, Aurora, etc., which
otherwise are also required for normal
cellular function.
Table 3.6 summarizes most of the client proteins of Cdc37 in association with
Hsp90. Further in yeast it has been shown that Cdc37 can function alone in kinase
biogenesis [Mandal et al., 2007]. Apart from this Cdc37 also interacts with several
non-kinase proteins like androgen receptor (for proper signaling), viral receptor38 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
transcriptase, the transcription factor MyoD and nitric oxide synthase [Harris et al.,
2006; Yun and Matts, 2005]. All these can be summarized into the fact that Cdc37
essentially has two roles; in one role it acts like a bridge between kinase and Hsp90
and modulates the ATPase activity of Hsp90 during the process of maturation of
kinases; and in the second role in which Cdc37 functions in an Hsp90 independent
manner.
Table 3.6: Cdc37 interacting proteins (other than Hsp90)*
Clients Interaction Evidence Reference
AKT (Protein
Kinase B)
Biochemical Endogenous Akt IPs with Hsp90 and Cdc37. Cdc37 can bind Akt
directly, not affected by Hsp90 inhibitors.
Basso et al. (2002) J. Biol. Chem. 277: 39858
Androgen
receptor
Genetic Yeast cdc37-34 has decreased activation of heterologous AR Rao et al.(2001) J. Biol. Chem. 276: 5814
Biochemical Human Cdc37 binds to ligand-binding domain of AR in vitro, partially
Hsp90dependent. N-terminal domain (1-173) is dominant negative
Fliss et al. (1997) Mol. Biol. Cell 8: 2501
Aurora B Genetic &
Biochemical
Mammalian & Drosophila Cdc37, inactivation of Hsp90 or Cdc37
reduces Aurora B levels, Aurora B or Cdc37 RNAi phenotypes are
almost indistinguishable. Co-IP
Lange et al. (2002) EMBO J. 21: 5364
B-Raf Biochemical Co-IP Vaughan et al. (2006) Mol. Cell 23: 697;
Grbovic et al. (2006) Proc. Natl. Acad. Sci.
USA 103, 57
Cak1 Genetic Synthetic lethal screen Mort-Bontemps-Soret et al. (2002) Mol. Genet.
Genomics 267: 447
Genetic Yeast cdc37-1 has reduced Cak1 level and activity. Cdc37 stabilises
Cak1 after translation
Farrell & Morgan (2000) Mol. Cell. Biol. 20:
749
Cdc2 Genetic &
Biochemical
S. pombe Cdc2 fails to associate with cyclin in cdc37 mutant strain;
genetic interactions and co-IP.
Turnbull et al. (2006) J. Cell Sci. 119: 292
Cdc5 Genetic Synthetic lethal screen Mort-Bontemps-Soret et al. (2002) Mol. Genet.
Genomics 267: 447
Cdc7 Genetic Synthetic lethal screen Mort-Bontemps-Soret et al. (2002) Mol. Genet.
Genomics 267: 447
Cdc15 Genetic Synthetic lethal screen (and kinase assay in S. pombe) S. cerevisiae: Mort-Bontemps-Soret et al.
(2002) Mol. Genet. Genomics 267: 447 / S.
pombe (=Cdc7) Liang and Fantes (2007) Euk.
Cell 6: 1089
Cdc25c Biochemical Co-IP Garcia-Morales et al. (2007) Oncogene 26:
7185
Cdc28 Genetic Yeast cdc37-1 mutant affects Cdc28/cyclin complex formation and
function
Gerber et al. (1995) Proc. Natl. Acad. Sci. USA
92: 4651
Genetic Yeast Cdc37 stabilises Cdc28 after translation Farrell & Morgan (2000) Mol. Cell. Biol. 20:
749
Genetic &
Biochemical
Yeast CDC37 is a multi-copy suppressor of cdc28. yeast two-hybrid
interaction between Cdc37 C-terminus and Cdc28 N-terminus
Mort-Bontemps-Soret et al. (2002) Mol. Genet.
Genomics 267: 447
Cdk2 Biochemical pull-down assays Prince et a. (2005) Biochem. 44: 15287
Cdk4 Biochemical Immunoprecipitation with mammalian Cdc37 and Hsp90 Dai et al. (1996) J. Biol. Chem. 271: 22030
Biochemical Mammalian co-IP (preferentially without cyclin) with Hsp90
CDC37 transgenic mice develop mammary tumours, i.e. can function
as an oncogene. Can co-operate with Cyclin D1 or with c-myc in
transformation of tissue. See also Schwarze et al. (2003) Cancer Res.
63: 4614.
Stepanova et al. (1996) Genes & Dev. 10: 1491
Stepanova et al. (2000) Mol. Cell. Biol.
20: 4462
Biochemical Yeast 2-hybrid with human Cdc37. GST-Cdc37 co-IP Lamphere et al. (1997) Oncogene 14: 1999
Cdk6 Biochemical GST-Cdc37 co-IP Lamphere et al. (1997) Oncogene 14: 1999
Cdk9 Biochemical co-IP with Cdk9 before assembly with cyclin T1 O’Keeffe et al. (2000) J. Biol. Chem. 275: 279
Cdk11 Biochemical co-IP Mikolajczyk and Nelson (2004) Biochem. J.
384: 461
CKII (casein ki-
nase II)
Genetic Multi-copy suppressor McCann & Glover (1995) Mol. Biol. Cell
(Supp.) 6: 133a
Biochemical in vitro chaperone assay with yeast Cdc37 Kimura et al. (1997) Genes & Dev. 11: 1775
Genetic Cdc37 required for CKII function and CKII for Cdc37 phosphorylation Bandhakavi et al. (2003) J. Biol. Chem.
278:2829
Crk1 Genetic &
Biochemical
Candida Crk1; 2-hybrid, co-IP, and genetic evidence. Ni et al. (2004) FEBS Lett. 561: 233
DAPK Biochemical co-IP Citri et al. (2006) J. Biol. Chem. 281: 143613.5. Cell division cycle protein 37 (Cdc37)-a kinome co-chaperone 39
Table 3.6: (continued...)
Clients Interaction Evidence Reference
EGF receptor
mutant
Biochemical co-IP Lavictoire et al. (2003) J. Biol. Chem. 278:
5292
Fused Biochemical co-IP Kise et al. (2006) Biochem. Biophys. Res.
Com. 351: 78
-Galactosidase Biochemical in vitro chaperone assay with yeast Cdc37 Kimura et al. (1997) Genes & Dev. 11: 1775
Gcn2 Genetic cdc37 mutant yeast strain grows poorly upon amino acid starvation Donzé & Picard (1999) Mol. Cell. Biol. 19:
8422
Glucocorticoid
receptor
Genetic Yeast cdc37-34 has slightly decreased activation of heterologous GR
at non-permissive temperature.
Fliss et al. (1997) Mol. Biol. Cell 8: 2501
Harc Biochemical Harc and Cdc37 form both homodimers and heterodimers Roiniotis et al. (2005) Biochem. 44: 6662
Hog1 Genetic &
Biochemical
Hog1 function affected by Cdc37 phosphorylation mutant in yeast;
co-IP
Hawle et al. (2007) Eukaryot. Cell 6: 521
Hck (src family
kinase)
Genetic &
Biochemical
Human Cdc37 overexpression partially suppresses tsHck499F pheno-
type, co-IP, Hck kinase domain necessary for binding
Scholz et al. (2000) Mol. Cell. Biol. 20: 6984
HRI Biochemical Human Cdc37 co-IP, maturation intermediates of HRI recruit Cdc37
to Hsp90 heterocomplex
Hartson et al. (2000) Biochem. 39: 7631
Biochemical Human Cdc37 associates with nascent HRI co-translationally and
persists during maturation and activation, speciﬁcally with immature
or inactive forms and not with active or repressed forms
Shao et al. (2001) J. Biol. Chem. 276: 206
IKK (IB
kinase)
Biochemical Human Cdc37 co-IP, in vitro pull downs, direct binding through
the kinase domain. Geldanamycin disrupts complex formation and
recruitment to receptor.
Chen et al. (2002) Mol. Cell 9: 401;
Bouwmeester et al. (2004) Nat. Cell Biol. 6:97
IRAK-1 Biochemical co-IP De Nardo et al. (2005) J. Biol. Chem. 280:
9813
JAK1 Biochemical co-IP Shang and Tomasi (2006) J. Biol. Chem. 281:
1876
Kin28 Genetic Synthetic lethal Valay et al. (1995) J. Mol. Biol. 249: 535
Ksr Biochemical part of a larger chaperone complex Sundaram et al. (1999) Mol. Cell. Biol. 19:
5523
Lck (src family
kinase)
Biochemical Co-IP with human Cdc37 Hartson et al. (2000) Biochem. 39: 7631
Lkb1 Biochemical Co-IP Boudeau et al. (2003) Biochem. J. 370: 849;
Nony et al. (2003) Oncogene 22: 9165
LRRK2 Biochemical co-IP Gloeckner et al. (2006) Hum. Mol. Genet. 15:
223; Wang et al. (2008) J. Neurosci. 28: 3384.
Luciferase
(ﬁreﬂy)
Biochemical in vitro chaperone assay with yeast Cdc37 Kimura et al. (1997) Genes & Dev. 11: 1775
MEKK1/MEKK3 Biochemical TAP puriﬁcation Bouwmeester et al. (2004) Nat. Cell Biol. 6:97
MLK3 Biochemical co-IP Zhang et al. (2004) J. Biol. Chem. 279: 19457
MPS1 Genetic multi-copy suppressor of mps1-1 & synthetic lethal (with cdc37-1) Schutz et al. (1997) J. Cell Biol. 136: 969
NIK Biochemical TAP puriﬁcation Bouwmeester et al. (2004) Nat. Cell Biol. 6:97
PDGF receptor

Biochemical co-IP Matei et al. (2007) J. Biol. Chem. 282:445
Pink1 Biochemical co-IP Weihofen et al. (2008) Hum. Mol. Genet.
17:602
PKC Biochemical TAP puriﬁcation Brajenovic et al. (2004) J. Biol. Chem. 279:
12804
Raf Biochemical Mammalian Cdc37 IP Perdew et al. (1997) Biochem. 36: 3600
Biochemical Mammalian Cdc37 IP, and Hsp90 Stancato et al. (1993) J. Biol. Chem. 268:
21711; Wartmann & Davis (1994) J. Biol.
Chem. 269: 6695
Biochemical Mammalian Cdc37 co-IP, Cdc37 directly binds Raf kinase domain,
separate from TPR domain protein heterocomplexes
Silverstein et al. (1998) J. Biol. Chem. 273:
20090
Biochemical Human Cdc37 co-IP, N-terminus of Cdc37 binds Raf1, C-terminus of
Cdc37 binds Hsp90, N-terminal 1-163 is dominant negative for Raf
activation
Grammatikakis et al. (1999) Mol. Cell. Biol.
19: 1661
RET/PTC1 Biochemical co-IP Marsee et al. (2004) J. Biol. Chem. 279:
43990
Reverse
Transcriptase
(Hepad-
navirus)
Biochemical Human Cdc37 IP and pull downs, speciﬁc, direct binding in vitro and
in vivo, and Ctermally truncated Cdc37 bound more strongly
Wang et al. (2002) J. Biol. Chem. 277: 24361
Sevenless Genetic In Drosophila a genetic link between Sevenless signaling & CDC37,
HSP83 & CDC37, p34cdc2 & CDC37
Cutforth & Rubin (1994) Cell 77: 1027
Spc1 (SAPK) Genetic &
Biochemical
S. pombe: accumulation and phosphorylation of stress kinase Spc1
is lower in cdc37 mutant; co-IP; Cdc37 requirement may be
independent of Hsp90.
Tatebe & Shiozaki (2003) Mol. Cell. Biol. 23:
5132
Slt2 Genetic &
Biochemical
Hog1 function affected by Cdc37 phosphorylation mutant in yeast;
co-IP, increased for phosphorylated (activated) form of Slt2
Hawle et al. (2007) Eukaryot. Cell 6: 521
v-Src Biochemical Mammalian Cdc37 co-IP, with Hsp90 Brugge (1986) Curr. Top. Microbiol. Immunol.
123: 1
Genetic Yeast cdc37-34 & cdc37-17 mutants have decreased src activity but
protein level unaffected
Dey et al. (1996) Mol. Biol. Cell 7: 140540 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
Table 3.6: (continued...)
Clients Interaction Evidence Reference
Genetic Yeast cdc37-1 had decreased src activity. Genetic link between HSC82
& HSP82 with CDC37
Kimura et al. (1997) Genes & Dev. 11: 1775
Biochemical Mammalian Cdc37 IP Perdew et al. (1997) Biochem. 36: 3600
Ste11 Genetic &
Biochemical
Cdc37 mutant has low Ste11 activity. Pull downs and co-IP Abbas-Terki et al. (2000) FEBS Lett. 467:111
TAK1 Biochemical TAP puriﬁcation Bouwmeester et al. (2004) Nat. Cell Biol. 6:97
TBK1 Biochemical TAP puriﬁcation Bouwmeester et al. (2004) Nat. Cell Biol. 6:97
Ydj1 Genetic Synthetic lethal screen Mort-Bontemps-Soret et al. (2002) Mol. Genet.
Genomics 267: 447
ZAP70 Genetic Rat Cdc37 overexpression restores expression of ZAP70 mutant
(protein tyrosine kinase involved in signal transduction throught the
T-cell receptor)
Matsuda et al. (1999) J. Biol. Chem. 274:
34515
*Table obtained from www.picard.ch/downloads/Cdc37interactors.pdf
3.5.2 Cdc37 promotes proliferation
Cdc37 was ﬁrst discovered in a yeast screen for cell division cycle proteins and
becomes misappropriated in several cancers. The important role of Cdc37 in sup-
porting Hsp90 activity and kinase function suggests that, like Hsp90, Cdc37 may
participate in maintaining malignant phenotype [Pascale et al., 2005; Prince et al.,
2005]. Cdc37 was found over expressed in human prostate cancer [Schwarze et al.,
2003; Stepanova et al., 2000b]. Cdc37 was also found to be up regulated in
hepatocellular carcinoma [Pascale et al., 2005; Prince et al., 2005]. In a genetically
engineered mouse model, Cdc37 acted as an oncogene, which was shown by the
fact that the targeted over expression in mammary and prostate glands induced
proliferative disorders leading to tumours [Stepanova et al., 2000a]. Further, Cdc37
also interacts with oncoproteins c-myc or cyclin D1 and is known to induce the
transformation in multiple tissues of mice. Additionally it is known that Hsp90
buffers the oncogenic mutations, and could be also extended the same function to
Cdc37. In fact, Cdc37 was ﬁrst found in mammalian cells in association with Hsp90
and the oncogenic kinase v-Src. Mutation in some of the key kinases involved in the
cell signaling allows them to develop ‘fast’ activity, at the same time also becoming
structurally ‘loose’, and the chaperoning complex of Cdc37-Hsp90 helps them in
maintaining this ‘fast and loose’ state promoting there prolonged existence [Gray
et al., 2008].
3.5.3 Cdc37 structure and function
Structurally, the 44.5 kDa protein Cdc37 can be dissected into three domains
(Figure 3.8)(MacLean and Picard, 2003; Shao et al., 2003a). Proteolytic
ﬁngerprinting studies indicate that it is comprised of an N-terminal domain
(residues 1-127 (Cdc37N), 15.5 kDa), a middle domain (residues 147-2763.5. Cell division cycle protein 37 (Cdc37)-a kinome co-chaperone 41
(Cdc37M), 16 kDa), and a C-terminal domain (residues 283-378 (Cdc37C),
10.5 kDa). Additional evidence suggests that the region between 128-147 could
comprise an additional domain, as its presence or absence in the deletion constructs
affect the kinase-binding and Hsp90-binding. The middle domain Cdc37M is highly
resistant to proteolytic digestion and was found to be the most stable domain
of Cdc37 [Zhang et al., 2004]. Several studies [Grammatikakis et al., 1999; Lee
et al., 2002; Scholz et al., 2000; Shao et al., 2001, 2003] have shown that Cdc37N
binds to the client proteins (e.g., kinases). A highly conserved region within
Cdc37N contains Ser13 as a unique phosphorylation site for the protein kinase
CKII. Phosphorylation seems to be an important mechanism for controlling the
binding afﬁnity to the client protein kinases and as a consequence thereof regulating
the activity of multiple protein kinases [Miyata and Nishida, 2004]. Recently, it
was shown that Hsp90 dependent activation of protein kinases requires chaperone
targeted dephosphorylation of Cdc37 by protein phosphatase 5 (PP5) [Vaughan
et al., 2008]. This suggests that a cycle of phosphorylation and dephosphorylation
of Cdc37 is necessary for kinase-client loading onto Hsp90. The Hsp90 binding
site is located in the middle domain of Cdc37, which also comprises a putative
dimerization region [Roe et al., 2004]. An extended -helix connects the Hsp90
binding site to the C-terminal domain, which might also be required for dimer
formation [Roe et al., 2004; Siligardi et al., 2002]. The structure of the N-terminal
domain is unknown, but sequence analysis predicts a high content of -helices [Roe
et al., 2004].
Cdc37 binds to Hsp90 with a dissociation constant of 1.2 to 3.8 M depending upon
the type of constructs used for the study, viz., human or yeast or Hsp90 or Hsp90
[Roe et al., 2004; Zhang et al., 2004]. The crystal structure of Cdc37MC (middle
and C-terminal domain) bound to Hsp90N (from yeast) is a heterotetrameric
complex, comprising of Hsp90 bound to a Cdc37 dimer. The function of Cdc37 to
inhibit the ATPase activity of Hsp90 is due to the long side chain of R167 that binds
to E33 of Hsp90, thereby inhibiting the ATPase reaction [Roe et al., 2004]. Several
structural and biochemical studies have conﬁrmed this interaction is key to the
function of this complex. Additional studies also indicate that the full length Cdc37
in its free form exists as a dimer with a dissociation constant of 5-10 M and 80
M [Roe et al., 2004]. However there are several contradicting results when taken
the results concerning the individual domains [Zhang et al., 2004]. Low resolution
cryo-electron microscopy images of the Hsp90-Cdc37-Cdk4 complex show that
Cdc37 is a monomer in this interaction [Vaughan et al., 2006]. However, these
studies utilized yeast Hsp90 and it was realized that it is necessary to investigate the42 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
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Figure 3.8: Domain architecture of Cdc37. (A) Schematic representation of the three
domains of Cdc37. (B) Schematic representation of the present understanding of the ternary
complex of Cdc37-Hsp90-kinase. The catalytic domains of protein kinase is represented in ribbon
diagram with its N-lobe (blue) and C-lobe (red). The KBD of Cdc37 binds to the N-lobe, HBD
binds to N-terminal of Hsp90 and Hsp90 binds both to N and C lobes while interacting with the
HBD of Cdc37. Figure 3.8(B) reproduced from Gray et al. [2008].
interaction with human Hsp90 to resolve the differences [Zhang et al., 2004]. In
this thesis we determine the structure of the human Hsp90N-Cdc37M complex
by NMR (various NMR methods used to study this protein-protein complex will
be discussed in Chapter 5). We also solved the X-ray crystal structure of human
Cdc37M at 1.88 Å in its monomeric form. Based on the available structural and
biochemical data the functioning of the Cdc37-Hsp90 chaperone machinery can be
summarized as shown in Figure 3.9.3.5. Cell division cycle protein 37 (Cdc37)-a kinome co-chaperone 43
Figure 3.9: Cdc37-Hsp90 chaper-
one machinery in kinase loading.
Cdc37, phosphorylated by CK2, binds
to kinases and forms a complex with
Hsp90. The PP5 (Ppt1 in yeast)
phosphatase binds to the C terminus
of Hsp90 and dephosphorylates Cdc37,
which subsequently dissociates from
the Hsp90 complex. ATP binding and
hydrolysis by Hsp90 and interaction
with additional cochaperones lead
to maturation and release of the
kinase. Figure reproduced from Mayer
et al. [2009].
3.5.4 Targeting Cdc37 in cancer
Cdc37 is upregulated in cancer cells when compared to the normal tissue. In
healthy prostate tissue Cdc37 is barely detectable, whereas it is readily observable
in prostate tumor tissue [Stepanova et al., 2000b]. As seen in the earlier section
(Cdc37 promotes proliferation), Cdc37 is involved in the maturation of many
oncogenic kinase clients and this was even further conﬁrmed by extensive siRNA-
mediated silencing of Cdc37. Further, siRNA-mediated silencing of Cdc37 resulted
in marked depletion of oncogenic kinases in human colon cancer cell lines[Smith
et al., 2009]. Inactivation of Cdc37 may decrease cell survival through multiple
pathways, permitting effective inhibition of signaling pathways and also breaking
resistance to cytotoxic therapy (Figure 3.10) [Gray et al., 2008; Smith and
Workman, 2009]. Therefore targeting of Cdc37 is predicted and proposed to have
relatively broad-spectrum anticancer activity due to its diverse set of its client
proteins. As compared to inhibition of Hsp90, the client selectivity of Cdc37 co-
chaperone is predominantly directed towards protein kinases. Therefore targeting
of Cdc37 may be beneﬁcial in kinase-addicted cancers. Additionally, targeting
of Cdc37 will be beneﬁcial in prostate cancer, in which androgen receptor(AR)
signaling is critical since the AR is an atypical, non-kinase client of Cdc37.
The potential approaches to pharmacologically target Cdc37 activity with small
molecules can fall into two categories:
1. Inhibition of activating phosphorylation of Cdc37 [Smith and Workman,
2009]- In humans CKII phosphorylates Cdc37 on Ser13 and is known to
be essential for modulation of the chaperone cycle. Inhibition of CKII with44 Chapter3. Importance of Study of Various Protein Families of Biomedical Relevance
Figure 3.10: Effects of depletion of Cdc37. Cdc37 depletion inhibits signal ﬂux through
at least three pathways in prostate carcinoma. These include the (a) extracellular signal-
regulated kinase (ERK), (b) Akt and (c) androgen receptor (AR) pathways. Depletion of Cdc37
also inhibits (d), the HSF1-mediated heat shock stress response that can be activated by
many anticancer agents. Well-characterized molecular clients for Cdc37 are indicated by blue
colouration. MEK, mitogen-activated protein kinase; PDK1, 3-phosphoinositide-dependent kinase
1; PI3K, phosphatidylinositol 3-kinase. Figure reproduced from Gray et al. [2008].
its inhibitor TBB (4,5,6,7-Tetrabromo-2-azabenzimidazole) suppressed Cdc37
phosphorylation and reduced the expression of kinase clients. Thus blocking
CKII-mediated activation of Cdc37 could be a possible route of therapeutic
intervention. Additionally PP5 is capable of targeted dephosphorylation of
Cdc37 within Hsp90 complexes. Over expressing PP5 in HCT116 human
colon cancer cells reduced the level of phosphorylated Cdc37, concomitantly
decreasing the expression of CRAF client protein kinase expression, demon-
strating that the kinase clients are also compromised. Hence modulation of
PP5 may offer an additional approach to reduce Cdc37 activity, but this would
require more detailed studies as its biochemical interactions are still not well
characterized.
2. Blocking functional protein-protein interactions that Cdc37 is involved
[Smith and Workman, 2009]- Designing small molecule inhibitors for inter-
fering with speciﬁc protein-protein interactions is technically more challenging
and needs extensive structural characterization and also identifying the ‘Hot
spots’ at the interface between the two proteins. Inhibition of Hsp90 or other
client proteins interacting with Cdc37 is another way to inhibit the function of
Cdc37. The interaction interface of the protein-protein complex Cdc37-Hsp90,
is well characterized structurally and has identiﬁed key residues involved in
the complex formation. Additionally, in this thesis we also have identiﬁed
a crucial ‘Hot spot’ residue which plays a key role in complex formation of3.5. Cell division cycle protein 37 (Cdc37)-a kinome co-chaperone 45
human Hsp90 and human Cdc37 (see Chapter 7). Low molecular weight
molecules that interfere with Cdc37 or Hsp90 or disrupt the Hsp90-Cdc37
complex have recently been proposed as a new class of anti-cancer agents
[Gray et al., 2008; Smith and Workman, 2009]. Gene based-expression studies
have identiﬁed the triterpene celastrol, representing a new class of non ATP-
competitive inhibitors of Hsp90 [Hieronymus et al., 2006]. Immunoprecipita-
tion in a pancreatic cell line and docking experiments suggested that celastrol
exerts its anti-proliferative activity by binding to the N-terminal domain of
Hsp90, thereby disrupting the complex between Hsp90N and Cdc37 [Zhang
et al., 2008a]. In vivo, celastrol showed signiﬁcant inhibition of tumor growth
in nude mice with prostate or pancreatic cancer [Yang et al., 2006; Zhang
et al., 2008a]. In contrast to these studies, in this thesis (see Chapter 8) we
elucidated that celastrol, which was thought to bind to Hsp90, in fact binds to
Cdc37 and disrupts this protein-protein complex.4
Small Molecule Inhibitors for Disrupting
Protein-Protein Interaction
P
rotein-protein interactions control and play a key role in biological pro-
cesses, including cellular growth and differentiation [Alberts, 1998; Gavin
et al., 2002]. Any loss of coordination in maintaining these protein-protein inter-
action becomes a triggering factor for many pathological processes, for example
cancer and Alzheimer’s disease [Cohen and Prusiner, 1998; Selkoe, 1998]. These
protein-protein interactions are very speciﬁc in function and hence offer a highly
selective target for pharmacological intervention. Thus, inhibition or disruption
of these interactions offers a promising novel approach for rational drug design
against a wide number of cellular targets. Discovering small molecule drugs to
disrupt protein-protein interaction is an enormous challenge [Wells and McClendon,
2007]. In this chapter we will look at some of the examples from the literature,
which attempts to disrupt the protein-protein interaction either by using antibodies,
peptides, and synthetic or natural small molecules. Of particular interest, we will
also discuss about disrupting the Cdc37-Hsp90, kinome co-chaperone-chaperone
complex using a recently identiﬁed triterpene small molecule celastrol.
4.1 Introduction
Most of the biological processes are not carried out by single proteins, but involves
many proteins acting together [Alberts, 1998]. For example the cell cycle-dependent
degradation of speciﬁc proteins involves a coordinated action of at least ten
proteins, called as the anaphase-promoting complex (APC) and involves several
other proteins in the downstream events until they reach the 20S proteasome, where
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ﬁnally the target protein is converted to small peptides. Protein-protein interactions
are also the key for carrying out fundamental cellular functions like intracellular
signal transduction and also maintaining the cytoskeletal architecture of the cell. In
humans, an estimate of roughly 40,000-200,000 protein-protein interactions
(human interactome) are thought to exist [Bork et al., 2004]. Only 20,000-30,000
are recorded in the literature for the human interactome. Inappropriate protein-
protein interaction can lead to diseases like cancer [White et al., 2008]. Hence,
selective small molecule targeting of protein-protein interactions is of great interest
for pharmaceutical sciences [Arkin, 2005; Arkin and Wells, 2004; Chène, 2006;
Fry and Vassilev, 2005; Sharma et al., 2002; Toogood, 2002; Yin and Hamilton,
2005]. Table 4.1 provides various examples of protein-protein interactions which
have been targeted either by using antibodies, peptides, small molecules, or natural
products [Loregian and Palù, 2005].
Table 4.1: Overview of protein-protein interactions inhibitors
Target protein-protein interaction Type of inhibitor References*
Enzyme subunit interactions
HSV-1 ribonucleotide reductase (R1/R2) Peptide Dutia et al. (1986); Cohen et al.
(1986)
Small molecule Liuzzi et al. (1994)
HSV-1 DNA polymerase (UL30/UL42) Peptide Marsden et al. (1994); Digard et al.
(1995)
Small molecule Pilger et al. (2004)
HCMV DNA polymerase (UL54/UL44) Peptide Loregian et al. (2003)
HIV protease dimerization Peptide Zhang et al. (1991)
Small molecule Song et al. (2001)
Natural product Fan et al. (1998)
HIV reverse transcriptase dimerization Peptide Divita et al. (1994)
HIV integrase dimerization Peptide Sourgen et al. (1996)
iNOS dimerization Small molecule McMillan et al. (2000)
Human gluthatione reductase dimerization Peptide Nordhoff et al. (1997)
Ligand/receptor interactions
Angiotensin II/angiotensin II receptor Peptide Moore and Fulton (1984)
Small molecule Duncia et al. (1992)
Fibrinogen/integrin GPIIbIIIa Antibody Vorchheimer et al. (1999)
Peptide McDowell and Gadek (1992)
Small molecule McDowell et al. (1994)
Vitronectin/integrin aVb3 Small molecule Keenan et al. (1998)
MMP2/integrin aVb3 Small molecule Boger et al. (2001)
VCAM/integrin a4b1 Small molecule Jackson et al. (1997)
MAdCAM/integrin a4b7 Small molecule Sircar et al. (2002)
ICAM/LFA-1 Antibody Marecki and Kirkpatrick (2004)
Small molecule Gadek et al. (2002)
IL-1/IL-1 receptor Peptide Yanofsky et al. (1996)
Sc antibody Chrunyk et al. (2000)
Small molecule Sarabu et al. (1997)
IL-2/IL-2 receptor a Antibody Ockey and Gadek (2002)
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Table 4.1: (continued...)
Target protein-protein interaction Type of inhibitor References*
Small molecule Tilley et al. (1997)
IL-4/IL-4 receptor a Peptide Domingues et al. (1999)
C5a/C5a receptor Peptide Finch et al. (1999)
NGF/p75 receptor Small molecule Owolabi et al. (1999)
Grb2 SH2/EGF receptor Small molecule Fretz et al. (2000)
Grb2 SH2/c-Met Small molecule Atabey et al. (2001)
p56lck/T-cell receptor Small molecule Proudfoot et al. (2001)
VEGF/KDR receptor Peptide Fairbrother et al. (1998)
Rhodopsin/Gt Peptide Martin et al. (1996)
Gt a subunit/PDE Peptide Skiba et al. (1995)
Rhodopsin/arrestin Peptide Krupnick et al. (1994)
Immunophilin protein FKB12/activin receptor R1 Small molecule Huang and Schreiber (1997)
PI 3-kinase (p85 subunit)/PDGF-b receptor Peptide Eaton et al. (1998)
Small molecule Eaton et al. (1998)
GRK3/GR Peptide Koch et al. (1993)
ZAP-70/T-cell receptor Peptide Wange et al. (1995)
PKA/AKAP Peptide Carr et al. (1992)
PKC/RACK1 Peptide Ron and Mochly-Rosen (1994)
IgG Fc/protein A of Staphylococcus aureus Peptide DeLano et al. (2000)
HIV gp120/CD4 receptor Peptide Ferrer and Harrison (1999)
Small molecule Chen et al. (1992)
HIV/RANTES/CCR5 Small molecule Baba et al. (1999)
erB receptor self-association Peptide Berezov et al. (2002)
hER-a self-association Peptide Yudt and Koide (2001)
ADR homodimerization Peptide Hebert et al. (1996)
Other protein-protein interactions
Bcl-2/Bak (BH3 domain) Small molecule Wang et al. (2000); Degterev et al.
(2001)
Natural product Tzung et al. (2001)
p53/MDM2 Peptide Picksley et al. (1994)
Small molecule Stoll et al. (2001)
Natural product Duncan et al. (2001)
Smac/IAPs Peptide Liu et al. (2000)
CaM/ATPase Small molecule Levin and Weiss (1980)
CaM/smMLCK Small molecule Orner et al. (2001)
CaM/CaM-dependent kinases Peptide Nevalainen et al. (1997)
Tubulin-a/b polymerization Small molecule Haggarty et al. (2000)
Natural product Usui et al. (1998)
Hsp90/p23 Small molecule Chiosis et al. (2001)
a1B/b3 subunits of human N-type calcium channel Small molecule Young et al. (1998)
IGF-1/IGFBP-1 Peptide Lowman et al. (1998)
Stat3 dimerization Peptide Ren et al. (2003)
HIV p24 polymerization Peptide Hilpert et al. (1999)
aADR, 2-adrenergic receptor; AKAP, A-kinase anchoring protein; Bcl-2, B-cell leukemia/lymphoma 2; BH3, Bcl-2 homology domain 3; CaM,
calmoduline; CCR5, CCchemokine receptor 5; c-Met, hepatocyte growth factor receptor; EGF, epidermal growth factor; GPIIbIIIa, glycoprotein
IIbIIIa; GR, G-protein-coupled receptor; GRK3, G-protein-coupled receptor kinase 3; Grb2, growth factor receptor bound protein 2; Gt, G protein
transducin; HCMV, human cytomegalovirus; hER-, human estrogen receptor-; HIV, human immunodeﬁciency virus; Hsp90, heat shock protein
90; HSV-1, herpes simplex virus type 1; IAPs, inhibitor of apoptosis proteins; ICAM-1, intercellular cell adhesion molecule 1; IGF-1, insuline-
like growth factor 1; IGFBP-1, insuline-like growth factor binding protein 1; IL, interleukin; iNOS, inducible nitric oxide synthase; KDR, kinase
insert domain containing receptor; LFA-1, lymphocyte functional antigen 1; MAdCAM, mucosal addressin cell adhesion molecule; MMP2, matrix
metalloproteinase 2; NGF, nerve growth factor; PDE, phosphodiesterase; PDGF-, platelet-derived growth factor-b; PI, phosphatidyl-inositol;
PKA, cAMP-dependent serine/threonine protein kinase A; PKC, protein kinase C; RACK1, receptor for activated C-kinase 1; sc antibody, single chain
antibody; SH2, Src homology domain 2; smMLCK, small muscle myosin light chain kinase; Stat3, signal transduction and activation of transcription
3; VCAM, vascular cellular adhesion molecule; VEGF, vascular endothelial growth factor. *For back references please refer Loregian and Palù [2005]50 Chapter4. Small Molecule Inhibitors for Disrupting Protein-Protein Interaction
4.1.1 Major challenges and approaches used for targeting
protein-protein interactions
Targeting protein-protein interactions as a strategy for preventing diseases is attrac-
tive, but it also comes at the cost of major difﬁculties to be overcome before an
inhibitor could be designed. The difﬁculties derive mainly because of either one
or more of the following nature of protein-protein interactions [Arkin, 2005; Arkin
and Wells, 2004; Cochran, 2000; Loregian and Palù, 2005; Wells and McClendon,
2007],
 The interaction interface might be very large and ﬂat
 Very few residues at the interface might contribute to the binding within the
contact surfaces
 A single point mutation in one of the subunit of the protein-protein interface
can lead to the disruption of the subunit interaction or reduce its binding
afﬁnity signiﬁcantly
 Afﬁnity of protein-protein interactions
The nature of protein-protein interfaces vary widely and not all interactions are
amenable for drug discovery as others do.
Several approaches have been tried to target protein-protein interactions viz.,
 Natural occurring small molecules. Example: Taxol [Downing, 2000] and
rapamycin [Choi et al., 1996]
 Small molecule substrates of enzymes as starting template for designing an-
tagonists. Examples include several enzymes
 Mapping the epitope of the proteins onto a small peptide or pep-
tidomimetic. Example: peptide targeting integrins GPIIbIIIa, v3 and
41 [Arkin and Wells, 2004]
 Random screening. Example: Vinca alkaloids against tubulin polymerization
 Identiﬁcation of ‘Hotspots’ (centralized regions of residues that are crucial for
the afﬁnity of the interaction) by various biophysical techniques, at the binding
interface of protein-protein interface aids in efﬁcient design of drugs. Exam-
ple: Ro26-4550 an inhibitor of a cytokine-receptor interaction [Arkin and
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4.1.2 Small molecule inhibitor of Hsp90-Cdc37 complex
In chapter 3, subsection 3.5.4, we have seen the importance of targeting the
protein-protein complex Hsp90-Cdc37. This protein-protein complex forms with a
KD = 1.2 M, and is considered to mediate carcinogenesis by stabilizing a variety
of different oncogenic kinases in malignant cells. Low molecular weight molecules
that interfere with Cdc37 or Hsp90 or disrupt the Hsp90-Cdc37 complex have
recently been proposed as a new class of anti-cancer agents [Gray et al., 2008;
Smith and Workman, 2009]. Gene based-expression studies have identiﬁed the
triterpene celastrol, representing a new class of non ATP-competitive inhibitors of
Hsp90 [Hieronymus et al., 2006]. Immunoprecipitation in a pancreatic cell line and
docking experiments suggested that celastrol exerts its anti-proliferative activity
by binding to the N-terminal domain of Hsp90 (Hsp90N), thereby disrupting the
complex between Hsp90N and Cdc37 [Zhang et al., 2008a]. In vivo, celastrol
showed signiﬁcant inhibition of tumor growth in nude mice with prostate or
pancreatic cancer [Yang et al., 2006; Zhang et al., 2008a].
However, in this thesis we established by NMR that celastrol disrupts the Hsp90-
Cdc37, by binding to Cdc37 (Figure 4.1), in contrast to the published reports
(see Chapter 8). Celastrol inactivates Cdc37 by a thiol-mediated mechanism
(Figure 4.2).52 Chapter4. Small Molecule Inhibitors for Disrupting Protein-Protein Interaction
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Figure 4.1: Binding of celastrol to Cdc37.
A) (left) 1H,15N HSQC spectrum of Hsp90N. (middle) 1H,15N HSQC spectrum
of Hsp90N-Cdc37 complex. (right) Upon addition of celastrol (1:7 of Hsp90N-
Cdc37:celastrol), the complex dissociates and the spectrum of free Hsp90N is
retained indicating that celastrol does not bind to Hsp90N. B) (left) 1H,15N HSQC
spectrum of full-length Cdc37 (45 kDa). (right) The cross-peaks disappear upon
addition of celastrol (1:7 of Cdc37:celastrol), indicating a complex formation with
Cdc37.
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Figure 4.2: Mechanism
of inactivation of Cdc37
by celastrol. Celastrol
inactivates Cdc37 either by
the formation of a covalent
adduct(s) with thiol(s) of
Cdc37, by formation of an
intramolecular disulﬁde bond
or by intermolecular aggre-
gates.5
NMR Methods to Study Protein-Protein
interactions
5.1 Introduction
C
haracterizing protein-protein interaction is vital for understanding the
molecular mechanism of cellular processes [Alberts, 1998]. Several exper-
imental techniques have been used to characterize protein interactions. Table 5.1
lists some of the genetic, biochemical and biophysical techniques used to analyze
protein interactions. Some of these techniques are used for screening a large
number of protein interactions in cell, viz., Yeast-2-hybrid system (Y2H), tandem
afﬁnity puriﬁcation (TAP) etc., and other methods mainly are used to characterizing
the biochemical, and physico-chemical properties of interaction.
Table 5.1: Diﬀerent methods used to characterize
protein-protein interactions
Method High-
throughput
approach
Living
cell assay
Type of interactions Type of characterization
Y2H + In vivo Physical interaction (binary) Identiﬁcation
Afﬁnity puriﬁcation-MS + In vitro Physical interaction (complex) Identiﬁcation
DNA microarrays/gene coex-
pression
+ In vitro Functional association Identiﬁcation
Protein microarrays + In vitro Physical interaction (complex) Identiﬁcation
Synthetic lethality + In vitro Functional association Identiﬁcation
Phage display + In vitro Physical interaction (complex) Identiﬁcation
X-ray crystallography - In vitro Physical interaction (complex) Structural and biological
characterization
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Table 5.1: (continued...)
Method High-
throughput
approach
Living
cell assay
Type of interactions Type of characterization
NMR spectroscopy - In vitro Physical interaction (complex) Kinetic, dynamic, struc-
tural and biological charac-
terization
Fluorescence resonance energy
transfer
- In vitro Physical interaction (binary) Dynamic and Biological
characterization
Surface plasmon resonance - In vitro Physical interaction (complex) Kinetic and dynamic char-
acterization
Atomic force microscopy - In vitro Physical interaction (binary) Mechanical and dynamic
characterization
Electron microscopy - In vitro Physical interaction (complex) Structural and biological
characterization
In this chapter, we will discuss more about Nuclear Magnetic Resonance(NMR)
spectroscopy, which is the major technique used in this thesis. We will specially
focus its application towards the study of protein-protein interaction.
5.2 Nuclear Magnetic Resonance (NMR) methods to
study proteins and protein complexes
5.2.1 Introduction
NMR spectroscopy is an experimental tool developed independently by Felix Bloch
and Edward Purcell in the year 1945, who were primarily interested in exploring
fundamental properties of matter. Since then in sixty years its applications
has grown enormously than ever they could have imagined. One such area of
application is structural biology, where in it is used to elucidate the structure and
function of biomacromolecules in the fascinating world of cellular organization. It
has become the only technique with the ability of studying kinetics, dynamics, and
structure determination at atomic resolution in solution and near to physiological
condition. Figure 5.1 shows timescale of dynamic processes of proteins and the
various experimental techniques that can detect on each timescale, with special
emphasis on NMR parameters. In contrast to the three-dimensional static structures
of proteins determined by X-ray crystallography, NMR adds the fourth dimension
‘time’ and thereby reveals the dynamic personality of these proteins, which becomes
fundamental for describing cellular function of proteins.
NMR phenomena is a property of all the atomic nuclei called the ‘spin’ and the most5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 55
Low-resolution
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Figure 5.1: Protein dynamics and methods to study. (A) Timescale of dynamic processes
in proteins and the experimental methods that can detect ﬂuctuations on each timescale
(modiﬁed from Henzler-Wildman and Kern [2007]). (B) The diﬀerent processes amenable to
NMR spectroscopy are indicated above the time arrow, below are the typical time windows for
diﬀerent molecular motions and events.56 Chapter5. NMR Methods to Study Protein-Protein interactions
commonly studied nuclei are the spin 1
2 particles, 1H, 13C, 15N and 31P. Proteins
are rich in protons and this property has been utilized and the ﬁrst 1D NMR
spectra of a protein (ribonuclease) was recorded in 1957 [Jardetzky and Jardetzky,
1957]. However, as proteins contain a large number of atoms, and hence it is
hard to expect that the resonance lines of individual atoms could be resolved
by a one dimensional spectra. Hence the current technological advancement in
NMR allows us to extend to multidimensional NMR experiments. Multidimensional
experiments are not limited to a single type of atoms such as protons (1H-1H COSY,
1H-1H TOCSY and 1H-1H NOESY). By isotopically enriching the proteins with
15N and 13C, an additional frequency domain can be added, thereby increasing
the spectral resolution and the information gained from multidimensional
experiments. Important is the heteronuclear single quantum coherence (HSQC)
experiment that correlates the resonance frequency of a proton with that of
the directly bonded hetero nucleus, example, the amide proton resonance with
amide nitrogen resonance. Table 5.2 summarizes a selection of important NMR
experiments.
Table 5.2: Important nD experiments
Experiment Correlated resonances References
COSY Directly J-coupled spins [Aue et al., 1976]
TOCSY All spins of a J-coupled spin system [Braunschweiler and Ernst,
1983]
NOESY All spins in close neighborhood (<
0.5 nm)
[Jeener et al., 1979]
HSQC Protons with directly bound to 15N
or 13C, ‘ﬁngerprint’
[Bax et al., 1990b;
Bodenhausen and Ruben,
1980; Müller, 1979; Norwood
et al., 1990]
HNCA HN
i with NH
i and C
i and C
i 1 [Farmer II et al., 1992; Grze-
siek and Bax, 1992c; Kay et al.,
1990]
HNCO HN
i with NH
i and C
0
i 1 [Grzesiek and Bax, 1992c; Kay
et al., 1990; Muhandiram and
Kay, 1994]
HN(CO)CA HN
i with NH
i and C
i 1 [Bax and Ikura, 1991; Grzesiek
and Bax, 1992a]
HCCH-TOCSY H with via 13C coupled protons of
the same amino acid
[Bax et al., 1990a; Olejniczak
et al., 1992]
CBCA(CO)NH C
i 1 and C

i 1with NH
i and HN
i [Grzesiek and Bax, 1992a,
1993]
CBCANH C
i , C

i , C
i 1 and C

i 1 with NH
i
and HN
i
[Grzesiek and Bax, 1992b]
HN(CO)CACB HN
i with NH
i and C
i 1 and C

i 1 [Yamazaki et al., 1994]
HNCACB HN
i with NH
i and C
i , C

i , C
i 1 and
C

i 1
[Muhandiram and Kay, 1994;
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However, the major disadvantage of NMR to study proteins and protein-protein
complexes is its size limitation. In the next subsection 5.2.2 we will see how one
typically tries to overcome this problem by using a combination of advanced NMR
experiments and protein properties.
5.2.2 Methods to study large proteins: use of advanced NMR
methods and optimization of protein domains to study
protein-protein interactions
Studying high molecular weight proteins and macromolecular complexes by NMR,
is limited by number of factors, viz.,
1. high complexity of the spectra due to extensive signal overlap
2. decreased sensitivity due to low concentrations of the sample
3. rapid transverse relaxation leads to even low sensitivity and signiﬁcant line
broadening of the signals
5.2.3 NMR methods
For large molecules, the relaxation rate is 1/T2 and thus the linewidth 1=2 =
1/(T2) is proportional to the rotational correlation time c. Since the rotational
correlation time, c is proportional to the molecular weight, the T2 is inversely
proportional to the molecular weight(MW)(Equation 5.1).
T2 =
1
MW
(5.1)
As the size of the molecule increases, the T2 becomes shorter. In larger molecules,
it becomes increasingly more difﬁcult to transfer magnetization between spins
because of the relaxation losses that are incurred during the polarization transfer
periods. There are two methods by which the T2 of the spins can be lengthened. The
ﬁrst involves changing the rotational correlation time of the sample by changing the
temperature, since c for a spherically rigid molecule will follow the Stokes-Einstein
equation (Equation 5.2).
c =
V 
T
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where V the volume of the protein,  the viscosity, and T the absolute tempera-
ture. The second method utilizes relaxation interference between dipolar coupling
and the chemical shift anisotropy. Considerable effort in this direction has been
made to overcome this limitation using deuteration, creative labeling schemes and
advanced pulse sequences such as TROSY [Pervushin et al., 1997] (transverse
relaxation optimized spectroscopy), CRIPT [Riek et al., 1999] (cross-correlated
relaxation-induced polarization transfer) and CRINEPT [Riek et al., 1999] (cross-
correlated relaxation-enhanced polarization transfer). Thus it has become possible
to record well resolved spectra and obtain some structural details for systems
up to 900 kDa [Fiaux et al., 2002; Horst et al., 2005; Kreishman-Deitrick et al.,
2003]. Methyl labeling strategies has enabled resonance assignment and structure
calculation of an 82 kDa monomeric protein [Tugarinov et al., 2005; Tugarinov and
Kay, 2004; Tugarinov et al., 2002].
5.2.4 Optimization of protein domains for NMR studies
Apart from the above described NMR methods, the most commonly used method to
overcome high-molecular weight problem is the “ divide-and-conquer” approach,
where constituent domains of a protein are individually cloned, expressed, and
puriﬁed. Theoretically, this strategy reduces the c by decreasing the molecular
weight, and there by increases the sharpness of the resonance signals.
Some of the methods used to identify the domain boundaries in proteins include
[Card and Gardner, 2005],
1. Computational methods
 Domain prediction methods
 Secondary structure prediction methods
2. Experimental methods
 Parallel fragment cloning and expression
 Choice of fusion protein
 E. coli cell lysate screening by NMR
Computational methods: Robust algorithms has been designed to identify
and annotate protein domains and secondary structural elements to locate
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expressed. Domain prediction methods utilizes the Hidden Markov Models [Krogh
et al., 1994] (HMM), wherein multiple alignments are based on the assumption
that structurally similar proteins could still vary largely in sequence, but there
should be conserved elements within the primary sequence that deﬁnes the folding,
structure and function of the target. Pfam and SMART libraries (a Simple Modular
Architecture Research Tool) are such tools based on this algorithm and are widely
used. SMART also offers additional advantage of identifying compositionally biased
regions such as transmembrane segments, which can assist in the rational design of
protein fragments with less aggregation properties for concentrations required for
NMR. Secondary structure prediction methods such as PHD, PREDATOR and JPred
also assist in identifying secondary structures and domain boundaries.
Experimental methods: Limited proteolytic digestion is one of the common
methods used to identify the stable domains in proteins [Cohen et al., 1995]. In
this thesis we have utilized this strategy for optimizing the domains of 45 kDa
protein Cdc37 for NMR study (Figure 5.2). Additionally one could also use
parallel expression approach, wherein multiple N- and C-termini ﬂanking domains
identiﬁed previously by computational methods are cloned with fusion proteins
(example protein GB1) to enhance solubility and then screened the expressed
protein by recording a 2D 1H,15N HSQC, whose foldedness can be easily assessed
by the dispersion of the backbone amide proton chemical shifts. Additionally, for
proteins less than 20 kDa, direct measuring of 2D 1H,15N HSQC of the E. coli cell
lysate from cultures over expressing proteins is very useful. This method has been
used for domain optimization of N-terminal PAS domain of human PAS kinase
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Figure 5.2: 1H,15N TROSY spectra (950 MHz) of different Cdc37 constructs. The
boundaries of each construct (eg: (A) full length, (B) N-terminal and Middle domain, (C) N-
terminal domain, (D) Middle domain) are schematically indicated below each spectrum. The inlay
shows three peaks stemming from the middle domain (Cdc37M), showing the same fold for this
domain in all constructs. The spectra were acquired at 298 K in the same buﬀer solution [50 mM
Hepes buﬀer (pH 7.5), 100 mM NaCl, 1 mM DTT and 10% D2O].5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 61
5.2.5 NMR based methods for the study of protein-protein inter-
action [Zuiderweg, 2002]
NMR provides the most informative but also is the most difﬁcult method for
studying large protein-protein complexes and its structure determination. In most
of the applications it is sufﬁcient just to map the protein-protein interface (or
the interaction site) and then use this information to dock the two proteins or
protein-ligand. Some of the important methods used for mapping the protein-
protein interface are,
1. Nuclear Overhauser Effect (NOE)
2. Chemical Shift Perturbation (CSP)
3. Cross-Saturation Transfer (CST)
4. Mapping with Dynamics
5. Mapping with Amide-Proton Exchange (H-D Exchange)
6. Mapping with Paramagnetics
7. Mapping with site-speciﬁc Spin-labeling
8. Relative positions of proteins using Residual Dipolar Couplings (RDC)
5.2.5.1 Nuclear Overhauser Effect (NOE)
Mapping of biomacromolecular interactions by using NOE method provides an
unambiguous information. NOE measures the interproton distances with a distance
proportionality of r 6. Using many NOE derived distance constraints between two
interacting partners and in addition to several thousands intramolecular NOEs, one
can arrive at a three-dimensional structure of the complex. This method is specially
useful to probe tightly binding partners ( kD = 10 M). Isotope edited NOE [Fesik
et al., 1988] (half-ﬁlter) is the most widely used technique to map protein-protein
interface. This requires that the two interacting macromolecules have different
isotope labeling patterns. For example, one partner has no labeling (1H, 12C, and
14N) while the other is labeled with stable isotopes, example 1H, 12C, 15N or 1H, 13C,
14N or sometimes even 1H, 2H, 13C, and 15N. The 40 kDa protein-protein complex
EIN-HPr (Enzyme I N-terminus-Histidine containing phospho carrier protein) was
solved exclusively by this method [Garrett et al., 1999]. Several examples of
protein-DNA exist as it is a very suitable method for using labeled protein and62 Chapter5. NMR Methods to Study Protein-Protein interactions
unlabeled nucleic acids. Examples in this class include the complex of the lac
repressor protein with lac operator DNA [Spronk et al., 1999].
5.2.5.2 Chemical Shift Perturbation (CSP)
CSP is the widely used NMR method to map the protein interfaces. The chemical
shift (resonance frequency) of a given spin in the protein reﬂects the chemical
environment and responds very sensitively to any small changes structurally. In a
nutshell, the 1H,15N HSQC spectrum of a protein is monitored when the unlabeled
interaction partner is titrated in (NMR titration), and the perturbations of the
chemical shifts are recorded. The quantiﬁcation of chemical shift () is made by
calculating the length of the vector that connects the two-dimensional end points,
normalized by typical shift ranges [Qin et al., 2001](Equation 5.3).
av = [(
2
HN + 
2
N=25)=2]
1=2 (5.3)
The maximum shift change resonance also provides estimates for the lower
limit of the dissociation rate constant. Some of the examples for which mapping
methodology was used include complexes between HPr-eEnzyme-II [Emerson
et al., 1995; Garrett et al., 1997], GB1-Fc [Otting, 1993], cRAF-Ras-GMPPNP
[Foster et al., 1998], 1Nef-CD4 complex [Grzesiek et al., 1996], etc. Generally,
one cannot use chemical shift to know what exactly happens at the interface on a
per atom basis, but it gives a picture of the local and global changes induced as a
result of complex formation. In other terms, they provide connectivity of putative
interaction site. Figure 5.3 shows the correlation of CSPs versus residues in Cdc37M
upon addition of Hsp90N and vice-versa.
NMR titration experiments in addition to providing the information for mapping
of the interface, it also gives a good estimation of the afﬁnity, stoichiometry, and
speciﬁcity of binding as well as the kinetics of binding. A key factor in the use of
NMR for measuring dissociation constants is its sensitivity to the rate of “chemical
exchange”.
Chemical exchange and NMR: In NMR, “chemical exchange” refers to any process
in which a nucleus exchanges between two or more environments in which its NMR
parameters (chemical shift, scalar or dipolar coupling, relaxation) differ. The effect
of this exchange process on the appearance of the NMR spectrum depends on the5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 63
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Figure 5.3: Titration of Cdc37M with Hsp90N and vice-versa. (A) Correlation of CSPs
versus residues in Cdc37M upon addition of Hsp90N (left) and surface representation of the
interaction sites of Cdc37M (yellow) for Hsp90N (> 0.15 ppm). (B) Correlation of CSPs versus
residues in Hsp90N upon addition of Cdc37M (left) and surface representation of the interaction
sites of Hsp90N (purple) for Cdc37M (> 0.1 ppm). For the CSPs, amide 1H and 15N resonance
shifts have been mapped and combined as Euclidian distances between peak maxima taking into
account the gyromagnetic ratio of proton and nitrogen (in 1H ppm). Missing bars indicate prolines
or amide resonances that have not been assigned.
rate of exchange relative to the magnitude of the difference in NMR parameters
between the two states.
The kinetics of exchange reaction are deﬁned by the following scheme:
A
k1


k2
B (5.4)
The kinetic rate constant for the conversion of A to B is k1 and the rate constant
for the reverse reaction is k2 (Equation 5.4). To characterize the different time
scales of exchange it is useful to deﬁne an apparent exchange rate, kex = k1 +
k2, and a frequency difference between the two states, ! = !A - !B. Table 5.364 Chapter5. NMR Methods to Study Protein-Protein interactions
summarizes the effects of exchange on the properties of the NMR spectrum. The left
columns describe the exchange in terms of the relationship between the frequency
separation ( = 1=2(!A - !B)) and the apparent exchange rate constant (kex=
k1 + k2). The remaining columns describe the effect of exchange on the spectrum
and the appropriate experimental technique to characterize the exchange rate. A
more comprehensive description of the methodologies that can be used to measure
chemical exchange can be found in Palmer et al. [2001] Note that the response
of the system to chemical exchange depends on the ratio of the exchange rate to
the frequency difference of the spins in each environment, i.e. kex/!. Figure 5.4
shows an example of effect of ligand binding on the NMR lineshapes.
Table 5.3: Summary of the eﬀects of exchange on the
properties of the NMR spectrum
Chemical
exchange type
Exchange rate * Observed spectrum Experimental
technique
Very slow kex <<  0 Two resonances Exchange spec-
troscopy
Slow kex <  <1 Two broadened reso-
nances
Line width mea-
surement
Intermediate kex   1 Complex line shape Line shape anal-
ysis
Fast kex >  >1 Single broadened
resonance
Spin-echo
R(cp)
Very fast kex >>  2 Single resonance Spin-lock R(!e)
* is a dimensionless parameter as deﬁned by Millet et al. [2000]
In Figure 5.4(B), one observes that some peaks disappear and reappear at a new
chemical shift, and other peaks just shifting in position, would indicate that some
peaks are undergoing exchange on a slow to intermediate timescale and some on
a fast time scale. The apparently disparate behavior of the peaks arises from the
dependence of the line shape on the chemical shift difference between the bound
and unbound states. Larger chemical shift differences lead to the appearance of
new peak concomitantly with loss of intensity at the original frequency and smaller
chemical shift differences give rise to a gradual shifting and broadening of the peak.
5.2.5.3 Cross-Saturation Transfer (CST)
CST [Takahashi et al., 2000] is an highly relevant quick interface mapping
technique. Cross-saturation is governed by the same physical process as that
of NOE experiment. The donating partner protein is not labeled, while the observed5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 65
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Figure 5.4: Effects of ligand binding on NMR lineshapes. (A)This ﬁgure illustrates the
eﬀect of slow (left), intermediate (middle), or fast (right) exchange on the spectrum of a
resonance, whose frequency is changed as a result of ligand binding.(B) Expanded region of
the overlaid 1H, 15N HSQC spectra from a titration of 15N-labeled S100B with CapZ peptide
[Kilby et al., 1997]. The protein concentration was 1 mM, and the spectra shown are for peptide
concentrations of 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.5 and 3.0 mM. Chemical shift changes for the
cross peaks of Ser62, Glu72 and Ala78 are indicated.
protein is perdeuterated and 15N labeled, but its amide deuterons are exchanged
back to protons (Figure 5.5).
The NMR experiment starts with a steady state saturation of, exclusively, all
aliphatic proton resonances of the donating partner. Cross-saturation carries the
saturation from the donor to the acceptor protein amide protons, where it is
detected using 1H,15N HSQC or, for larger proteins, 1H,15N TROSY. Those acceptor
cross-peaks that change in intensity upon donor saturation are very likely to be
close to the intermolecular interface. The labeling can be reversed to obtain the
other interface. This method has been successfully used for mapping the interface
between Mbp1(Mlu1 cell cycle binding protein 1)-DNA complex [Lane et al., 2001],
Cytochrome b5-Cytochrome c Complex [Deep et al., 2005] etc. In this thesis, we
have used this experiment to map the binding interface of Cdc37M-Hsp90N complex
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Figure 5.5: Principle of the cross-saturation transfer NMR experiment.
Figure 5.6: Cross-saturation transfer method used for Cdc37M-Hsp90N complex. Plot
of the intensity ratios of the crosspeaks in the cross-saturation transfer experiment. The intensity
ratios of the backbone amide resonance of Cdc37M in complex with Hsp90N with irradiation
to those of without irradiation measured in 10 % H2O / 90 % D2O. Surface representation of
Cdc37M, where residues with intensity ratio less than 0.78 are colored in yellow.
For weakly binding proteins another variation of the above experiment is transferred
cross-saturation experiment (TCS) [Nakanishi et al., 2002]. This method has been
successfully used in mapping the epitopes of ligand proteins for binding to a
membrane protein (agitoxin2 (AgTx2) to the KcsA K+ channel) [Takeuchi et al.,
2003], a membrane (mastoparan bound to the lipid bilayer) [Nakamura et al.,
2005] and the heterogenous system of the extracellular matrix (A3 domain of
von Willebrand factor (vWF-A3) and ﬁbrillar collagen) [Nishida et al., 2003]. It
has recently been used to map interfaces of a 164 kDa protein-protein complex (B
domain of protein A and intact IgG) [Nakanishi et al., 2002]. TCS method is very5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 67
robust and could tolerate wide sample conditions, which is exempliﬁed by its use
to map the binding faces of ligand proteins to membrane embedded in liposomes
that were attached to solid beads (bead-linked proteoliposomes, composed of a
potassium channel, KcsA, embedded in the lipid bilayer (KcsA-proteoliposomes),
and used them to map the interaction interface between KcsA and its pore-blocking
peptide, agitoxin2 (AgTx2)) [Yokogawa et al., 2005].
5.2.5.4 Mapping with dynamics
15N relaxation experiments in NMR is used to describe dynamics in proteins. Use of
these experiments to map the interface has a mixed message, since, in some cases
the dynamics gets quenched and some others not. The former case is exempliﬁed
by the rigidiﬁcation of the residues at the interface of the NSyp SH2 domain
(tyrosine phosphatase) with peptide [Kay et al., 1998], shows increase in the order
parameter for the bound state in comparison to its free state. Another example is,
15N transverse relaxation rates for the free lipolyl domain and its complex with
E1 component of the pyruvate dehydrogenase shows a loss of fast motion in the
complex in comparison to the free form. However, the interaction of hydrophobic
peptides with hydrophobic contact area of the PLCC SH2 domain (C-terminal SH2
domain of phospholipase C-
1) shows no change in dynamics [Kay et al., 1996].
5.2.5.5 Mapping with amide-proton exchange (H-D Exchange)
Using amide-proton exchange one could map the interfaces of the protein. The
solvent accessibility of the transiently unfolded areas allow the exchange of protons
or deuterons, to take place on a timescales ranging from minutes to months. The
formation of protein-protein complex is expected to protect the interface from such
exchange. This method has been used for very high afﬁnity interactions like antigen-
antibody viz., epitopes of Der p 2 could be determined in the presence and absence
of antibodies [Mueller et al., 2001].
5.2.5.6 Mapping with paramagnetics
Paramangnetic tools also appears to be a promising NMR method to identify protein-
protein interface. This is based on the principle that if a protein is kept in a
paramagnetic solution, only its surface residues will be affected by the paramagnetic
line broadening. Interaction site between the catalytic domain of matrix metallo-
proteinase 3 and its protein inhibitor TIMP was obtained by comparing the line68 Chapter5. NMR Methods to Study Protein-Protein interactions
broadening of the amide-proton of mettaloproteinase by paramagnetic gadolinium-
EDTA in the presence and absence of TIMP [Arumugam et al., 1998].
5.2.5.7 Mapping with site-speciﬁc spin labeling
TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl), a free stable radical nitroxide can
interact speciﬁcally with cysteine groups on the protein surface [Jahnke et al.,
2001]. The NMR line broadening of the resonances are proportional to the 1/r6
and hence useful distance restraints can be obtained from this data, which could
be used for calculation of a structure. TE33-peptide complex model was calculated
using this method [Scherf et al., 1995].
5.2.5.8 Relative positions of proteins using Residual Dipolar Couplings (RDC)
Dipolar coupling between the nuclei in a biomolecule averages to zero when it
tumbles in a isotropic solution. But now suppose that the protein (biomolecule)
is not dissolved in isotropic solution but rather in a media that leads to fractional
alignment, then the dipolar coupling does not average to zero. The result is that
small dipolar splittings (residual dipolar couplings, RDCs) are retained in the
solution NMR spectra. The weak alignment can be obtained using magnetic ﬁelds,
or in dilute solutions of bicelles or ﬁlamentous phages [Hansen et al., 1998; Tjandra
and Bax, 1997; Tolman et al., 1997]. RDCs thus obtained has been used to obtain
relative domain orientation [Fischer et al., 1999; Mueller et al., 2000] and or
relative protein orientations in a multiprotein complex [Clore, 2000].
5.2.6 NMR based methods to calculate three-dimensional struc-
tures of protein complexes
The NMR structure determination is still mainly based on two pieces of information
extracted from the NMR data, the determination of interatomic distances (NOEs),
and dihedral angles. This information usually has to be completed by independent
information from other sources describing the physical model including the covalent
structure of the protein (Table 5.4). In addition, a number of other NMR-derived
restraints can be measured that help to obtain a more reﬁned structure.5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 69
Table 5.4: Restraints used for the NMR structure calculation
Data Information
External restraints describing the physical model
Covalent structure of amino acids and ligands (bond lengths, bond
angles, dihedral angles, van der Waals radii, connectivity of atoms)
Possible positions of atoms in the confor-
mational space
Amino acid sequence and possible ligands Deﬁnition of the whole molecular com-
plex
Disulﬁde bridges and other side-chain connections Further restriction of the conformational
space
Interatomic potentials (e.g., electrostatic potentials, Lennard–Jones
potentials)
Further restriction of the conformational
space
Homology models Faster optimization
NMR derived data
NOE Interatomic distances
J-coupling Dihedral angles
Chemical shift Dihedral angles, interatomic distances,
relative orientation of groups
Residual dipolar couplings Interatomic distances and orientation
HNCO-type polarization transfer Pairwise hydrogen bonding
Temperature dependence of amide chemical shifts Hydrogen bonding
Hydrogen exchange rates Hydrogen bonding
Non-averaged chemical shift anisotropy Orientations of bond vectors, distance
information
For large protein complexes, it is often very difﬁcult to obtain enough NMR data to
calculate high quality structures. It might become even more mandatory to obtain a
structure with limited set of experimental data specially in situations like proteomics
and high throughput screening. Hence a combination of computational and NMR
data is now being successfully used for obtaining structures of large biomolecular
complexes. Two broad ways of calculating structures are,
1. Calculation of structures with limited set of experimental data: Before
proceeding to the docking procedure of protein-protein or protein-ligand,
one has to know the 3D structure of the individual components. One such
method is ROSETTA [Bowers et al., 2000] which uses NMR chemical shift data
along with NOE data. Other methods involve use of NMR data with standard
structure calculation procedures such as CNS or X-PLOR.
2. Docking of proteins on the basis of experimental data: NMR is particularly
powerful in mapping the interfaces, allowing the study of weak and transient
complexes that can be very difﬁcult to be studied by other techniques. If the
structures of the two individual components in a protein-protein interaction
are known, then one could dock these two individual structures based on the
experimentally obtained data. McCoy and Wyss [2002] ﬁrst showed the use of
CSP as a structural restraint for solving structures of protein complexes. Some70 Chapter5. NMR Methods to Study Protein-Protein interactions
of the docking programs like BiGGER use experimental data only for scoring
the ﬁnal structures obtained. HADDOCK (High Ambiguity Driven biomolecular
DOCKing) is the most widely used docking program, which uses ambiguous in-
teraction restraints [Dominguez et al., 2003]. In the HADDOCK approach, CSP
data are translated into ambiguous restraints to drive the docking process. The
CSP interaction restraints can also be combined with RDC data allowing a
better deﬁnition of the relative orientation of the components. In this thesis
we have used CSP, CST, NOE and RDC data to obtain the structure of human
Cdc37M-Hsp90N , protein-protein complex (Figure 5.7).5.2. Nuclear Magnetic Resonance (NMR) methods to study proteins and protein complexes 71
Figure 5.7: NMR data driven docking model of human Cdc37M-Hsp90N complex. (A)
Surface representation of Cdc37M. (Left) The molecular surface is color-coded by electrostatic
potential, as calculated with DELPHI. Potentials less than -10 kT are red, those greater than
+10 kT are blue, and neutral potentials (0 kT) are white. The color in between is produced
by linear extrapolation. (Middle) CSPs from Figure 5.3 (> 0.15 ppm) in yellow mapped on
to the structure. (Right) cross-saturation transfer experiment in which residues with intensity
ratios less than 0.78 are mapped on to the surface (yellow). (B) Surface representation of human
Hsp90N (1YES.pdb). (Left) The molecular surface is color-coded by electrostatic potential, as
calculated with DELPHI. (Right) CSPs from Figure 5.3 (> 0.1 ppm) in purple mapped on to the
structure. (C) Bundle of the Cdc37M-Hsp90N complex as obtained using HADDOCK, with and
without using RDCs. For the calculation without RDCs (left), the ten best docking results for
each of the two major HADDOCK clusters are shown and for the calculation with RDCs (right)
the ten best docking results are shown. The active/passive restraints were used as deﬁned in the
materials and methods section and are colored respectively in red and yellow for Hsp90N or blue
and dark-green for Cdc37M. The RDC tensors for alignment in either polyacrylamide (PAA) gel or
pf1 Phages are indicated below. (D) Correlation of the experimental versus back calculated RDCs
for the free form X-ray structures of Cdc37M (blue) and Hsp90N (red). Protons were added to
the X-ray structures using CNS 1.1 [Brünger, 1998] without using the RDCs. RDCs were back
calculated using the program PALES [Zweckstetter and Bax, 2000] with the bestFit option. (Left)
Correlation plot in PAA gel alignment medium with Cdc37M in blue (25 RDCs, Correlation co-
eﬃcient of 0.822) and Hsp90N in red (52 RDCs, Correlation co-eﬃcient of 0.903). (Right)
Correlation plot in pf1 phages alignment medium with Cdc37 in blue (42 RDCs, Correlation
co-eﬃcient of 0.816) and Hsp90N in red (79 RDCs, Correlation co-eﬃcient of 0.964).6
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In this article we used NMR to study the folding and activity of cAMP-dependent
protein kinase (PKA, a surrogate of oncogenic kinase AKT/PKB) mutants.
AKT/PKB is a oncogenic protein kinase, which is a very well validated drug
target. Therefore, obtaining speciﬁc small molecule inhibitors for Akt/PKB is
highly desirable. A major obstacle on this way is the production of large quantities
of pure and active Akt/PKB protein for structural studies, since it cannot be
expressed in Escherichia coli in a functional form. Furthermore, Akt/PKB has to be
phosphorylated on the activation loop as well as in a regulatory sequence, called
the hydrophobic motif . Since both PKA and Akt/PKB belong to the AGC-family
of protein kinases and share high sequence homology, PKA has been used as a
surrogate kinase for Akt/PKB.
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PKA has four phosphorylation sites and undergoes autophosphorylation when
expressed in E. coli. But the autophosphorylation is not uniform and hence results
in mixture of differently phosphorylated isoforms, leading to requirement of an
additional puriﬁcation step and also making it not very suitable for precision-
oriented structural studies. In this contribution we made several phospho-mutants
of PKA, accessed their folding by using TROSY NMR and also compared their
activity with wild-type.
The author of this thesis has performed all molecular biology work and NMR
analysis, in part together with Dr. Thomas Langer and Dr. Martin Vogtherr.Folding and activity of cAMP-dependent protein kinase mutants
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Abstract The catalytic subunit of cAMP-dependent protein ki-
nase (PKA) can easily be expressed in Escherichia coli and is
catalytically active. Four phosphorylation sites are known in
PKA (S10, S139, T197 and S338), and the isolated recombinant
protein is a mixture of diﬀerent phosphorylated forms. Obtaining
uniformly phosphorylated protein requires separation of the pro-
tein preparation leading to signiﬁcant loss in protein yield. It is
found that the mutant S10A/S139D/S338D has similar proper-
ties as the wild-type protein, whereas additional replacement of
T197 with either E or D reduces protein expression yield as well
as folding propensity of the protein. Due to its high sequence
homology to Akt/PKB, which cannot easily be expressed in E.
coli, PKA has been used as a surrogate kinase for drug design.
Several mutations within the ATP binding site have been de-
scribed to make PKA even more similar to Akt/PKB. Two pro-
teins with Akt/PKB-like mutations in the ATP binding site were
made (PKAB6 and PKAB8), and in addition S10, S139 and
S338 phosphorylation sites have been removed. These proteins
can be expressed in high yields but have reduced activity com-
pared to the wild-type. Proper folding of all proteins was ana-
lyzed by 2D
1H,
15N-TROSY NMR experiments.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Nuclear magnetic resonance; Protein kinase A;
PKA; Akt; Protein phosphorylation
1. Introduction
Protein kinases are a major protein class that regulate a mul-
titude of cellular processes. This is achieved by catalyzing the
transfer of the c-phosphate from ATP to the target protein,
thereby changing its activity. Due to their indispensable func-
tion in cellular signaling, deregulation of certain protein ki-
nases result in disease. Inhibition of these deregulated
protein kinases by small molecule inhibitors is pharmaceuti-
cally relevant [1,2]. Successful examples of this strategy are
Gleevec (imatinib), which inhibits cAbl [3], or Iressa (geﬁtinib),
which targets the kinase domain of EGFR [4]. Akt/PKB is a
protein kinase that has been found frequently in a constitu-
tively active form in human cancers. The central role of Akt/
PKB is well validated [5,6]. Therefore, obtaining speciﬁc small
molecule inhibitors for Akt/PKB is highly desirable. A major
obstacle on this way is the production of large quantities of
pure and active Akt/PKB protein for structural studies, since
it cannot be expressed in Escherichia coli in a functional form.
Furthermore, Akt/PKB has to be phosphorylated on the acti-
vation loop as well as in a regulatory sequence, called the
hydrophobic motif [6]. Since both PKA and Akt/PKB belong
to the AGC-family of protein kinases and share high sequence
homology, PKA has been used as a surrogate kinase for Akt/
PKB. To make PKA more similar to Akt/PKB distinct muta-
tions within the ATP-binding region have successfully been
produced [7,8]. PKA has also been used as a surrogate for
Rho-kinase [9].
Nearly all protein kinases are regulated by phosphorylation
themselves. The most critical part hereby lies in the so-called
activation loop. Upon phosphorylation of a certain residue
within the activation loop, the protein kinase active site is
reoriented to allow proper ATP and substrate binding. When
expressed in E. coli, PKA is catalytically active and undergoes
autophosphorylation. There are four phosphorylation sites
within PKA: S10, S139, T197 and S338. The recombinantly ex-
pressed protein is a mixture of diﬀerently phosphorylated iso-
forms with 2, 3 or 4 phosphate groups; the protein lacks a
unique phosphorylation pattern [10–12]. Phosphorylation of
T197 in the activation loop is essential for activity. Changing
T197 to alanine results in a folded, but unstable and inactive
protein. Phosphorylation of S338 has no inﬂuence on activity
but enhances protein stability [11,13]. For PKA, phosphoryla-
tion of residue S10 has not been found in preparations from
mammalian sources and a physiological role of S10 phosphor-
ylation has only recently been proposed [14]. Also, PKA from
mammalian tissues with phosphorylated S139 has not been ob-
served and there are currently no clues for any functional rel-
evance. The extent of phosphorylation of S10 and S139 in E.
coli is obviously dependent on the expression conditions.
To avoid the need for separating diﬀerently phosphory-
lated PKA isoforms we wondered whether it is possible to
produce active protein where the catalytic non-relevant
phosphorylation sites have been removed or even a ‘‘dephos-
pho’’-PKA lacking all phosphorylation sites. Since phos-
phorylation of S10 disorders the N-terminal helix [14] we
replaced S10 with alanine, whereas S139 and S338 were
changed to aspartate (PKA-3P). T197 was either replaced
by aspartate or glutamate resulting in PKA-4P(D) and
PKA-4P(E).
Since PKA serves as a Akt/PKB surrogate kinase in the
drug discovery process, two PKA constructs with 6 and 8
*Corresponding authors. Fax: +49 69 798 29515.
E-mail addresses: t.langer@nmr.uni-frankfurt.de (T. Langer),
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FEBS 29720 FEBS Letters 579 (2005) 4049–4054mutations in the ATP binding region were made (PKAB6:
Q84E/V104T/V123A/L173M/Q181K/F187L and additionally
S53T/L82K for PKAB8). Finally, the S10A, S139D and
S338D mutations were also introduced in the PKAB con-
structs yielding PKAB6-3P and PKAB8-3P, respectively.
The folding of all expressed proteins was checked by 2D
1H,
15N TROSY nuclear magnetic resonance spectroscopy
(NMR) and the activity of the proteins were assessed by
standard assays for enzymatic activity.
2. Materials and methods
2.1. Cloning, expression and puriﬁcation of PKA
PKA was expressed in E. coli strain Bl21 (DE3)/pLysS (Novagen)
as described [13]. The DNA coding for PKA was originally cloned
from CHO cells (references cited in [13]). Site speciﬁc mutagenesis
was done following the Quick Change protocol (Stratagene). All
constructs have been veriﬁed by sequencing. To obtain uniformly
15N labeled protein, cells were grown in M9 minimal-medium
containing
15NH4Cl (Eurisotop, Saarbru ¨cken, Germany) as the sole
nitrogen source. For all constructs, cell growth and protein expres-
sion was performed under the same conditions. Cells were grown
in the presence of appropriate antibiotics at 37 C until the OD600
reached 0.6 and then recombinant protein production was initiated
by adding 1 mM IPTG (isopropyl-b-D D-thiogalactopyranoside).
Induction was carried out for 4 h at 28 C and cells were harvested
by centrifugation for 15 min at 4500g. PKA proteins were puriﬁed
with the aid of a His-tag as described in detail previously [13].
The His-tag was removed using a Tobacco Etch virus (Tev)-cleavage
site.
2.2. NMR spectroscopy
All protein samples were measured in the same buﬀer (150 mM
NaCl, 5 mM DTT, 50 mM HEPES, pH 6.5, 1 mM TSP, in 90%
H2O/10% D2O). Protein concentration was 0.25 mM for all prepara-
tions except for the ‘‘dephospho’’-forms PKA-4P(D) and PKA-
4P(E), where the protein was concentrated to 0.1 mM. 800 MHz 1D-
Watergate and 2D-TROSY [15] experiments (128 T1 increments) were
acquired at 298 K on a Bruker DRX800 spectrometer.
2.3. Enzymatic assay
Enzymatic activity of PKA proteins was checked with the aid of a
luminescent kinase assay following the manufacturers recommenda-
tions (Kinase-Glo, Promega, Madison, WI, USA). Kemptide (Prome-
ga) was used as substrate. The assay were performed in 96 well plates
with 50 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT, 10 mM
MgCl2, 2.5 lM ATP and 5 lM substrate peptide. The amount of em-
ployed PKA proteins was 74 nM in all assays. Samples were incubated
for 90 min at room temperature before addition of the Kinase-Glo
solution. After 20 min, luminescence was recorded with a Veritas
microplate luminometer (Turner BioSystems, Sunnyvale, CA, USA).
Data were analyzed using GraphPad Prism (GraphPad Software,
Inc., San Diego, CA, USA).
3. Results
All proteins were expressed under identical conditions at
28 C. For the ‘‘dephospho’’-PKA-4P(D) and PKA-4P(E)
proteins, most of the protein was expressed as insoluble inclu-
sion bodies. However, the yield of soluble protein was 1.5
and 1.0 mg/l M9 minimal medium for PKA-4P(D) and
PKA-4P(E), respectively. Typical expression yields for wild-
type PKA are 10 mg/l. For PKAB6 and PKAB8 similar
amounts of 10 mg/l were obtained. Interestingly, even higher
yields were obtained from the corresponding 3P forms (15–
20 mg/l). Except for the ‘‘dephospho’’-PKA-4P proteins, all
PKA mutants could easily be concentrated up to 0.5 mM
without precipitation. Therefore, PKA-4P(D) and PKA-
4P(E) were only concentrated to 0.1 mM for NMR measure-
ments. The phosphorylation sites of PKA are depicted in
Fig. 1.
In order to evaluate whether the expressed proteins are cor-
rectly folded, 2D
1H,
15N TROSY NMR spectra were recorded
and compared with the corresponding spectrum of wild-type
PKA, for which NMR backbone assignment of PKA has re-
cently been published by us [13]. As shown in Fig. 2(a),
PKA-3P is properly folded. Some peaks are shifted, which is
obviously a result of the mutations. Concerning PKA-4P(D)
and PKA-4P(E) samples, there are certain amounts of un-
folded protein or only partially folded protein (Fig. 2(b) and
(c)).
Several PKAB chimeras have been characterized both func-
tionally and structurally [7,8]. We have extended this principle
by introducing further mutations leading to the new chimeras
PKAB6 and PKAB8 (Fig. 3). S53T and L82K are outside of
the ATP-binding pocket and may allow for designing small
molecule inhibitors that extend beyond the ATP-binding pock-
et and therefore confer more selectivity. Since PKA-3P can
easily be expressed and is stable, the corresponding mutations
were introduced in PKAB6 and PKAB8, resulting in PKAB6-
3P and PKAB8-3P, respectively. Again, correct folding of all
PKAB proteins was conﬁrmed by 2D
1H,
15N-NMR spectros-
copy. The diﬀerent PKA mutants display shifted peaks but the
overall peak pattern is similar compared to wild-type PKA
(Fig. 4).
Catalytic activity was monitored with a luminescent kinase
assay. The activity of wild-type PKA was set to 100%. The
results are shown in Fig. 5. PKA-3P is as active as wild-type
PKA and even the ‘‘dephospho’’-PKA-4P(D) and PKA-
4P(E) proteins display 57% and 39%, activity, respectively,
compared to wild-type PKA. PKAB6 and PKAB8 have re-
duced activity (15% and 10%, respectively). These results
were unexpected, but as a consequence of the introduced
Fig. 1. Structure of the PKA catalytic subunit. The structure is drawn
from pdb-ﬁle 1CTP with Swiss pdb-viewer. The side chains of the
amino acids that can be phosphorylated are shown as spheres. A
unique feature of PKA is the A-helix. The ATP-binding cleft lies
between the N- and C-terminal lobe.
4050 T. Langer et al. / FEBS Letters 579 (2005) 4049–4054mutations, substrate binding might be compromised. Inter-
estingly, PKAB6-3P and PKAB8-3P were more active as
the corresponding phosphorylateable forms (28% and 43%
compared to wild-type PKA for PKAB6-3 and PKAB8-3,
respectively).
4. Discussion
PKA containing S10A, S139Dand S338D mutations can eas-
ily be expressed in E. coli, the protein is folded and as active as
wild-type PKA. Replacing the additional phosphorylation site
Fig. 2. Comparison of TROSY spectra of wild-type PKA (black) with ‘‘dephospho’’-PKA mutants. (a) PKA-3P (green), (b) PKA-4P(D) (blue) and
(c) PKA-4P(E) (red). See text for details.
T. Langer et al. / FEBS Letters 579 (2005) 4049–4054 4051T197 by either D or E yields poorly soluble protein. Similar re-
sults have been described for the single mutants PKA T197D
and PKA T197E [11]. As reported previously PKA T197E
was found to be nearly inactive whereas PKA T197D has an
activity comparable to the wild-type [11]. By contrast, we have
measured signiﬁcant, albeit lower activity for both the PKA-
4P(D) and the PKA-4P(E) mutants (57% and 39% activity,
respectively) relative to the wild type. The physiological role
of S10 has been elucidated recently [14]. The N-terminus of
PKA folds into the so-called A-helix which is unique for
PKA. Mammalian PKA is myristoylated on Gly1, and Asn2
is deamidated. These modiﬁcations are absent if PKA is ex-
pressed in E. coli. Phosphorylation of S10 is presumed to alter
the structure and hence regulate the localization of PKA. It
does so by inducing destabilization and disorder of the ﬁrst nine
amino acids in S10-phosphorylated PKA, which otherwise
adopts an a-helical conformation in S10 unphosphorylated
PKA [14]. In an earlier report, Yonemoto et al. [11] describe
that PKA with only the S10A mutation yields poor soluble pro-
tein. However, the PKA-3P mutant with additional S139D and
S338D mutations is soluble, properly folded and can be ex-
pressed in high yields. Insertion of either aspartate or glutamate
instead of T197, which lies within the activation loop, resulted
in poorly soluble protein of lower quality. These observations
might be explained in that way, that S139D and S338D muta-
tions have a positive eﬀect on protein folding. This would be in
accordance with the protein stabilising eﬀect of S338 phosphor-
ylation. Replacing S338 by alanine yields a more unstable, but
fully active protein [13]. In contrast, changing S139 to alanine
does not display adverse eﬀects [11].
4.1. PKAB chimeras
PKA has been used as a surrogate kinase for Akt/PKB and
Rho [7–9]. To enhance the usefulness of PKA as Akt/PKB sur-
rogate, several mutations have been introduced within the
ATP binding site that correspond to Akt/PKB residues. Here,
we extend such PKAB chimeras with the introduction of S53T,
L82K and V104T mutations. S53 and L82 that are outside the
ATP-binding-pocket may be helpful in the design of inhibitors
Fig. 2 (continued)
Fig. 3. ATP binding site of PKA with bound ATP. The structure is
drawn from pdb-ﬁle 1ATP with Swiss pdb-viewer. The hinge region,
connecting the N- and C-terminal lobe of the protein, is indicated.
Mutations to enhance Akt/PKB similarity are displayed. Mutations
depicted in magenta belong to PKAB6 and the additional mutations
(indicated in blue) S53T and L82K pertain to PKAB8.
4052 T. Langer et al. / FEBS Letters 579 (2005) 4049–4054that protrude from the ATP-binding pocket. PKAB6 and
PKAB8 can easily be expressed in E. coli and are properly
folded. Both mutants are less active than wild-type PKA. This
may be due to reduced aﬃnity for ATP or the substrate pep-
tide as a consequence of the introduced mutations. A 12-fold
reduced aﬃnity for ATP has been reported for the PKA
Q84E/V123A/L173M/F187L mutant. The increase in yield
and activity for mutations at the phosphorylation sites
(S10A, S139D and S338D) is remarkable. This allows expres-
sion of PKA and PKAB chimeras with only the T197 phos-
phorylation site remained. Since no further phosphorylation
sites are present, no mixtures of diﬀerently phosphorylated
Fig. 4. Comparison of TROSY spectra of wild-type PKA (black) with the PKAB chimerical proteins. (a) PKAB6 (magenta), PKAB6-3P(green) and
(b) PKAB8 (blue), PKAB8-3P (yellow).
T. Langer et al. / FEBS Letters 579 (2005) 4049–4054 4053isoforms occur and consequently there is no need for further
separation. This should be highly advantageous when the pro-
tein is used for X-ray crystallography and functional studies.
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The two articles present liquid-state NMR studies of the 40 kDa human Cdc37-
Hsp90, protein-protein complex. It also sets a model example of how NMR can be
used to study such high molecular weight complexes.
The ﬁrst contribution describes the complete backbone resonance assignment of
the human Hsp90 binding domain of Cdc37.
In the second contribution, the structure of the 40 kDa Cdc37-Hsp90 complex was
determined by using a combination of NMR, X-ray and data driven computational
docking. The X-ray structure of the human Hsp90 binding domain of Cdc37,
was solved in its monomeric form. Further, it also describes how residual dipolar
couplings (RDCs) was used to arrive at the more reﬁned structure of the complex. It
also emphasizes how NMR data was used to identify the ‘Hot Spot’ in the large
interaction interface of the protein-protein complex, which was further conﬁrmed
by mutational studies.
The author of this thesis has performed all the molecular biology and NMR
experiments and analysis. X-ray crystal structure of Cdc37 was solved together
with Prof. Dr. C. Roy D. Lancaster and the structure of the complex together with
Dr. Hendrik R. A. Jonker.Letters to the Editor
NMR assignment of the novel Helicobacter pylori protein JHP1348
DOI 10.1007/s10858-005-8529-0
Helicobacter pylori is a pathogenic bacterium that infects a large proportion of the population worldwide. It is
the causative agent for most cases of gastritis, gastric ulcer, and can lead to gastric cancer. Although the
genomes of two strains of H. pylori have been sequenced, approximately one third of the open reading frames
have no known homologs and no assigned functions (Tomb et al., 1997). Using a structural genomics par-
adigm, we searched the genome of H. pylori strain J99 for open reading frames encoding for functionally
uncharacterized proteins with properties that would make their structural determination feasible by solution
NMR techniques. JHP1348 is a putative periplasmic protein of 113 amino acids. Nearly all backbone and
sidechain
1H,
13C, and
15N resonances have been assigned using 2D and 3D heteronuclear NMR experiments
(Sattler et al., 1999). Only C’ resonance assignments for L18, which precedes a proline, and E111, which is the
C-terminal residue, are missing. Over 87% of sidechain
1H,
13C, and
15N resonances have been assigned. The
chemical shifts have been deposited in the BioMagResBank under accession number 6640.
References: Tomb et al. (1997) Nature, 388, 539–547; Sattler et al. (1999) Prog. NMR Spectrosc., 34, 93–158.
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Cdc37 belongs to the cohort of cochaperones that assist Hsp90 to function correctly and is mainly associated
with Hsp90. Most of the client proteins interacting with Hsp90/Cdc37 are crucial elements of signaling
pathways inside the cell. A predominant group herein are protein kinases. Hence, Cdc37 was assigned as a
kinase targeting subunit of Hsp90 (MacLean and Picard, 2003). Cdc37 can be dissected into three diﬀerent
domains. An N-terminal client binding domain, a middle domain binding Hsp90 and a C terminal domain
without yet known function. Recently, a crystal structure of the middle domain bound to the N-terminal ATP-
binding domain of Hsp90 became available (Roe et al. 2004). The Hsp90 binding domain of human Cdc37
comprising amino acids 147–276 were overexpressed in E. coli and 3D heteronuclear NMR experiments with
2H,
13C,
15N and 2D NMR experiments with uniformly
15N labelled protein were used for assignment. For the
130 residue fragment of Cdc37 the backbone assignments are essentially complete with exception of Pro 230.
From the triple resonance experiments, further backbone and non-aromatic side chain assignments were made
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Supplementary Figure 1. Sreeramulu et al.   The Human Cdc37Hsp90 Complex Studied by Heteronuclear
NMR Spectroscopy*
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Thecelldivisioncycleprotein37(Cdc37)andthe90-kDaheat
shockprotein(Hsp90)aremolecularchaperones,whicharecru-
cial elements in the protein signaling pathway. The largest class
of client proteins for Cdc37 and Hsp90 are protein kinases. The
catalytic domains of these kinases are stabilized by Cdc37, and
their proper folding and functioning is dependent on Hsp90.
Here, we present the x-ray crystal structure of the 16-kDa mid-
dle domain of human Cdc37 at 1.88 A ˚ resolution and the struc-
ture of this domain in complex with the 23-kDa N-terminal
domain of human Hsp90 based on heteronuclear solution state
NMR data and docking. Our results demonstrate that the mid-
dle domain of Cdc37 exists as a monomer. NMR and mutagen-
esis experiments reveal Leu-205 in Cdc37 as a key residue ena-
bling complex formation. These findings can be very useful in
the development of small molecule inhibitors against cancer.
The 90-kDa heat shock protein (Hsp90)
3 is an abundant and
essential protein, accounting for 1–2% of the total protein
amount in unstressed eukaryotic cells. A 2- to 10-fold higher
expression level of Hsp90 is found in cancer cells and virally
transformed cells (1–3), suggesting a crucial role of Hsp90 for
growth and/or survival of tumor cells. Hsp90 is a protein chap-
eronethathelpsavarietyofclientproteinstoadopttheirnative
conformation. Several co-chaperones such as Hop/Sti1,
FKBP52, cyclophilin 40, and p50/Cdc37 are identified to be
associated with Hsp90. These co-chaperones are required for
binding to diverse client proteins and controlling the ATPase
cycle of Hsp90 (4–6). Hsp90 is composed of three domains: an
N-terminaldomainof25-kDa,amiddledomainof35-kDa,
and a C-terminal domain of 10-kDa (7). The ATP-binding
site of Hsp90 is located in the N-terminal domain. Low molec-
ular weight compounds that interfere with ATP-binding such
as geldanamycin or radicicol inhibit the Hsp90 function by
competing for the interaction site.
Many of the client proteins of Hsp90 are crucial elements of
thecellularsignaltransductionpathway.Proteinkinasesrepre-
sent the largest class of Hsp90 client proteins, and many have
been shown to cause cancer when deregulated. These protein
kinasesdependonHsp90fortheirproperfoldingandfunction-
ing suggesting that Hsp90 itself is a valid anti-cancer target of
pharmaceutical interest (8).
Hsp90 does not directly bind to protein kinases, but this
interaction is mediated by the co-chaperone Cdc37/p50.
Hence, Cdc37 has also been dubbed as a kinase targeting sub-
unit of the Hsp90 machinery (9). Interestingly, Cdc37 is also
able to act as a chaperone by itself independent of Hsp90 (10).
Thecelldivisioncycleprotein37(Cdc37)wasfirstidentified
inSaccharomycescerevisiaeasaproteinrequiredforthe“Start”
event in the cell division cycle (11). In yeast, cdc37 mutations
causesyntheticlethality(asdefinedbyKaelin(56))incombina-
tion with thermosensitive cdc28 or kin28 mutations (12, 13).
ThemammalianhomologofCdc37,alsoreferredtoasp50
cdc37,
was first identified within a complex consisting of the Rous
sarcoma virus encoded oncogene pp60
v-scr and Hsp90 (14, 15).
Further studies confirmed that protein kinases are the most
favored targets of Cdc37 (16). A plethora of other oncogenic
kinases, including Raf isoforms, Akt, and ErbB2, have been
identified as potential clients of Cdc37 (17–20). Expression of
Cdc37 is up-regulated in cancer cells and tissues and can pro-
mote tumorigenesis when overexpressed (21, 22). In addition,
Cdc37caninhibittheATPaseactivityofHsp90impliedinpro-
motingtheassemblyofkinaseclientswithbothchaperonepro-
teins (23, 24).
Structurally, the 44.5-kDa protein Cdc37 can be dissected
into three domains (10, 25). Proteolytic fingerprinting studies
indicatethatitiscomprisedofanN-terminaldomain(residues
1–127 (Cdc37N), 15.5 kDa), a middle domain (residues 147–
276 (Cdc37M), 16 kDa), and a C-terminal domain (residues
283–378 (Cdc37C), 10.5 kDa). The middle domain Cdc37M is
* This work was supported by the SPINE (Structural Proteomics in Europe)
projectoftheEuropeancommissionandbytheClusterofExcellence:Mac-
romolecularComplexes(DeutscheForschungsgemeinschaft).Thecostsof
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charges. This article must therefore be hereby marked “advertisement”i n
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Theatomiccoordinatesandstructurefactors(codes2W0Gand2K5B)havebeen
deposited in the Protein Data Bank, Research Collaboratory for Structural
Bioinformatics,RutgersUniversity,NewBrunswick,NJ(http://www.rcsb.org/).
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2 To whom correspondence should be addressed: Tel.: 49-69-79829737; Fax:
49-69-79829515; E-mail: schwalbe@nmr.uni-frankfurt.de.
3 The abbreviations used are: Hsp90, 90-kDa heat shock protein; Cdc37, cell
division cycle protein 37; CSP, chemical shift perturbation; CST, cross-sat-
urationtransfer;HADDOCK,highambiguity-drivenbiomoleculardocking;
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 highlyresistanttoproteolyticdigestionandwasfoundtobethe
most stable domain of Cdc37 (26). Several studies (19, 27–30)
have shown that Cdc37N binds to the client proteins (e.g.
kinases). A highly conserved region within Cdc37N contains
Ser-13 as a unique phosphorylation site for the protein kinase
CKII. Phosphorylation seems to be an important mechanism
for controlling the binding affinity to the client protein kinases
andasaconsequencethereofregulatingtheactivityofmultiple
protein kinases (31). The Hsp90 binding site is located in the
middle domain of Cdc37, which also comprises a putative di-
merization region (32). An extended -helix connects the
Hsp90bindingsitetotheC-terminaldomain,whichmightalso
be required for dimer formation (24, 32). The structure of the
N-terminal domain is yet unknown but sequence analysis pre-
dicts a high content of -helices (32).
The crystal structure of Cdc37MC (middle and C-terminal
domain) bound to Hsp90N (from yeast) is a heterotetrameric
complex, comprising Hsp90 bound to a Cdc37 dimer (32). The
function of Cdc37 to inhibit the ATPase activity of Hsp90
(24) is due to the extended side chain of Arg-167 that binds
to Glu-33 of Hsp90, thereby inhibiting the ATPase reaction.
AdditionalstudiesindicatethatCdc37Mexistsasamonomer
(26). Low resolution cryoelectron microscopy images of the
Hsp90Cdc37Cdk4 complex show that Cdc37 is a monomer in
this interaction (33). However, these studies utilized yeast
Hsp90, and it was realized that it is necessary to investigate the
interaction with human Hsp90 (26) to resolve the differences.
Here, we report the structure determination of the human
Hsp90NCdc37McomplexbasedontheNMRbackboneassign-
ments of Cdc37M (34) and Hsp90N (35). The interface of the
complex between human Cdc37M and Hsp90N could be
mappedbasedonNMRchemicalshiftperturbation(CSP)stud-
ies, and cross-saturation transfer (CST) techniques. Subse-
quently,wesolvedthex-raycrystalstructureofhumanCdc37M
at 1.88 Å in its monomeric form. The structure of the
Cdc37MHsp90N complex was generated by incorporating
NMR data (CSPs and CSTs as ambiguous distance restraints
and RDCs as orientational restraints) in the HADDOCK (36)
docking protocol.
EXPERIMENTAL PROCEDURES
Cdc37 Cloning, Expression, and Purification—From the
cDNA(Invitrogen)thebasepairscorrespondingtoaminoacids
1–126, 147–276, 1–283, and 1–378 of human Cdc37 were
amplified by PCR using 5-ACACAACCATGGTGGACTAC-
AGCGTGTGGGACCAC-3,5 -ACACAAGGATCCTTCAC-
TTGCTGAAGCCGTCTTTGCTGAGC-3,5 -AAACCATG-
GGGAAACACAAGACCTTCGTGGAAAAATACG-3,5 -
AAGCAAGGATCCTTCACTTCATGGCCTTCTCGATGC-
GCAG-3,5 -ACACAAGGATCCTTCAGCGCTCCTCCT-
CCTCGTACTCCTTC-3,5 -TCTTTATTTTCAGGGCGC-
CATGGTGGACTACAGCGT-3, and 5-GCAGCCGGATC-
CTTCACACACTGACATCC-3 as primers, respectively. The
PCR product was double digested with NcoI and BamHI and
cloned into the derivatized pKM263 (6xHis tag ProtGB1-Tev
between Nde1 and Xho1) vector, which harbors ProtGB1 to
enhance the solubility of the expressed fusion partner. The
authenticity of the clone construct was confirmed by nucleo-
tide sequencing. Escherichia coli strain BL21(DE3) (Novagen)
containingthedesiredplasmidwasgrowninLuria-Bertani(LB)
broth medium at 37 °C supplemented with 34 g/ml chloram-
phenicol.Proteinexpressionwasinducedwiththeadditionof1
mM isopropyl 1-thio--D-galactopyranoside when the A600
reached 0.6–0.7. The culture was incubated in 5-liter Erlen-
meyer flask for 5–6 h with aeration (160 rpm) at 37 °C before
the cells were harvested by centrifugation (5,000  g, 15 min,
4 °C). The cell pellet was resuspended in lysis buffer (50 mM
Tris-HCl (pH 8.0), 0.5 M NaCl, 5 mM of -mercaptoethanol)
withadditionof2mg/mllysozymeand100units/mlbenzonase
(Merck, Darmstadt, Germany) protein suspension. After soni-
cation (10, 60-s pulse on, and 180-s pulse off) in an ice bath,
the cell debris was removed by centrifugation (18,000  g,4 5
min,4 °C)toyieldasupernatantcontainingthesolubleprotein.
The supernatant was applied to a nickel-nitrilotriacetic acid
FastFlow column (Qiagen) following the manufacturer’s rec-
ommendations. After Tev-protease cleavage to remove the His
tag ProtGB1, the protein was applied again on a nickel-nitrilo-
triacetic acid column. The pooled protein fractions were fur-
ther purified by gel filtration on a Hiload 26/60 Superdex 75
preparative grade column (Amersham Pharmacia Biosciences)
in Hepes 50 mM (pH 7.5), NaCl 100 mM,a n d1m M DTT. The
protein-containing fractions were pooled, concentrated, and
either immediately used for the experiments or stored at
20 °C. The
15N-labeled protein was produced by using M9
minimal media with
15NH4Cl (1 g/liter) as the sole nitrogen
source. Uniformly triple (
2H,
13C, and
15N) or double (
2H and
15N) labeled protein was produced using Silantes OD2 media.
The degree of isotopic enrichment for the Silantes media was
98%forallisotopes(manufacturer’sdata).Forselectivelabel-
ing with
15N-labeled amino acids, the following
15N-labeled
amino acids were used: alanine, arginine, lysine, methionine,
isoleucine, leucine, valine, phenylalanine, tyrosine, and trypto-
phan (Spectra Stable Isotopes, Germany). The procedure
applied for selective amino acid labeling is essentially the same
as described in the literature (37).
Hsp90N Cloning, Expression, and Purification—From the
cDNA(Stratagene)thebasepairscorrespondingtoaminoacids
18–223 (N-terminal domain) of human Hsp90 were amplified
by PCR using 5-AAACCATGGGGGAGACGTTCGCCTTT-
CAGG-3 and 5-GCAGCCGGATCCTCACTCCACAAAAA-
GAG-3asprimers.ThePCRproductwasdoubledigestedwith
NcoI and BamHI and was cloned into the derivatized pKM263,
with a Protein G B1 domain (ProtGB1) fusion protein located
C-terminallybehindastretchofsixhistidinesandatevcleavage
site under the control of a T7-promoter (see above). The pro-
tein was expressed and purified in the same way as Cdc37,
except for the post induction temperature, which was 25 °C. In
addition,tetra-selectivelabelingwith
15N-glycine,
15N-alanine,
15N-phenylalanine, and
15N-leucine was carried out as de-
scribed above.
Due to the design of the expression vectors, Cdc37 and
Hsp90N constructs carry two (GA) or four (GAMG) additional
amino acids at the N terminus. High expression levels were
achievedafterinductionwith1mMisopropyl1-thio--D-galac-
topyranoside at 37 °C for Cdc37 and 25 °C for Hsp90N and
95% of the fused protein was found in the soluble fraction.
TheHumanCdc37Hsp90ComplexStudiedbyNMR
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 Typically,30mg/literofpure(95%)proteinswasobtainedafter
cleavage of protein G. The final samples were dialyzed against
the NMR buffer (Hepes 50 mM (pH 7.5), NaCl 100 mM, and 1
mM DTT).
Mutagenesis—Mutants of Cdc37M were created with Quik-
Change kit (Stratagene), and sequenced to confirm the incor-
poration of the correct mutation. The mutant proteins were
purified following the same protocol as the wild-type Cdc37M.
NMR Spectroscopy—NMR experiments were performed at
298 K, on Bruker 600-, 700-, 800-, 900-, and 950-MHz spec-
trometers equipped with cryogenic triple-resonance probes.
For the Cdc37MHsp90N complex a ratio of 1:1 was used for all
measurements. The spectrometer was locked on D2O. The
spectrawereprocessedusingTopspin2.0(BrukerBiospin)and
analyzed using either SPARKY 3.113
4 or CARA 1.8.3 (39). The
resonancesforthefreeformofCdc37MatpH5.5andHsp90Nat
pH7.5havebeenassignedbefore(34).SpectraofCdc37MatpH
7.4 have been assigned by performing a pH series (5.0, 5.5, 6.0,
6.5, 7.0, 7.5, and 8.0) with 2,2-dimethyl-2-silapentane-5-sul-
fonic acid as an internal standard for calibration. Sequential
backbone assignment of
15N-labeled Cdc37M in complex with
unlabeledHsp90Nandviceversawasachievedbyoverlayingthe
1H,
15N-HSQC spectra of free Cdc37M (or Hsp90N) and
Cdc37M (or Hsp90) in complex and verified by the NOE pat-
ternsfromahighresolutionthree-dimensional
1H,
15N-NOESY
HSQC spectrum and selective
15N-amino acid labeling (ala-
nine, arginine, glycine, isoleucine, leucine, lysine, methionine,
phenylalanine, tryptophan, tyrosine, and valine). Additionally,
a three-dimensional
1H,
15N-NOESY HSQC spectrum for
Hsp90N with a tetra-selectively labeled sample in which only
glycine, alanine, phenylalanine, and leucine were
15N-labeled
was used to assist the assignment.
1D(H,N) RDCs were meas-
ured for the Cdc37MHsp90N complex (in which both proteins
were
15N-labeled) in pf1 phage (5 g/liter, Profos) and in 4%
polyacrylamide(PAA)gelalignmentmediaat700MHz.The
1D
(H,N) were extracted from IPAP-(
1H,
15N)-HSQC spectra (40,
41). Signals that could be traced back reliably and determined
unambiguouslywereanalyzedusingMODULE(42)andPALES
(43). CST experiments were carried out at 25 °C according to
the procedure of Takahashi et al. (57). The sample contained 1
mM of
2H,
15N,
13 C-labeled Cdc37M protein with the unlabeled
Hsp90N protein in
1H2O/
2H2O (1:9, v/v) containing 50 mM
Hepes (pH 7.5), 1 mM DTT, and 100 mM NaCl. The Gaussian
pulse scheme was used for saturation of aliphatic protons with
irradiation frequency set to 1.1 ppm. A saturation time of 2.0 s
was employed.
X-ray Crystallography—Initial screening for crystallization
conditions of Cdc37M was performed using screening kits pur-
chased from JB (Jena Bioscience). These trials were successful,
with five promising conditions producing crystals. The protein
samples that did not give crystals were analyzed by mass spec-
trometry, which identified that they contained small fractions
of proteins with an increased molecular mass of 75, 150, and
228 Da. We attributed this observation to the formation of
mixed disulfides of -mercaptoethanol with the four free cys-
teines of Cdc37M. Therefore, -mercaptoethanol was omitted
from the further protein preparations. The final diffracting
qualitycrystalsweregrownfromCdc37M(Hepes,50mM,NaCl,
100 mM, pH 7.5, “protein buffer”) at a final concentration of 1.1
mM, in solution containing Hepes, 100 mM, pH 7.5, sodium
acetate, 100 mM, 22% polyethylene glycol 4000, (“reservoir
buffer”). Crystal drops were setup using the sitting drop vapor
diffusion method at 18 °C. Crystals were transferred in a step-
wise manner into solutions of increasing glycerol concentra-
tions of 5, 10, 15, 20, and 25%, respectively, based on one vol-
ume of protein buffer and two volumes of reservoir buffer, and
flash-cooled in an X-Stream 2000 nitrogen stream at 140 K.
Diffraction data were collected using a Rigaku R-Axis IV image
plate detector at a wavelength of 1.5418 Å (CuK radiation
from a MicroMax-007 Microfocus generator). In addition to a
high exposure data set consisting of 360 images of 1.0° rota-
tions,alowexposure(one-thirdoftheexposuretimeperimage
of that for high exposure) data set was collected consisting of
240 images of 1.5° rotations. The oscillation images were pro-
cessedwiththeHKL/DENZOprogrampackage(44).Thecrys-
tals belong to the hexagonal space group P61 with unit cell
dimensions a  b  48.67 Å and c  104.26 Å. Scaling and
merging of the oscillation images was performed with SCALE-
PACK(44).Datareductionandapproximateabsolutescalingof
thedatawereperformedwithTRUNCATEfromtheCCP4pro-
gram suite (45). The phase problem was solved by molecular
replacement using the program AMoRe (46) from the CCP4
suite,thediffractiondatabetween15Åand3Åresolution,and
a Cdc37 search model constructed from PDB entry 1US7 (32),
extendingfromresidueHis-148toresidueLys-276andconsist-
ing of 1086 non-hydrogen atoms. The top solution with rota-
tion angles   45.52°,   150.55°,   311.52° and transla-
tions Tx  0.3117 and Ty  0.0954 (fractional coordinates)
was associated with a correlation coefficient of 58.2% and an
R-factor of 40.4%. After rigid body refinement with Refmac5
(47), the R-factor for the data between 42.14 Å and 1.88 Å was
43.8%(RfreeT43.9%).Afterseveralcyclesofrestrainedrefine-
ment with Refmac5, the modeling of tightly bound water mol-
ecules, and manual rebuilding with COOT (48), the final struc-
ture was obtained.
Docking—Calculation of the Cdc37MHsp90N complex was
achieved using a high ambiguity driven docking (HADDOCK
2.0) approach with CNS 1.1 (49) essentially as described in the
literature (36). The ambiguous interaction restraints have been
defined for the residues that exhibited significant NMR amide
chemical shift changes and/or strong saturation transfer upon
interaction with its partner protein. For Hsp90, residues 117,
121,123,124,125,126,and129havebeendefinedasactiveand
residues 28, 32, 40, 46, 51, 54, 55, 114, 116, 119, 120, 122, 127,
130,132,133,and134aspassive.Thehelix(112–124)andadja-
cent loop region from residues 106–127 were left fully flexible
to offer freedom to the orientation of this helix. Additional
hydrogen-bond restraints were added to keep the secondary
structure of this helix. For Cdc37M, residues 160, 161, 164, 165,
166, 167, 168, 193, 202, 204, 205, and 208 have been defined as
active and residues 156, 157, 158, 169, 170, 174, 189, 192, 196,
197, 200, 201, 203, 207, 211, 242, and 249 as passive. The loop
region 164–168 was left fully flexible during the docking. One
4 T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San
Francisco.
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 intermolecularNOE(Ala-117-HNtoAla-204-HB),asobtained
fromNOESYexperiments,fittedverywellwiththeinitialdock-
ingresultsandwasincludedinthefinalcalculation.Toenhance
the convergence,
1D(H,N) RDCs obtained both in 4% PAA gel
andin5g/literpf1phagealignmentmedia,wereincludedinthe
calculation and the axial (Da) and rhombic (Dr) components of
the alignment tensor were estimated using PALES (43). For the
initial rigid-body docking, only the RDCs in the stable second-
ary structure elements were used,
whereas in the further refinement
steps, all RDCs were used. The final
valuesforDaandDrwere8.21and
0.62 for the phage alignment and
9.39 and 0.45 for the alignment in
the PAA gel. The dockings were
performed using our Cdc37M crys-
tal structure and the Hsp90 crystal
structure (pdb: 1YES) (7). The pro-
tein allhdg 5.3 force field (50) was
used for the calculations. The 200
final water-refined docking results
are clustered at the interface within
a threshold of 3.0 Å pairwise back-
bone r.m.s.d. The top-ranked en-
semble, according to the average
interaction energy and buried sur-
face area, was accepted as the best
representative of the complex.
RESULTS
Comparing Different Constructs
of Cdc37 and Hsp90—The study of
the rather large complex formed
between the 45-kDa Cdc37 protein
and the 23-kDa N-terminal domain
of Hsp90 is a challenge for NMR
spectroscopic studies. To study this
complex, we reduced the bound-
aries of Cdc37 to obtain a construct
that retains its structural and func-
tional properties and is suitable for
NMR studies. Beside the Hsp90N
bindingdomainofCdc37(147–276,
Cdc37M), for which we recently
published the NMR assignments
(34), also the following Cdc37 con-
structs were investigated: full-
length Cdc37 (1–378), the kinase
binding domain (1–126, Cdc37N),
and both kinase and Hsp90N bind-
ing domains (1–283, Cdc37NM).
The suitability of the Cdc37 con-
structsforNMRwasinvestigatedby
recording
1H,
15N-TROSY spectra
(Fig. 1). The spectrum of the full-
length Cdc37 revealed considerable
signal overlap and, in addition, sig-
nals that indicate unfolded regions
(Fig. 1A). For Cdc37N, the spectrum shows again signal overlap
and evidence for a high content of partially unfolded and/or
helical regions (Fig. 1C). Cdc37M shows a nicely resolved high
resolution
1H,
15N-TROSY spectrum (with 131 out of the 133
expected amide resonances), which indicates that this Hsp90-
binding domain of Cdc37 is properly folded (34) (Fig. 1D). It
was suspected that the Cdc37N might become more structured
when it is together with the middle domain. Nevertheless, for
FIGURE1.
1H,
15N-TROSYspectra(950MHz)ofdifferentCdc37constructs.Theboundariesofeachconstruct
(e.g. A, full-length; B, N-terminal and middle domain; C, N-terminal domain; and D, middle domain) are sche-
matically indicated below each spectrum. The insert shows three peaks stemming from the middle domain
(Cdc37M) showing the same fold for this domain in all constructs. The spectra were acquired at 298 K in the
same buffer solution (50 mM Hepes buffer (pH 7.5), 100 mM NaCl, 1 mM DTT, and 10% D2O).
TheHumanCdc37Hsp90ComplexStudiedbyNMR
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 the corresponding Cdc37NM construct the
1H,
15N-TROSY
spectra indicated insufficient chemical shift dispersion (Fig.
1B). The amide signals originating from Cdc37M (shown spe-
cificallyforthreepeaksasintheinsertinFig.1D)havethesame
chemicalshiftsasinthefull-lengthCdc37andCdc37NM(Fig.1,
AandB),indicatingthatthefoldoftheCdc37Misthesameasin
thefull-lengthprotein.Hence,the16-kDaCdc37Mdomainwas
used for all further NMR experiments. For Hsp90, the 23-kDa
construct comprising the N-terminal ATP-binding domain
(18–223) known to interact with Cdc37 was used throughout
this study (35).
Structure of Human Cdc37M—In the x-ray structure of the
complex between yeast Hsp90 and human Cdc37, the middle
domain of the Cdc37 protein forms a homodimeric interaction
with a symmetry-related molecule (32). So far, the structure of
Cdc37isonlyavailableinthecomplexwithHsp90.However,by
NMR, we do not see any evidence for dimer formation of
Cdc37M. To elucidate whether Cdc37M also forms dimers
when crystallized without Hsp90, we solved the x-ray structure
of free Cdc37M. The obtained resolution after refinement was
1.88 Å with the characteristics summarized in Table 1. The
structure of Cdc37M is entirely helical consisting of a 6-helix
bundle(148–243)connectedtoasinglelonghelix(245–276)as
shown in Fig. 2. In the crystals, Cdc37M is a monomer, which is
in excellent agreement with NMR diffusion-based measure-
ments showing that Cdc37M exists as a monomer in solution
withanRg
exp21.3Åandatheoretical(51)predictedRg
theo
22.2 Å. These findings agree very well with previous findings
based on SAXS (26) and electron microscopy (33) data. The
overall structure of this free-form monomeric Cdc37M is very
similar to the x-ray structure of the dimeric Cdc37M when in
complex with the yeast Hsp90 (32). The average r.m.s.d.
betweenthestructuresforallheavyatomsis0.8Åforthe6-he-
lix bundle (148–243) and 1.3 Å for the full domain (148–276).
The largest differences are observed in the loop connection
(242–251) to the single long 7 helix, which is exactly at the
previously proposed dimerization interface (32). Interestingly,
this region is also near to Hsp90 and may thus expose a poten-
tialadditionalinteractionsite.Furthermore,wefoundtwopos-
sibleconformationsforthesidechainsofArg-167andGln-208
in the Cdc37M crystals, which are also slightly different from
the conformation found in the previously reported structure.
Both residues reside in and near the interaction interface with
Hsp90.
Assignment of Human Cdc37M and Human Hsp90N—The
1H,
15Nand
13Cbackboneandside-chainresonanceassignment
ofthefree-formCdc37MhasbeenreportedpreviouslyatpH5.5
(34). Because the interaction studies with Hsp90N have to be
conducted at pH 7.5, we reassigned the amide resonances of
Cdc37M at this different condition. Hence, we performed a
series of NMR experiments ranging from pH 5.0 through pH
8.0 with a 0.5 pH unit increment, and used 2,2-dimethyl-2-
silapentane-5-sulfonic acid as an internal standard for calibra-
tion. Using the
1H,
15N-HSQC spectra from the pH series we
FIGURE 2. X-ray structure of Cdc37M. A, x-ray structure of Cdc37M in ribbon
representation.Thehelicesareindicated.B,theaminoacidsequenceandthe
secondary structure boundaries of Cdc37M are represented schematically.
TABLE1
Crystallographic data collection and refinement statistics
All data Highest resolution
bin
Data
Resolution limits (Å) 42.14-1.88 1.95-1.88
No. of measured reflections 368,290 41,732
No. of unique reflections 11,278 1,134
Redundancy 32.7 36.8
Completeness (%) 98.7 100
Completeness with I 2 (%) 94.1 86.1
I/(I) 49.8 18.7
Rsym (%) 5.8 30.6
B value from Wilson plot (Å
2) 35.5
Mosaicity (°) 1.1
Solvent content (%) 43
Refinement
Resolution limits (Å) 42.14-1.88 1.93-1.88
Test set selection Random (5%  609) Random (5%  46)
RfreeT (%) 24.6 45.0
Rwork (%) 21.2 29.1
Rworktest (%) 21.3
Number of non-hydrogen
atoms
1130
Mean B value (Å
2) 29.3
r.m.s.d. values
From ideal bond lengths (Å) 0.018
From ideal bond angles (°) 1.544
Ramachandran plot
Favorable (%) 93.2
Additional (%) 6.8
Generous (number) 0
Disallowed (number) 0
TheHumanCdc37Hsp90ComplexStudiedbyNMR
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 wereabletonearlycompletelyassignCdc37M(99%oftheback-
bone amide resonances) at pH 7.5.
The
1H,
15N and
13C backbone and side-chain resonances of
the human Hsp90N (18–223) at pH 7.5 in its free form have
beenassignedpreviously(35).Theamidebackboneassignment
was complete with the exception of four stretches (Gln-23 to
Glu-25,Leu-107toLys-116,Ser-165toGly-168,andPhe-213to
Tyr-216) and the amino acids Phe-37, Asn-40, Leu-45, Thr-65,
Lys-74, Leu-76, Lys-84, Gly-132, Phe-138, Ser-140, Asp-156,
Thr-176, Glu-199, and Gln-212.
Mapping of the Binding Interface of the Cdc37M/Hsp90N
Complex by NMR—To map the Cdc37M binding site for
Hsp90N, NMR titrations were performed with
15N-labeled
Cdc37MandunlabeledHsp90Nat25 °CandpH7.5.Anoverlay
of the
1H,
15N-HSQC spectra of free Cdc37M and the
Cdc37MHsp90N complex is shown in Fig. 3A. These spectra
reveal significant changes in the combined amide chemical
shifts(
1H,
15N)oftheCdc37MuponadditionofHsp90N(uptoa
molarratioof1:1).Manypeaksinthetwo-dimensional
1H,
15N-
HSQC spectrum of Cdc37M are either significantly shifted or
disappear (exchanged broadened) from the spectra indicating
complex formation. The assignment of the shifted peaks was
confirmed by using a combination of
15N amino acid-selective
labeling and three-dimensional
1H,
15N-NOESY-HSQC spec-
tra. To facilitate the assignment in the complex, Cdc37M was
selectively labeled with ten different
15N-labeled amino acids
(Ala, Arg, Ile, Leu, Lys, Met, Phe, Trp, Tyr, and Val). Except for
those signals that broadened beyond detection, all other peaks
could be assigned unambiguously. The residues of Cdc37M
revealing the largest combined (
1H,
15N) chemical shift pertur-
bation (CSP  0.15 ppm) upon binding Hsp90N are Phe-162,
Arg-167, Trp-168, Trp-193, Lys-202, Ala-204, Val-209, and
Met-216 (Fig. 4A). Furthermore, amino acids Leu-165, Arg-
166, Ile-195, Leu-205, and Glu-207 show a strong decrease in
signal intensity. To further analyze the interaction site of
Cdc37M, we performed a CST experiment. This experiment
was carried out using
2H,
15N,
13C-labeled Cdc37M protein with
the unlabeled Hsp90N protein in
1H2O/
2H2O (1:9, v/v). The
Cdc37M residues that appear to be in the interface (0.78
intensityratio)regionincludeLys-160,Met-164,Arg-166,Arg-
167,Trp-168,Leu-205,Glu-207,Gln-208,andIle-214(Fig.4B).
When we combine CSPs, CSTs, and the decrease of signal
intensity and map the binding site onto the Cdc37M crystal
structure,twodistinctregionsappeartobeinvolvedincomplex
formation. The first region is composed of the loop (residues
164–167), and the second region is defined by the loop con-
necting-helices3and4andthebeginningregionofthe-he-
lix 4 (residues 203–208).
The reciprocal experiments using
15N-labeled Hsp90N and
unlabeled Cdc37M to identify the residues of human Hsp90N
involvedintheinteractionwiththeCdc37Mwerecarriedoutas
well. An overlay of the
1H,
15N-HSQC spectra of free Hsp90N
FIGURE3.Cdc37MbindingtoHsp90N.Overlayofthe
1H,
15N-HSQCspectra(900MHz)ofCdc37Minitsfreeform(red)withHsp90Nboundform(green)(A)andof
Hsp90Ninitsfree(red)withCdc37M-boundform(green)(B).ThebackboneassignmentsareshownforthefreeformofCdc37M(A)andHsp90N(B),andsomeof
themajorpeakshiftsareindicatedbyarrows.Thespectrawereacquiredat298Kinthesamebuffersolution(50mMHepesbuffer(pH7.5),100mMNaCl,1mM
DTT, and 10% D2O).
TheHumanCdc37Hsp90ComplexStudiedbyNMR
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 and the Hsp90NCdc37M (molar ratio 1:1) complex is shown in
Fig.3B.TheshiftedamideresonancesofHsp90Nwereassigned
using a combination of selectively labeled samples and three-
dimensional
1H,
15N-NOESY-HSQC
spectrum. Hsp90N was selectively
labeled with six different
15N-
labeled amino acids (Ala, Gly, Ile,
Leu, Met, and Phe). An additional
three-dimensional
1H,
15N-NOESY-
HSQC spectrum was recorded for a
sample in which four different
aminoacids(Ala,Gly,Phe,andLeu)
were selectively
15N-labeled. The
Hsp90N amide CSPs upon binding
toCdc37Mwereanalyzedtocharac-
terize the amino acids potentially
involved in the interaction. The
largestcombined(
1H,
15N)chemical
shift changes (0.10 ppm) are
observed for a few residues in the
first, second, and fifth -helix (resi-
dues 29, 55, and 103, respectively),
andmanyresiduesinthesixth-he-
lix (residues 117–119 and 121–126)
aswellasintheseventh-helix(res-
idues 128, 129, and 131). These res-
idues define two distinct Hsp90N
interacting sites for Cdc37M, which
are located on one side of the mole-
cule and are localized around a
hydrophobic patch (Fig. 4C).
Determination of the Human
Cdc37MHsp90N Complex Structure—
Based on the interaction interface
as determined from CSPs and
CSTs (Fig. 5, A and B) we calcu-
lated the structure of the binary
Cdc37MHsp90N complex using
HADDOCK (36). The calculations
were performed using the crystal
structures of human Cdc37M deter-
minedhereandHsp90Nintheopen
conformation (pdb: 1YES (7)). The
initial docking model proposed a
number of possible solutions that
differedintherelativeorientationof
the proteins (Fig. 5C). To resolve
this ambiguity, we measured two
sets of RDCs of the complex. RDCs
could be obtained using either 5
g/liter phage pf1 phage alignment
medium(Profos)oralignmentin4%
polyacrylamide gels. Both sets of
1D(N,H)RDCvalueswereextracted
from IPAP-(
1H,
15N)-HSQC spectra
and yielded a linearly independent
overall alignment tensor (Fig. 5C)
and thus provided additional infor-
mation on the relative orientation of the two proteins. The
RDCs have been measured on a sample containing both
15N-
labeled Cdc37M and
15N-labeled Hsp90N in a 1:1 ratio.
FIGURE 4. Titration of Cdc37M with Hsp90N and vice versa. A, correlation of CSPs versus residues in Cdc37M
uponadditionofHsp90N(left)andsurfacerepresentationoftheinteractionsitesofCdc37M(yellow)forHsp90N
(0.15ppm).B,plotoftheintensityratiosofthecross-peaksinthecross-saturationtransferexperiment(left).
The intensity ratios of the backbone amide resonance of Cdc37M in complex with Hsp90N with irradiation to
thoseofwithoutirradiationmeasuredin10%H2O/90%D2O.SurfacerepresentationofCdc37M,whereresidues
withintensityratioof0.78arecoloredinyellow(right).C,correlationofCSPsversusresiduesinHsp90Nupon
additionofCdc37M(left)andsurfacerepresentationoftheinteractionsitesofHsp90N(purple)forCdc37M(0.1
ppm). For the CSPs, amide
1H and
15N resonance shifts have been mapped and combined as Euclidian dis-
tancesbetweenpeakmaximatakingintoaccountthegyromagneticratioofprotonandnitrogen(in
1Hppm).
Missing bars indicate prolines or amide resonances that have not been assigned.
TheHumanCdc37Hsp90ComplexStudiedbyNMR
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 Although some amide signals of both proteins overlap, there is
sufficientdispersiontoidentifymanyresiduesfromCdc37Mor
Hsp90N. In the phage alignment media, we could reliably iden-
tify 42
1D(N,H) RDCs for Cdc37M and 79
1D(N,H) RDCs for
Hsp90N. Despite the line broadening in the polyacrylamide gel
alignment, we could reliably identify 25
1D(N,H) RDCs for
Cdc37M and 52
1D(N,H) RDCs for Hsp90N. The RDCs fit
already very well with the free-form
protein structures of Cdc37M and
Hsp90N (Fig. 5D) indicating that
their overall structure will not
change much when in complex. In
addition to the RDCs, we measured
intermolecular NOEs. Two-dimen-
sional
15N-edited NOESY spectra
were recorded for the free
15N,
2H
Cdc37M and Hsp90N proteins as
well as two-dimensional and three-
dimensional
15N-filtered NOESY
spectra for the
15N,
2H-labeled pro-
tein when in complex with the
14N,
1H(unlabeled)partner.Inthese
experiments, we could identify sev-
eral intermolecular cross-peaks.
However,becausenofullside-chain
assignment is available, in most
cases we could not unambiguously
assign them. Based on dockings
using the interaction interface
eitherwithorwithouttheRDCs,we
included one strong intermolecular
NOE as observed for Hsp90N Ala-
117-HN to Cdc37M Ala-204-HB in
the final docking calculation.
In the final docking calculations,
the active and passive residues in
the interaction site and the flexible
interfaces have been included as
stated in under “Experimental Pro-
cedures” as well as both sets of
RDCsandthestrongintermolecular
NOE. The top-ranked docking
model for the Cdc37MHsp90N
complex (Fig. 5C) shows the prefer-
ential binding mode and includes
185 out of 200 final structures when
clustered within the 3.0 Å pairwise
backbone r.m.s.d. These final struc-
tures have been analyzed whether
they satisfy the biochemical and
structural restraints. The active res-
idue 168 of Cdc37M causes viola-
tionsata2Åambiguousinteraction
restraint cut-off, but is still accepta-
bleatadistanceof3ÅfromHsp90N.
Cdc37M-Hsp90N Interface and
Structural Reorganization upon
Complex Formation—The interface
between Cdc37M and Hsp90N buries a total surface area of
1579 	 92 Å
2, which is highly comparable to the interface for
the average proteinprotein complex (1600 	 400 Å
2) (52).
There are two main Cdc37MHsp90N interaction regions that
together form the interface. The hydrophobic core is mainly
formed by the interaction of Cdc37M residues in the 4 and 5
helix with the residues in the Hsp90N 6 helix and adjacent
FIGURE5.NMRdatadrivendockingmodelofhumanCdc37MHsp90Ncomplex.A,surfacerepresentationof
Cdc37M. Left: The molecular surface is color-coded by electrostatic potential, as calculated with DELPHI (38).
Potentialslessthan10kTarered,thosegreaterthan10kTareblue,andneutralpotentials(0kT)arewhite.
The color in between is produced by linear extrapolation. Middle, CSPs from Fig. 4A (0.15 ppm) in yellow
mapped onto the structure. Right, cross-saturation transfer experiment (Fig. 4B) in which residues with inten-
sityratios0.78aremappedontothesurface(yellow).B,surfacerepresentationofhumanHsp90N(1YES.pdb).
Left, the molecular surface is color-coded by electrostatic potential, as calculated with DELPHI (38). Right, CSPs
from Fig. 4C (0.1 ppm) in purple mapped onto the structure. C, bundle of the Cdc37MHsp90N complex as
obtained using HADDOCK, with and without using RDCs. For the calculation without RDCs (left), the ten best
docking results for each of the two major HADDOCK clusters are shown, and for the calculation with RDCs
(right)thetenbestdockingresultsareshown.Theactive/passiverestraintswereusedasdefinedunder“Exper-
imental Procedures” and are colored, respectively, in red and yellow for Hsp90N or blue and dark-green for
Cdc37M. The RDC tensors for alignment in either polyacrylamide (PAA) gel or pf1 Phages are indicated below.
D, correlation of the experimental versus back calculated RDCs for the free-form x-ray structures of Cdc37M
(blue)andHsp90N(red).Protonswereaddedtothex-raystructuresusingCNS1.1(49)withoutusingtheRDCs.
RDCswereback-calculatedusingtheprogramPALES(43)withthebestFitoption. Left:correlationplotinPAA
gel alignment medium with Cdc37 in blue (25 RDCs, correlation coefficient of 0.822) and Hsp90N in red (52
RDCs, correlation coefficient of 0.903). Right: correlation plot in pf1 phages alignment medium with Cdc37 in
blue (42 RDCs, correlation coefficient of 0.816) and Hsp90N in red (79 RDCs, correlation coefficient of 0.964).
TheHumanCdc37Hsp90ComplexStudiedbyNMR
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 residues. Additionally, the Cdc37M 1, 2 helices and connect-
ing loop interact with the Hsp90N 7 helix and adjacent loop
regions, involving many charged residues. Our docking results
show an ensemble with many electrostatic and hydrophobic
contacts as shown in Fig. 6. Electrostatic interactions are gen-
erally observed between the residues Arg-166, Arg-167, and
Asp-170 of Cdc37M and Gln-133 of Hsp90N (hydrogen bonds
are often observed for Cdc37M residues Arg-166 and Arg-167
to residue Gln-133 of Hsp90N). The hydrophobic core involves
residues Met-164, Trp-193, Ala-204, and Leu-205 of Cdc37M
andAla-117,Ala-121,Ala-124,Ala-126,Met-130,andPhe-134
of Hsp90N. Upon Hsp90N binding, there are no large confor-
mationalchangesinCdc37M,exceptintheflexibleloopregions
ofthemolecule.Whensuperimpos-
ing the Cdc37MHsp90N complex
onto the uncomplexed molecules
(coordinatesfromourCdc37Mcrys-
tal structure and 1YES for Hsp90N),
the r.m.s.d. on the C atoms is 0.7 Å
for Cdc37M and 0.8 Å for Hsp90N
(0.5 Å for Hsp90N when excluding
residues 106–127). The difference
in the helical region (residues 106–
127) of Hsp90N is due to the
involvement of this region as a
hydrophobic core in the complex
structure.
Residue Leu-205 of Cdc37 Is Crit-
ical for the Complex Formation—
Our structure of the Hsp90N
Cdc37M complex indicates the
important residues involved at the protein-protein interface.
These residues can be divided into two categories: one forms
typical salt bridge interactions, and the other forms the hydro-
phobic core of the complex as described previously. NMR
cross-saturation transfer data show that Leu-205 in Cdc37M
experiences the largest decrease in signal intensity. To assess
the role of Leu-205, we mutated this residue to phenylalanine,
isoleucine, alanine, glycine, aspartic acid, and glutamic acid.
Thetwo-dimensional
1H,
15N-HSQCspectraofallmutantstyp-
ically retain the spectra of the wild-type, except for the region
around the mutation, indicating that there are no large confor-
mational changes brought about by the mutation. Typically,
NMRcanidentifyprotein-proteininteractionsevenwithaslow
affinityas5m M(KD).Thewild-typeCdc37MbindstoHsp90N
with a KD of 4.0 M (26, 32) and shows strong changes in the
1H,
15N-HSQC spectrum upon complex formation. For
mutantsL205DandL205Q,changesinthe
1H,
15N-HSQCcan-
not be observed ([Cdc37M]:[Hsp90N]  1:4), indicating that
thoseCdc37MmutantsdonotbindanymoretoHsp90N(Fig.7).
ControlexperimentsshowedthattheL205FandL205Imutants
retained the interaction, whereas there was a significant
decrease in the affinity for mutants L205A and L205G. The
observation supports that residue Leu-205 of Cdc37M drives
the complex formation by its hydrophobic nature.
Comparison with Previously Published Yeast Hsp90N-Hu-
man Cdc37 Crystal Structure—In our study we used human
Hsp90N, which has 69% sequence identity (Fig. 8) with that of
the yeast homologue (32). However, the residues of Hsp90 in
contact with Cdc37 are well conserved to a large extent, with
the exception of Gln-123, which is serine in the case of yeast
homologue. A superposition of our structure of the human
Cdc37MHsp90N complex with the Cdc37 (human)-Hsp90
(yeast) crystal structure (pdb: 1US7) (32) reveals a similar over-
all conformation, with an r.m.s.d. of 1.0 Å, when fitted onto the
C atoms of the Cdc37. The interface of our NMR-based solu-
tion structure has a buried surface area of 1600 Å
2, which is
distinctlylargerthanthe1100Å
2ofthecrystalstructure.Our
human Cdc37MHsp90N structure is thus more compact than
the previously reported heterogeneous structure. The most
FIGURE6.SchematicrepresentationoftheinteractioninterfaceofNMRcalculatedCdc37MHsp90Ncom-
plexstructure.Thepositivelycharged,negativelycharged,neutral,andhydrophobicaminoacidsarecolored
in red, blue, green, and gray, respectively.
FIGURE 7. Cdc37M-L205D mutant does not bind to Hsp90N.
1H,
15N-HSQC
spectralregionshowingtheamidesignalforLys-202,forwildtype-free(red),
mutant-free (orange), wild type in complex with Hsp90N (1:1) (green), and
mutant in the presence of Hsp90N (1:4) (blue).
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 eminent differences in Cdc37M are observed in the 6-7-loop
region.Thisdifferencealreadyobservedinthefree-formcrystal
structureandverylikelytoarisefromthefactthatCdc37exists
as a dimer in the crystal structure. Furthermore, changes are
observed for the orientation of some side chains (Arg-167 and
Gln-208) in the 1-2 region of Cdc37M.
DISCUSSION
Studyingtheprotein-proteininteractionofthefull-length
human Cdc37 (45 kDa) with human Hsp90N (23 kDa) at
molecular detail by NMR is most challenging due to the rel-
ative large size of this complex. Because the best quality
NMR spectra was obtained with the Cdc37M domain, which
is known to interact with Hsp90, this study was focused on
the examination of the Cdc37M structure and its interaction
with Hsp90N. An x-ray structure of human Cdc37M in com-
plex with yeast Hsp90N was already available (32). In this
study, an albeit longer Cdc37 construct (amino acids 148–
347) was used. Interestingly, this construct was found to
form a dimer. The core of the dimer interface has been
reported to be around Gln-247 and Tyr-248 and the pro-
longed C terminus, which forms a small three-helix bundle
(292–347), is not at all involved in dimer formation (32).
However, we did not observe any evidence for dimer forma-
tion with the constructs used in our study. Also our experi-
ments on the Cdc37MHsp90N complex did not show signals
thatindicateformationoflargercomplexes.Theexistenceof
Cdc37M as a monomer was strongly supported by the high
resolution x-ray structure of uncomplexed Cdc37M (Fig. 2).
It should be noted, however, that the overall structure of
monomeric and dimeric Cdc37M remains the same. The
largest differences between the structures are found in the
previously reported dimer interface, which is most probably
caused by crystal packing and which is interestingly near to
Hsp90 in the complex. Our findings for monomeric Cdc37
arealsoconsistentwithrecentobservationsfromVaughanet
al. (33) who analyzed a complex of Hsp90Cdc37Cdk4 by
cryoelectron microscopy.
The interaction interface between human Cdc37M and
Hsp90N was mapped based on NMR studies. Mapping of the
CSPsandCSTsontothestructuresrevealstwoeminentsurface
areascorrespondingtoasmallareawithchargedresiduesanda
large hydrophobic area. Subsequently, the docking program
HADDOCK was used to calculate the NMR-based structure of
the complex. When only using the ambiguous distance
restraints that are based on all the
existing data (CSPs, CSTs, and
NOE) for the docking calculation,
the final solutions did not con-
verge and yielded two possible
clusters with a different orienta-
tion. A single solution was
obtained when we incorporated
RDCs in our calculations. The
overall conformation of the final
NMR-based structure of the
human complex is very similar to
the known crystal structure of the
heterogeneous complex. However, there are some clear dif-
ferences observed for specific intermolecular contacts in the
distinctlylargerinteractioninterface,mostprobablycausing
this structure to be slightly more compact.
The Hsp90 residues in the interface of the complex are very
wellconserved,exceptforGln-123,whichisserineincaseofthe
yeast homologue. In the crystal structure with the yeast homo-
logue of Hsp90, this serine residue forms an intermolecular
hydrogen bond with the Lys-202 side chain of Cdc37. In our
model of the human complex, however, we find that the Gln-
123 side chain is just outside the binding interface, and makes
no significant contribution to the interaction. Instead, in this
case,thenearbysidechainoftheGlu-120residueofthehuman
Hsp90 generally forms a hydrogen bond with the Lys-202 side
chain of Cdc37. An important hydrogen bond is formed
between Glu-47 (human sequence numbering) of Hsp90 and
Arg-167ofCdc37,whichisconsideredtobethekeyinteraction
that arrests the ATPase action of Hsp90 (32). In the best struc-
ture from our docking bundle, we indeed also observe this
hydrogen bond. However, we do not observe this hydrogen
bond in all the docking structures, which is most probably a
result of the two possible conformations for the side chain of
Arg-167thatweobservedinourfree-formCdc37Mx-raystruc-
ture, that we use for our docking. We suppose that this side
chain is flexible in the free-form Cdc37 and stabilizes the com-
plex by forming an intermolecular hydrogen bond with Hsp90.
Furthermore, in the heterogeneous crystal structure of the
complex, the backbone oxygen of Hsp90 residue Gln-133
(human sequence numbering) accepts an intermolecular
hydrogen bond from the side-chain Gln-208 of Cdc37, and its
side-chain oxygen forms intermolecular hydrogen bonds with
the backbone Arg-166 and Arg-167 amides of Cdc37. In our
humancomplexwedidnotobservetheinteractionbetweenthe
Hsp90 residue Gln-133 and the Cdc37 residue Gln-208. This
could again be a result of the two possible conformations
observed for this Gln-208 side chain we observed in the free-
form x-ray structure, but on the other hand for the different
orientationofthissidechaininourhumanmodel,weobserved
that the amino moiety is rather close to the side-chain hydroxy
of the Ser-113 residue of Hsp90, with which it may possibly
form an intermolecular hydrogen bond. The hydrogen bonds
betweenthesidechainofHsp90residueGln-133andtheback-
bone Arg-166 and Arg-167 amides of Cdc37 is very well main-
tained in our human structure of the complex. Furthermore,
the hydrophobic core in our NMR-based structure of the com-
FIGURE 8. Sequence alignment of human Hsp90N and yeast Hsp90N. The shaded region is the region that
interacts with Cdc37M and forms the hydrophobic core of the interface.
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 plex includes the proximity of Ala-124 of Hsp90N and Trp-193
of Cdc37M, which are slightly further apart from each other in
the heterogeneous crystal structure.
In recent years, the Hsp90 protein became attractive as a phar-
maceutical anti-cancer target. Many protein kinases, of which
some might be causative for cancer when deregulated or overex-
pressed,requireHsp90tobemaintainedinafunctionalstate.Tar-
geting of Hsp90 thus seems to be attractive, because several pro-
tein kinases can be targeted at the same time. The Hsp90-specific
inhibitor, 17-allylamino-17-demethoxy geldanamycin is already
undergoingclinicaltrials(53).Hsp90-specificinhibitorsknownso
fararedirectedagainsttheATP-bindingpocketofHsp90.Because
Hsp90needsco-chaperonestofulfillitsfunctionandoneofthese,
Cdc37, is mainly found in combination with regulation of protein
kinases, the whole Hsp90Cdc37 complex could be considered as
an interesting drug target. In addition, increased levels of Cdc37
haveshowntoenhancecancercellgrowth(54).Adrugthatinhib-
its the formation of this complex might be a very valuable com-
pound. Knowing the interaction interface of the Cdc37
Hsp90 is a prerequisite for designing substances inhibiting
formation of the Hsp90Cdc37. In our study we analyzed the
humanCdc37MHsp90Ncomplexingreatdetail,andidentified
Leu-205 of Cdc37 as a key residue. This residue resides in the
interface and makes many contacts with different residues of
Hsp90 to stabilize the complex. Mutational analysis of Leu-205
indicates that the hydrophobic nature of this critical residue
promotes the complex formation.
Very recently, a compound was identified that disrupts the
Hsp90Cdc37 complex in cancer cells (55) supporting the idea
to target the Hsp90-Cdc37 interaction. We expect that the
structureofthehumanCdc37MHsp90Ncomplexsolvedinthis
studycanbeusedtoassistfurtherstudiesinthedevelopmentof
small molecule inhibitors.
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Small Molecule Inhibitor for the Protein-Protein
(Cdc37-Hsp90) Complex Studied by NMR
8.1 Research Article
Molecular Mechanism of Inhibition of the Human Protein
Complex Hsp90-Cdc37, A Kinome Chaperone-
Cochaperone, by Triterpene Celastrol
Sridhar Sreeramulu, Santosh Lakshmi Gande, Michael Göbel, Harald Schwalbe,
Angewandte Chemie International Edition, 2009, In press.
In this article we described about a small molecule inhibitor for disrupting the
protein-protein (Hsp90-Cdc37) complex.
Here we show by NMR how celastrol, a recently identiﬁed triterpene targeting
Hsp90, in fact binds to Cdc37 and disrupts this tightly binding (kD = 1.2 M)
complex. Further we also delineate as to which domains in Cdc37 are the targets
for the binding of celastrol and also give experimental evidence for the exact
mechanism of action.
The author of this thesis has performed all the UV, CD, and NMR experiments and
analysis. The molecular biology work was performed together with Dr. Santosh
Lakshmi Gande.
77  1
Protein-protein complex inhibitor  DOI: 10.1002/anie.200((will be filled in by the editorial staff)) 
Molecular Mechanism of Inhibition of the Human Protein Complex 
Hsp90-Cdc37, a Kinome Chaperone-Cochaperone, by Triterpene 
Celastrol** 
Sridhar Sreeramulu, Santosh Lakshmi Gande, Michael Göbel and Harald Schwalbe* 
 
Inhibition of the ATPase activity of the kinome chaperone Hsp90 
has long been known as molecular target for anticancer therapy. 
Cdc37, a cochaperone of Hsp90 in mammalian cells, targets protein 
kinases and is upregulated in various cancers.
[1, 2] The protein-
protein complex forms with a KD = 1.2 μM, and is considered to 
mediate carcinogenesis by stabilizing a variety of different 
oncogenic kinases in malignant cells. However, Cdc37 as well as 
Hsp90 can act also alone, at least in yeast. Low molecular weight 
molecules that interfere with Cdc37 or Hsp90 or disrupt the Hsp90-
Cdc37 complex have recently been proposed as a new class of anti-
cancer agents.
[3, 4] Gene based-expression studies have identified the 
triterpene celastrol, representing a new class of non ATP-
competitive inhibitors of Hsp90.
[5] Immunoprecipitation in a 
pancreatic cell line and docking experiments suggested that celastrol 
exerts its anti-proliferative activity by binding to the N-terminal 
domain of Hsp90 (Hsp90N), thereby disrupting the complex between 
Hsp90N and Cdc37.
[6] In vivo, celastrol showed significant inhibition 
of tumor growth in nude mice with prostate or pancreatic cancer.
[6, 7] 
In this communication, we investigate in detail how celastrol 
disrupts the human Hsp90-Cdc37 complex. 
1H,
15N-HSQC 
(heteronuclear spin quantum correlation) NMR (nuclear magnetic 
resonance) experiments detect ligand binding to a target through 
chemical-shift perturbations (CSPs).
[8-10] We investigated the effects 
of celastrol on the complex of 
1H,
15N-labeled Hsp90N (23 kDa) with 
unlabeled full-length Cdc37 (45 kDa) (Figure 1A). Due to the 
increased transverse relaxation rates of the protein in complex (ca. 
70 kDa), the HSQC spectrum of the complex resulted in broadening 
of most of the cross peaks, indicating complex formation. Addition 
of celastrol dissociated the complex and restored the HSQC 
spectrum of free Hsp90N. Surprisingly, the HSQC spectrum of free 
Hsp90N and the spectrum obtained after the addition of celastrol to 
the Hsp90N-Cdc37 complex matched exactly, revealing that 
celastrol disrupted the complex by a mechanism other than binding 
to Hsp90N. Changes in chemical shifts indicative of binding upon 
the addition of celastrol to free Hsp90N could not be observed (see 
Supporting Information 1 (SI 1)). 
 
Figure 1. Binding of celastrol to Cdc37. A) (left) 
1H,
15N HSQC 
spectrum of Hsp90N. (middle) 
1H,
15N HSQC spectrum of Hsp90N-
Cdc37 complex. (right) Upon addition of celastrol (1:7 of Hsp90N-
Cdc37:celastrol), the complex dissociates and the spectrum of free 
Hsp90N is retained indicating that celastrol does not bind to Hsp90N. 
B) (left) 
1H,
15N HSQC spectrum of full-length Cdc37 (45 kDa). (right) 
The cross-peaks disappear upon addition of celastrol (1:7 of 
Cdc37:celastrol), indicating a complex formation with Cdc37. 
Then, we studied the interaction between Cdc37 and celastrol. 
For this purpose, we recorded a 
1H,
15N-HSQC spectrum of 
15N-
labeled Cdc37 (Figure 1B). Upon addition of celastrol to Cdc37, 
most of the cross peaks in the HSQC disappeared indicating 
interaction of the protein with the ligand. The loss of resonance 
signals in the HSQC spectrum could be due to aggregation of 
protein induced by the ligand. Celastrol has an orange color and 
becomes colorless upon addition to Cdc37, which suggests a loss of 
its chromophore as quantified by UV spectroscopy 
[11] (see SI 2).  
Celastrol possesses electrophilic sites within the A and B ring 
(Scheme 1), where nucleophilic groups of amino acid residues react 
to form covalent Michael adducts.
[7, 12, 13] In fact, mass spectrometry 
of Cdc37 in the presence of celastrol exhibited a mass increase of 
450 Da, which corresponds to the molecular weight of celastrol (see 
SI 3).  
[∗]  M. Pharm. S. Sreeramulu, Dr. S. L. Gande, Prof. Dr. M. 
Göbel, Prof. Dr. H. Schwalbe 
Johann Wolfgang Goethe-University, Frankfurt am Main, 
Institute for Organic Chemistry and Chemical Biology, 
Center for Biomolecular Magnetic Resonance (BMRZ), 
Max-von-Laue-Strasse 7, D-60438 Frankfurt am Main, 
Germany 
Fax: (+)49 69 79829515 
E-mail: schwalbe@nmr.uni-frankfurt.de 
Homepage: http://schwalbe.org.chemie.uni-frankfurt.de/ 
[∗∗]  Cdc37: Cell division cycle protein 37, Hsp90: Heat shock 
protein 90. We thank Mr. Frédéric tournay at the Jardin 
Botanique de l'Universite Louis Pasteur, France, for kindly 
providing the photograph of the plant Tripterygium wilfordii. 
This work was supported by the SPINEII project of the 
European commission and by the Cluster of Excellence: 
Macromolecular Complex (DFG) 
  Supporting information for this article is available on the 
WWW under http://www.angewandte.org or from the 
author.   2
 
 
Scheme 1. Molecular mechanism for the addition of celastrol to thiol 
of Cdc37. The quinone methide region of celastrol is highlighted in a 
blue box in the structure. The thiol of Cdc37 reacts with the α,β-
unsaturated ketone of celastrol through Michael addition reaction, 
resulting in the formation of an adduct at C6. 
To confirm that celastrol modifies the cysteine residue(s) in 
Cdc37, we blocked all nine cysteine residues of full-length Cdc37 
with N-ethylmaleimide (NEM). NEM-labeled Cdc37 no longer 
reacted with celastrol and the mixture did not show any change in 
the UV spectrum indicating that cysteine(s) undergo(es) chemical 
reactions with celastrol upon binding (see SI 4). Circular dichroism 
(CD) spectra for the wild-type Cdc37 and Cdc37_NEM showed a 
decrease in secondary structure, indicating that covalent 
modification of the free cysteines alters the conformation of the 
protein (see SI 5). Further, the HSQC spectrum of Hsp90N  remained 
unchanged upon addition of Cdc37_NEM, indicating that 
modification of thiols is sufficient to inhibit the interaction between 
Hsp90N and Cdc37. Free cysteine can undergo a covalent addition 
reaction with celastrol, as the lipophilic celastrol becomes water 
soluble after addition of cysteine at a pH of 7.4, loses its absorption 
at 440 nm and reveals chemical shift changes in 1D proton NMR, 
characteristic for the Michael adduct at C6 in ring B of the triterpene 
(see SI 6). 
Michael adduct formation using cysteine thiol groups as 
nucleophile is highly dependent on pH. Under physiological 
conditions, the reaction is fast and reversible, thereby the ligand 
escapes from high GSH-concentration present in living cells (0.5-10 
mM) and reaches the target protein.
[14]  
 
Figure 2. Binding of celastrol to Cdc37N. (left) 
1H,
15N HSQC spectrum 
of free Cdc37N. (middle) Some of the cross-peaks disappear upon 
addition of celastrol that forms a complex with Cdc37N (1:2). (right) 
Most of the cross-peaks disappear upon further addition of celastrol to 
Cdc37N (1:8). 
Cdc37 is composed of three domains, the N-terminal kinase 
binding domain (Cdc37N, residues 1-126) with three free cysteines, 
the middle, Hsp90N binding domain (Cdc37M, residues 147-276) 
with four free cysteines and the C-terminal domain (Cdc37C, 
residues 282-376) of unknown function with two free cysteines (see 
SI 7). In order to delineate which of these domains is responsible for 
binding celastrol, individual domain constructs were expressed. 
Cdc37N reduced celastrol and resulted in an inactivated form, as 
observed in the 
1H,
15N-HSQC spectrum (Figure 2). Cdc37M alone 
precipitated upon addition of celastrol, but did not reduce the 
compound, while the construct with the middle and the C-terminal 
domain (Cdc37MC) reacted with celastrol, but also precipitated. This 
observation suggests that the N-terminal domain is mainly 
responsible for reducing celastrol and binding. Additionally, when 
the cysteines were blocked using NEM, the Cdc37N no longer 
interacted with celastrol (see SI 8). 
Further, in order to see which of the three cysteines of Cdc37N 
are involved in the interaction with celastrol, we made double 
cysteine mutants retaining one cysteine (Cdc37N-C57S-C64S, 
Cdc37N-C54S-C64S, Cdc37N-C54S-C57S). Circular dichroism 
(CD) spectra for the wild-type and mutant Cdc37N are mostly 
similar, indicating that there are no changes in secondary structure 
(see SI 5). We monitored the decrease in absorbance at 440 nm after 
the addition of various constructs of Cdc37 to celastrol. Cdc37N and 
all the three mutants reduced celastrol and were comparable to the 
wild-type (see SI 4), indicating they are all reactive. 
 
Figure 3. Mechanism of inactivation of Cdc37 by celastrol. Celastrol 
inactivates Cdc37 either by the formation of a covalent adduct(s) with 
thiol(s) of Cdc37, by formation of an intramolecular disulfide bond or 
by intermolecular aggregates. 
   In conclusion, we report that celastrol binds to Cdc37 but not 
to Hsp90N as previously described. This study is important as it will 
shift medicinal chemistry efforts towards the correct target within 
the protein-protein complex. Celastrol inactivates Cdc37 by 
covalently binding to it or by forming either an intra- or 
intermolecular protein disulfide (Figure 3). Reactivities of individual 
cysteines varies slightly (as seen from the UV results), depending on 
accessibility and the stabilization interaction of the adjacent amino 
acids, celastrol binds to one of the cysteines. The interaction 
between Cdc37-Hsp90 also involves a large hydrophobic core at the 
interface.
[15] Adjacent to the hydrophobic core is C203 from Cdc37M, 
which is exposed to the surface. Celastrol harbors a hydrophobic 
structure  apart from the quinone methide moiety. Hence, celastrol 
could be involved disrupting this hydrophobic core. The binding of 
celastrol induces large changes in conformation of the N-terminal 
kinase binding domain and also the middle Hsp90N binding domain 
of Cdc37, thereby disrupting the Cdc37-Hsp90N complex which is 
crucial for stabilizing oncogenic kinases in various cancers.
[3] Our 
results indicates that the N-terminal kinase binding and middle 
Hsp90N domain of Cdc37 are the molecular target for the triterpene   3
celastrol. In light of the considerable potential of Cdc37 as a drug 
target and binding of celastrol to it, these results can now be used to 
further understand the molecular basis for inhibiting this key Cdc37-
Hsp90 complex in cancer cells. 
Experimental Section 
(see Supporting Information) 
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Experimental Section 
Protein expression and purification: The human Cdc37, Cdc37N and Hsp90N was expressed in E. coli strain BL21 
(DE3) and purified by nickel affinity chromatography as described previously.
[15] The uniformly 
15N enriched protein 
samples were prepared by growing the bacteria in minimal media containing 
15N-NH4Cl. After the purification the 
protein was dialyzed against a buffer containing 50 mM Hepes pH 7.4, 100 mM NaCl, 50 μM of TCEP, concentrated 
(approximately to 1 mM) and stored at -20 °C. 
Mutagenesis:  Mutants of Cdc37N were created with QuickChange kit (Stratagene), and sequenced to confirm the 
incorporation of the correct mutation. The mutant proteins were purified following the same protocol as the wild-type. 
NMR spectroscopy: NMR experiments were performed at 298 K, on Bruker 600, 800, 900 and 950 MHz spectrometers 
equipped with cryogenic triple-resonance probes. For the Cdc37-Hsp90N complex a ratio of 1:1 was used for all 
measurements. Typically, NMR samples contained 0.6 ml of up to 0.15 mM protein in 50 mM Hepes pH 7.4, 100 mM 
NaCl, 0.05 % NaN3. The spectra were processed using Topspin 2.0 (Bruker Biospin) and analyzed using SPARKY 
3.113. 
NMR titrations with celastrol: Celastrol was purchased from Shangai Yingxuan Pharmaceutical Science & Technology 
Co., LTD. Since celastrol is not soluble in the buffer used for NMR samples (as judged by the 1D 
1H NMR spectrum), 
DMSO-d6 stock solution of celastrol was used for NMR measurements. The effect of DMSO-d6 on the proteins and the 
protein complex was checked to be negligible up to 3 % v/v of DMSO-d6. 
To check whether celastrol might bind to Hsp90N, we carried out titration of celastrol with 
15N Hsp90N and could 
positively determine that celastrol does not bind to Hsp90N. No major changes in the Hsp90N spectrum were observed 
even up to a ratio of 1:7 (Hsp90N: celastrol). In similar fashion experiments were carried out for Cdc37, Cdc37N and the 
Hsp90N-Cdc37 complex. 
For studying the interaction between free cysteine and celastrol, we performed the reaction in Phosphate buffer saline 
pH 7.4. Celastrol and free cysteine was mixed in a ratio of 1:20 and then recorded the 1D 
1H NMR spectrum. Further, 
on long standing of the mixture of cysteine (or N-acetyl cysteine or GSH) and celastrol, one observes a white 
precipitate due to the polymerization of the reduced celastrol. 
N-Ethylmaleimide (NEM) labelling: Free cysteine residues in Cdc37/Cdc37N were blocked using NEM reagent (Pierce 
Biotechnology, Inc., Rockford, IL). The reaction was carried out in a buffer containing 50 mM Hepes pH 7.2, 100 mM 
NaCl. Cdc37 was allowed to react with NEM (1:10) for 2 hrs at room temperature, subsequently, the excess NEM was 
removed by dialysis (Slide-A-Lyzer). The NEM labeling was confirmed by MALDI-TOF mass spectrometry. 
1MALDI-TOF mass spectrometry analysis: Cdc37 (in our case we used the 
15N labeled protein) was incubated with 
celastrol (1:7) in a buffer containing 50 mM Hepes pH 7.4, 100 mM NaCl, 0.05 % NaN3 for 10 minutes. A MALDI-
TOF mass spectrometry spectrum was then obtained with a Voyager Elite. 
Measurement of UV spectra: Samples were mixed at indicated concentrations in a buffer containing 50 mM Hepes pH 
7.4, 100 mM NaCl and then monitored between 200 and 600 nm by using UV spectrophotometer (Cary 50 Bio UV-
visible spectrophotometer, Varian). All spectra were later smoothened (Savitzky-Golay method) and plotted using 
Origin (version 8). 
Measurement of circular dichroism (CD) spectra: All measurements were carried out with
  a Jasco J-810 CD 
spectropolarimeter in a cuvette with a path length of 0.1 cm. The scanning speed
 was 50 nm/min, bandwidth 0.1 nm, 
and a response time of 1 s.
 In each experiment, measurements were done at 25 °C and
 3 spectra were summed and 
averaged. All protein samples were typically either 5 μM or 15 μM in a buffer containing 5 mM Hepes pH 7.4, 10 mM 
NaCl. The concentration of protein was measured by using Nanodrop spectrophotometer, ND-1000, PEQLAB. 
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Figure S1. Celastrol does not bind to Hsp90N. (left) 1H,15N HSQC spectrum of free Hsp90N. (right) 1H,15N HSQC spectrum of Hsp90N plus celastrol (1:7). Both spectra 
remain identical, indicating that celastrol does not bind to Hsp90N.
3Figure S2.  Change of UV spectrum of celastrol upon binding to Cdc37. A) UV spectrum of 100 mM of celastrol before (black) and after 
incubation with 10 mM Cdc37 for 30 minutes (cyan). B) Structure of celastrol with the chromophore region shown in pink. 
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4Figure S3.  Covalent binding of celastrol to Cdc37. Mass spectrometry analysis of Cdc37 with and without celastrol. After incubating Cdc37 with celastrol, the molecular 
weight of the Cdc37-celastrol complex was investigated by MALDI-TOF. The molecular mass difference of 450 Da suggests that celastrol (Molecular weight: 450 Da) is 
covalently bound to Cdc37. 
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Figure S4. UV absorption spectra of celastrol monitored after addition of Cdc37, Cdc37N and the three cysteine mutants 
of Cdc37N. The decrease in absorbance of celastrol (100 mM, black) at 440 nm after the addition of various constructs of 
Cdc37 was monitored by UV (7 mM of Cdc37, 7 mM of Cdc37N and mutants). As seen from the graph, the reaction 
proceeds in a similar fashion for all the constructs during the first 60 seconds (red) and varies thereafter, indicating that 
the cysteines of Cdc37N are as reactive as in the Cdc37 full length protein. After 900 seconds the absorbance becomes 
stable, and the addition of another 3 mM (Cdc37) or 7 mM (Cdc37N or mutants) of protein results in complete reduction of 
celastrol (cyan). If we block the cysteines with NEM (last two spectra), Cdc37 is no longer able to react with celastrol, 
endorsing the fact that free cysteines are the clear targets. 
7Figure S5. CD spectra of Cdc37, Cdc37N and Cdc37N mutants. (left) CD spectra of wild type Cdc37 (5 mM) and Cdc37 in which all the free cysteines are 
coupled to NEM. (right) CD spectra of Cdc37N (15 mM), Cdc37N_NEM and the cysteine mutants. The spectra of the mutants show no significant changes 
compared to the wild type, indicating no change in secondary structure due to mutation. 
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Figure S6.  Celastrol forms Michael adduct with cysteine. A) Overlay of 1D 1H NMR spectra of  celastrol with and without 
cysteine in phosphate buffer pH 7.4 (PBS) / DMSO. Since celastrol is sparingly soluble in water, we do not see any signal 
for celastrol in PBS. In the 1D 1H NMR spectrum of celastrol upon addition of cysteine, the insoluble celastrol now is 
reduced by cysteine and becomes water soluble. In the 1D 1H NMR spectrum of celastrol with cysteine in PBS, the signals 
for the H1 and H7 protons appear after the reaction with cysteine. H6 in reduced celastrol is shifted and could not be 
detected because of its overlap with the water signal. As celastrol is soluble in DMSO, all signals (H1, H6 and H7) could be 
observed in the 1D 1H NMR spectrum. B) Schematic representation of the conceived reaction.
9Cysteine Residues
54 57 64 183 194 203 233 308 336
1 126147 276 378
Kinase binding 
domain
Hsp90 binding 
domain
Unkown
Cdc37N Cdc37M Cdc37C
Figure S7. Schematic representation of the three domains of Cdc37 and the cysteine distribution. 
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Figure S8. Cysteines in Cdc37N are responsible for the binding of celastrol. (left) 1H,15N HSQC spectrum of Cdc37N in which all three cysteines are 
covalently bound to NEM. (right) 1H,15N HSQC spectrum of Cdc37N-NEM after the addition of celastrol (1:8). Both spectra remains the same, indicating that 
there is no complex formation with celastrol, endorsing the fact that cysteines are the main target of celastrol.
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D
ie folgende Arbeit beschäftigt sich mit der Untersuchung von Proteinen und
Protein-Protein-Komplexen von biomedizinischer Bedeutung mittels
Kernmagnetresonanzspektroskopie (NMR-Spektroskopie). Zu verstehen, wie
biologische Systeme arbeiten von der Stufe eines einzelnen Proteins hin zu
komplexeren Protein-Protein-Komplexen und letztlich zur dadurch vermittelten
Weitergabe eines Signals, ist ein wichtiger Schritt, um Heilmittel für viele
Krankheiten zu ﬁnden. Krebs ist eine solche Krankheit, die durch unkontrollierte
Zellteilung, die oft durch Proteinkinasen gefördert wird, charakterisiert ist
[Teicher, 2000]. Daher werden Proteinkinasen oftmals als Rezeptoren der Bindung
kleiner Inhibitormoleküle benutzt. Dabei wird oft das Problem mangelnder
Zielselektivität beobachtet, verursacht durch die hohe Sequenzähnlichkeit zwischen
unterschiedlichen Mitgliedern der Kinasen-Familie [Fabbro et al., 2002; Noble et al.,
2004].
Akt/PKB ist eine Proteinkinase, die häuﬁg in einer grundlegend aktiven Form in
humanen Krebsarten gefunden wurde. Akt/PKB ist ein klinisch validiertes Ziel und
daher ist die Entwicklung kleiner Inhibitormoleküle gegen diese Kinase höchst
erstrebenswert [Brognard et al., 2001; Hanada et al., 2004].
Akt/PKB kann nicht einfach in E. coli exprimiert werden. Daher wurde die cAMP-
abhängige Kinase (PKA), die eine hohe Sequenz-Homologie zu Akt/PKB aufweist,
als so genannte Surrogatkinase für die Wirkstoffentwicklung benutzt.
Alternativ dazu beﬁnden sich Wirkstoffe, die das molekulare Chaperon Hsp90
7980 ZUSAMMENFASSUNG UND ÜBERBLICK
inhibieren, gerade in klinischen Studien. Ihr Wirkmechanismus beruht auf der
Inhibition der Funktion des Hsp90, den Fehlfaltungs-induzierten Abbau vieler
Kinasen fördern zu können [Whitesell and Lindquist, 2005]. Kürzlich wurde
mit Cdc37 ein Co-Chaperon von Hsp90 in Säugetierzellen identiﬁziert, das an
Proteinkinasen bindet. In verschiedenen Krebsarten ist die Expression von Cdc37
hochreguliert [Lee et al., 2002; Pearl, 2005]. Der Protein-Protein-Komplex (Hsp90-
Cdc37) bildet sich mit einem KD = 1,2 M und wird durch die Stabilisierung
einer Vielfalt von verschiedenen onkogenen Kinasen in bösartigen Zellen als
krebsauslösend betrachtet.
Eine Kombination aus NMR-Spektroskopie und Röntgenkristallographie wurde
in dieser Arbeit angewendet, um diese Proteine oder Protein-Protein-Komplexe
in hoher struktureller Auﬂösung zu untersuchen. Diese Untersuchungen, die
Wechselwirkungen in den Protein-Protein-Komplexen mit atomarer Auﬂösung zu
bestimmen sind wichtig, da es uns so die Identiﬁkation einerseits der ‚Hot Spots‘ der
Protein-Protein-Wechselwirkungsgrenzﬂäche, sowie in der weiteren Entwicklung,
der kleinen Inhibitor-Moleküle ermöglichen wird [Wells and McClendon, 2007].
Der erste Teil der Arbeit stellt dem Leser die Welt der strukturellen Proteomik
und seine Bedeutung vor. Kapitel 2 diskutiert eine Vielzahl von Projekten, die in
der Post-humanen-Genom-Ära in verschiedenen Ländern weltweit unternommen
worden sind, um dreidimensionale Strukturen einer beachtlichen Gruppe von
Proteinen eines Organismus erhalten, das ‚Proteom‘. Kapitel 2 berichtet außerdem
vom EU-geförderten Projekt ‚Structural Proteomics in Europe‘ (SPINE), das seine
Untersuchungen auf Proteine und Protein-Protein-Komplexe von biomedizinischer
Bedeutung begrenzt hat und zeigt explizit PDB-Statistiken von dreidimensionalen
Strukturen mit großem Molekulargewicht, die durch NMR-Spektroskopie aufgeklärt
wurden.
Die Bedeutung der Untersuchung von Proteinen, die einen Bezug zu Krebs haben,
wie die Proteinkinasen Hsp90 und Cdc37, wird im Kapitel 3 vorgestellt. Kapitel
4 gibt dem Leser einen Einblick in die Bedeutung der Entwicklung kleiner
Inhibitormoleküle zur Trennung von Protein-Protein-Interaktionen, um Krankheiten
vorzubeugen. Kapitel 5 gibt letztlich einen Überblick über die verschiedenen NMR-
Methoden, die für die Untersuchungen von Protein-Protein-Wechselwirkungen
genutzt wurden. Dieses Kapitel führt den Leser außerdem in die Bedeutung von
Protein-Protein-Interaktionen in zellulären Prozessen ein.German Summary 81
Der zweite Teil der Arbeit, der kumulativ ist, umfasst die durchgeführte
Forschungsarbeit. Kapitel 6 beschreibt, wie NMR-Spektroskopie genutzt wurde,
um Zugang zur korrekten Faltung der Proteinkinase A (PKA) zu erhalten. Weiterhin
wird darüber berichtet, wie Mutationen der Phosphorylierungsorte in PKA die
Expressionsebene, die Stabilität und die Aktivität der Kinase beeinﬂussen.
Abbildung 8.1: Faltung und Aktivität
der cAMP-abhängigen Proteinkinasenmu-
tanten. Der Vergleich der TROSY-Spektren
des Wildtyps (schwarz) und der ‚dephopho‘-
PKA-Mutante, PKA-3P (grün), zeigt, dass die
Mutanten korrekt gefaltet sind. Weitere Details
sind in Kapitel 6 zu ﬁnden.
Ergebnisse:
 Etablierung von PKA mit drei Phospho-Mutationen, die in E. coli exprimiert
werden kann, was sonst ein großes Hindernis zur Synthese der meisten
humanen Kinasen ist
 Nachweis durch NMR-Spektroskopie, das die PKA mit den drei Phospho-
Mutationen (40 kDa) korrekt gefaltet sind
 Nachweis, dass es keine Mischungen der Isoformen aufgrund unter-
schiedlicher Phosphorylierung gibt, da hier nur ein Phosphorylierungort im
Akivierungs-Loop vorhanden ist. Dieses Proteinkonstrukt wird sehr hilfreich
sein für Untersuchungen von Protein-Ligand-Interaktionen.
 Etablierung der Tatsache, dass diese Mutanten aktiv und korrekt gefaltet
sind, was nun höchst vorteilhaft für weitere funktionelle und strukturelle
Untersuchungen sein kann
Kapitel 7 erläutert, wie wir die Strukturvorhersage eines humanen Cdc37M-
Hsp90N-Protein-Protein-Komplexes (40 kDa) mittels NMR-Spektroskopie in
Kombination mit Röntgenkristallographie erzielen konnten. Weiterhin konnten82 ZUSAMMENFASSUNG UND ÜBERBLICK
wir die Lage des ‚Hot Spots‘ in der großen Wechselwirkungsgrenzﬂäche des Protein-
Protein-Komplexes genau feststellen.
Abbildung 8.2: NMR-Studien des humanen Cdc37M-Hsp90N-Komplexes. Eine
Kombination aus Domänenoptimierung, NMR-spektroskopischen Methoden (Resonanzzuord-
nung, Abbilden der chemischen Verschiebungsstörung, Kreuzsättigungstransfer, RDC’s),
Röntgenkristallographie und Docking mit HADDOCK wurde benutzt, um die Lösungsstruktur
des 39 kDa humanen Cdc37M-Hsp90N-Komplexes zu ermitteln. Weitere Details sind in Kapitel 7
zu ﬁnden.
Ergebnisse:
 Aufzeigen der Domänengrenzen, Reinigung und NMR-Bedingungen für Cdc37
(45 kDa)
 Komplette (99.5 %) Rückgratresonanzzuordnung der Hsp90-Bindungsdomäne
von Cdc37
 Bestimmung der Struktur der humanen Hsp90-Bindungsdomäne von Cdc37
durch Röntgenkristallographie in Zusammenarbeit mit Prof. Dr. Roy Lancaster
 Abbildung der Wechselwirkungsgrenzﬂäche von Cdc37-Hsp90 durch
Benutzung einer Vielzahl von NMR-Techniken, was als Beispiel für weitere
Studien von großen Protein-Protein-Komplexen dientGerman Summary 83
 Erfolgreiche Nutzung von residualen dipolaren Kopplungen (RDC’s) für eine
genauere Strukturvorhersage des Protein-Protein-Komplexes
 Ermitteln der Struktur des humanen Cdc37-Hsp90 (40 kDa), durch Benutzung
einer Kombination von NMR-Spektroskopie, Röntgenkristallographie und
docking auf dem neuesten Stand der Technik
 PDB-Statistiken zeigen, dass es bis heute nur 49 Strukturen mit einem
Molekular-gewicht über 39 kDa gibt, relativ zu 7728 durch NMR gelösten
Strukturen. Die Struktur von Cdc37-Hsp90 ist eine der 49 Strukturen, die
durch NMR gelöst wurde.
 Identiﬁzierung des ‚Hot Spots‘ in der großen Wechselwirkungsgrenzﬂäche
durch NMR und weitere Bestätigung durch eine Kombination aus Punktmu-
tationen und NMR
Kapitel 8 beschreibt am Ende die NMR-Ergebnisse, dass Celastrol, ein kürzlich
identiﬁziertes Triterpen, an Cdc37, nicht aber wie in der Literatur berichtet,
an Hsp90 bindet und den Cdc37-Hsp90-Komplex zerstört. Weiterhin wird der
molekulare Inhibierungsmechnismus von Cdc37, gelöst durch NMR, aufgezeigt.
Abbildung 8.3: Celastrol bindet an Cdc37. Das „Cell division cycle“-Protein 37 (Cdc37)
und das „Heat shock“-Protein (Hsp90) sind molekulare Chaperone, die für die Faltung und die
Stabilisierung der Proteinkinasen, inklusive der onkogenen Kinasen, entscheidend sind. Hier zeigen
wir durch NMR-Spektroskopie, dass Celastrol, ein kürzlich identiﬁziertes Triterpen nicht wie in
der Literatur berichtet an Hsp90, sondern an Cdc37 bindet und somit den Cdc37-Hsp90-Komplex
zerstört. Celastrol inaktiviert Cdc37 durch einen Thiol-vermittelten Mechanismus. Weitere Details
sind in Kapitel 8 zu ﬁnden.84 ZUSAMMENFASSUNG UND ÜBERBLICK
Ergebnisse:
 Nachweis, dass Cdc37 das richtige Ziel für Celastrol innerhalb des Protein-
Protein-Komplexes (Cdc37-Hsp90) ist.
 Etablierung des exakten Mechanismus der Interaktion zwischen Celastrol und
Cdc37 durch NMR
 Feststellung, dass die N-terminale und die mittlere Domäne von Cdc37 für die
Bindung von Celastrol verantwortlich sind
 Diese Untersuchungen weisen die weitere Entwicklung von Inhibitoren zum
richtigen molekularen Target innerhalb der Protein-Protein-Komplexe.
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